Original Article
Effects of Intensive Glucose Lowering in Type 2 Diabetes
N Engl J Med 2008; 358:2545-2559June 12, 2008
- Abstract
Background
Epidemiologic studies have shown a relationship between glycated hemoglobin levels and cardiovascular events in patients with type 2 diabetes. We investigated whether intensive therapy to target normal glycated hemoglobin levels would reduce cardiovascular events in patients with type 2 diabetes who had either established cardiovascular disease or additional cardiovascular risk factors.
Methods
In this randomized study, 10,251 patients (mean age, 62.2 years) with a median glycated hemoglobin level of 8.1% were assigned to receive intensive therapy (targeting a glycated hemoglobin level below 6.0%) or standard therapy (targeting a level from 7.0 to 7.9%). Of these patients, 38% were women, and 35% had had a previous cardiovascular event. The primary outcome was a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes. The finding of higher mortality in the intensive-therapy group led to a discontinuation of intensive therapy after a mean of 3.5 years of follow-up.
Results
At 1 year, stable median glycated hemoglobin levels of 6.4% and 7.5% were achieved in the intensive-therapy group and the standard-therapy group, respectively. During follow-up, the primary outcome occurred in 352 patients in the intensive-therapy group, as compared with 371 in the standard-therapy group (hazard ratio, 0.90; 95% confidence interval [CI], 0.78 to 1.04; P=0.16). At the same time, 257 patients in the intensive-therapy group died, as compared with 203 patients in the standard-therapy group (hazard ratio, 1.22; 95% CI, 1.01 to 1.46; P=0.04). Hypoglycemia requiring assistance and weight gain of more than 10 kg were more frequent in the intensive-therapy group (P<0.001).
Conclusions
As compared with standard therapy, the use of intensive therapy to target normal glycated hemoglobin levels for 3.5 years increased mortality and did not significantly reduce major cardiovascular events. These findings identify a previously unrecognized harm of intensive glucose lowering in high-risk patients with type 2 diabetes. (ClinicalTrials.gov number, NCT00000620.)
Media in This Article
Figure 1
Median Glycated Hemoglobin Levels at Each Study Visit.Figure 2
Kaplan–Meier Curves for the Primary Outcome and Death from Any Cause.Article Activity
- Article
Type 2 diabetes mellitus is a metabolic disease that is diagnosed on the basis of sustained hyperglycemia. People with type 2 diabetes are at elevated risk for a number of serious health problems, including cardiovascular disease, premature death, blindness, kidney failure, amputations, fractures, frailty, depression, and cognitive decline.1 In prospective epidemiologic studies, the incidence of many of these outcomes is directly associated with the degree of hyperglycemia, as measured by the plasma glucose or the glycated hemoglobin level, a measure of the mean blood glucose level during the previous 2 to 3 months. Thus, after adjustment for other risk factors, an increase of 1% in the glycated hemoglobin level is associated with an increase of 18% in the risk of cardiovascular events,2 an increase of 12 to 14% in the risk of death,3,4 and an increase of 37% in the risk of retinopathy or renal failure.4
The graded relationship between the glycated hemoglobin level and cardiovascular events and death suggested that a therapeutic strategy to lower glycated hemoglobin levels might reduce these outcomes. This hypothesis was supported by findings from some but not all previous clinical trials.1 However, the hypothesis was not explicitly tested in adequately powered, randomized trials focusing on cardiovascular outcomes. Nevertheless, data from basic science, epidemiologic analysis, and limited trials have been used to support guideline recommendations to target near-normal levels of glycated hemoglobin and glucose in selected patients with type 2 diabetes mellitus,5-8 despite a paucity of evidence regarding the risks and benefits of doing so with currently available therapies.
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial was specifically designed to determine whether a therapeutic strategy targeting normal glycated hemoglobin levels (i.e., below 6.0%) would reduce the rate of cardiovascular events, as compared with a strategy targeting glycated hemoglobin levels from 7.0 to 7.9% in middle-aged and older people with type 2 diabetes mellitus and either established cardiovascular disease or additional cardiovascular risk factors. The finding of higher mortality in the intensive-therapy group led to a decision to terminate the intensive regimen in February 2008, 17 months before the scheduled end of the study. We report the effects of the intensive intervention on mortality and the primary composite outcome of major cardiovascular events in all patients and in prespecified subgroups.
Methods
Eligibility and Study Design
The rationale and design of the trial and a description of the glycemia intervention have been reported previously.9,10 Briefly, the ongoing multicenter clinical study, which is sponsored by the National Heart, Lung, and Blood Institute (NHLBI), is being conducted in 77 clinical centers (aggregated within seven networks) across the United States and Canada. We recruited volunteers who had type 2 diabetes mellitus and a glycated hemoglobin level of 7.5% or more and who either were between the ages of 40 and 79 years and had cardiovascular disease or were between the ages of 55 and 79 years and had anatomical evidence of significant atherosclerosis, albuminuria, left ventricular hypertrophy, or at least two additional risk factors for cardiovascular disease (dyslipidemia, hypertension, current status as a smoker, or obesity).9 Key exclusion criteria included frequent or recent serious hypoglycemic events, unwillingness to do home glucose monitoring or inject insulin, a body-mass index (the weight in kilograms divided by the square of the height in meters) of more than 45, a serum creatinine level of more than 1.5 mg per deciliter (133 μmol per liter), or other serious illness.
All 10,251 patients were randomly assigned to receive comprehensive intensive therapy targeting a glycated hemoglobin level of less than 6.0% or to receive standard therapy targeting a level of 7.0 to 7.9%. With the use of a double two-by-two factorial design, 4733 patients were randomly assigned to lower their blood pressure by receiving either intensive therapy (systolic blood-pressure target, <120 mm Hg) or standard therapy (systolic blood-pressure target, <140 mm Hg). In addition, 5518 patients were randomly assigned to receive either fenofibrate or placebo while maintaining good control of low-density lipoprotein cholesterol with simvastatin.11 These blood-pressure and lipid trials are continuing, and results regarding them remain masked. The study protocol was approved by the institutional review board or ethics committee at each center, as well as by a review panel at the NHLBI. All patients provided written informed consent.
Patients received instructional materials and behavioral counseling regarding diabetes care and were provided with glucose-lowering medications (from a study-supervised formulary) and glucose-monitoring supplies. Any marketed antihyperglycemic therapy that was not provided by the formulary could also be prescribed to any patient but was not provided by study investigators. Therapeutic regimens were individualized at the discretion of the investigators and patients on the basis of study-group assignment and the response to therapy. Adverse effects of therapy were carefully audited both locally and centrally to ensure the safety of the patients.12
Patients in the intensive-therapy group attended monthly visits for the first 4 months and then every 2 months thereafter, with at least one interim phone call, with the aim of rapidly and safely reducing glycated hemoglobin levels to below 6.0%. Additional visits were scheduled as needed to achieve glycemic goals, as described previously.9,10 Patients in the standard-therapy group had glycemic-management visits every 4 months.
Primary and Secondary Outcomes
The prespecified primary outcome was the first occurrence of nonfatal myocardial infarction or nonfatal stroke or death from cardiovascular causes. The latter included death from myocardial infarction, heart failure, arrhythmia, invasive cardiovascular interventions, cardiovascular causes after noncardiovascular surgery, stroke, unexpected death presumed to be from ischemic cardiovascular disease occurring within 24 hours after the onset of symptoms, and death from other vascular diseases.9 Death from any cause was one of several prespecified secondary outcomes. Study investigators also measured the effect of the intervention on microvascular disease, hypoglycemia, cognition, and quality of life, although these outcomes are not reported here. Key outcomes were adjudicated by a central committee whose members were unaware of study-group assignments on the basis of predefined criteria.13 A central laboratory that was unaware of study-group assignments analyzed blood for glycated hemoglobin levels. Study investigators outside the coordinating center and NHLBI project office were unaware of the accumulating rates of study outcomes.
Safety and Efficacy Analyses
An independent, 10-member data and safety monitoring committee that was appointed by the NHLBI reviewed the interim results approximately every 6 months. The committee's role was to monitor the primary outcome and deaths from any cause, ensure the safety of patients, make recommendations to continue or alter the study design, and advise the NHLBI if there was clear evidence of benefit or harm. After reviewing mortality trends for several months (and as part of a preplanned safety analysis), on January 8, 2008, the committee concluded that the harm associated with the increased rate of death from any cause in the intensive-therapy group, as compared with that in the standard-therapy group, outweighed any potential benefits and recommended that the intensive regimen be discontinued for safety reasons. This recommendation was accepted by the NHLBI. Patients were informed of this decision on February 5, 2008, and were subsequently switched to standard glycemic therapy. The public was informed of the decision in a press release on February 6, 2008. This report is based on data that were submitted to the coordinating center through December 10, 2007, and that were used by the data and safety monitoring committee to make its recommendation. Some of the adjudications of the causes of death were completed after that date.
Statistical Analysis
The study was designed to have a power of 89% to detect a 15% reduction in the rate of the primary outcome for patients in the intensive-therapy group, as compared with the standard-therapy group, assuming a two-sided alpha level of 0.05, a primary-outcome rate of 2.9% per year in the standard-therapy group, and a planned average follow-up of approximately 5.6 years. The original number of patients and power determinations for each study group were made under the assumption that the blood-pressure and lipid interventions would produce the effect sizes for which they were designed.9
All statistical analyses were conducted at the coordinating center with the use of S-Plus software, version 8.0 (Insightful) or SAS software, version 9.1 (SAS Institute). Baseline characteristics were compared in the two study groups with the use of chi-square tests and two-sample t-tests. At each assessment visit, glycated hemoglobin levels were summarized with the use of medians and interquartile ranges. Exposure to glucose-lowering drugs was summarized according to study group as the number of patients who received a prescription for a medication and the total person-years of prescriptions. The incidence of key safety outcomes — including severe hypoglycemia, heart failure, motor vehicle accidents in which the patient was the driver, fluid retention, elevated aminotransferase levels, and weight gain — were compared with the use of Fisher's exact test.
Analyses of primary and secondary outcomes were performed with the use of time-to-event methods according to the intention-to-treat principle, and occurrences of these outcomes in the two study groups were compared with the use of hazard ratios and 95% confidence intervals. Two-sided P values were obtained from likelihood-ratio tests from Cox proportional-hazards regression analyses. Our inspection of plots of survival estimates versus follow-up time indicated that the assumption of proportional hazards for the glycemia intervention appeared to be valid. The Cox models contained a term representing study-group assignments plus terms accounting for the following prespecified stratifying variables: assignment to either the blood-pressure trial or the lipid trial, assignment to the intensive blood-pressure intervention in the blood-pressure trial, assignment to receive fibrate in the lipid trial, the seven clinical-center networks, and the presence or absence of a previous cardiovascular event. An analysis of how sensitive the results were to inclusion of these variables as stratifying factors rather than as covariates in the Cox model was also performed. Event rates are expressed as the percentage of events per follow-up year, taking into account censoring of follow-up data. Kaplan–Meier estimates were used to obtain the proportion of patients who had an event during follow-up.
We assessed the consistency of the effect of study-group assignment on total mortality and the primary outcome among prespecified subgroups using statistical tests of interaction between the treatment effect and the subgroup within the Cox model. We report all nominal P values, unadjusted for the multiplicity associated with the various tests performed for this study or monitoring of the primary and mortality end points by the data and safety monitoring committee. Since we conducted 15 statistical tests of hypotheses related to secondary end points and subgroups, there was a 54% chance (i.e., 1−[1−0.05]15) that at least one of these tests would be statistically significant at an alpha level of 0.05, assuming independence between tests.
Post hoc exploratory analyses to identify factors associated with higher mortality in the intensive-therapy group examined baseline characteristics, hypoglycemic events, risk factors for hypoglycemic events, single medications prescribed, combinations of medications prescribed, cointerventions, changes in weight, achieved blood pressure, achieved glycated hemoglobin levels, and occurrence of a cardiovascular event during follow-up. Detailed analyses of these and other potential causal factors or mechanisms will be reported separately.
Results
Patients
A total of 10,251 men and women with a mean (±SD) age of 62.2±6.8 years and a median glycated hemoglobin level of 8.1% (interquartile range, 7.6 to 8.9) were randomly assigned to either the intensive-therapy group or the standard-therapy group (see the figure in the Supplementary Appendix, available with the full text of this article at www.nejm.org). Approximately 38% of the entire cohort of patients were women. Recruitment occurred in two phases: 1174 patients were recruited during a 20-week period from January to June 2001, and 9077 patients were recruited from February 2003 to October 2005.14 Key baseline characteristics were similar in the two study groups (Table 1Table 1
Characteristics of the Patients at Baseline.). The mean duration of follow-up at the time the data and safety monitoring committee recommended the discontinuation of the intensive regimen was 3.5 years (median, 3.4).The two therapeutic strategies rapidly achieved different glycated hemoglobin levels (Figure 1Figure 1
Median Glycated Hemoglobin Levels at Each Study Visit.). Within 4 months after randomization, the median glycated hemoglobin level had fallen from 8.1% at baseline to 6.7% (interquartile range, 6.2 to 7.2) in the intensive-therapy group and to 7.5% (interquartile range, 7.0 to 8.2) in the standard-therapy group. Stable median levels of 6.4% (interquartile range, 6.1 to 7.0) and 7.5% (interquartile range, 7.0 to 8.1), respectively, were achieved in the two groups at 1 year and were maintained throughout the follow-up period.The lower glycated hemoglobin levels in the intensive-therapy group were associated with a greater exposure to drugs from every class (Table 2Table 2
Prescribed Glucose-Lowering Drugs.). There were also more frequent changes in the dose or the number of drugs used. The glucose-lowering regimen was modified by adding or removing a drug or by increasing or decreasing the dose of an oral agent or insulin (by ≥10% of the previous dose) a mean number of 4.4 times per year in the intensive-therapy group and 2.0 times per year in the standard-therapy group.As compared with the standard-therapy group, the intensive-therapy group had significantly higher rates of hypoglycemia, weight gain, and fluid retention (Table 3Table 3
Adverse Events, Clinical Measures, Tobacco Use, and Use of Nonglycemic Medication after Randomization.). The annualized rate of hypoglycemic episodes requiring medical assistance was 3.1% in the intensive-therapy group and 1.0% in the standard-therapy group, and the mean weight gain at 3 years was 3.5 kg and 0.4 kg in the two groups, respectively. One death in each group was classified as probably related to hypoglycemia, according to the adjudicated analysis of causes of death. Patients in the two groups had similar exposure to cardiovascular protective interventions and had similar changes in nonglycemic characteristics associated with cardiovascular events (Table 3). Significantly fewer patients in the intensive-therapy group received an angiotensin-converting–enzyme inhibitor than in the standard-therapy group (69.7% vs. 71.9%, P=0.02). However, blood-pressure levels were slightly lower in the intensive-therapy group.During the intervention period, the primary composite outcome of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes occurred in 723 patients, and there were 460 deaths from any cause. In the data reviewed by the data and safety monitoring committee, vital status was ascertained in 97.8% of patients within the previous 12 months; 50 patients (0.5%, including 26 patients in the intensive-therapy group and 24 in the standard-therapy group) were lost to follow-up, and 162 patients (1.6%, including 84 in the intensive-therapy group and 78 in the standard-therapy group) withdrew consent. The mean follow-up time for patients who either withdrew consent or were lost to follow-up was 1.2 years in the intensive-therapy group and 1.0 year in the standard-therapy group (P=0.22). There were fewer occurrences of the composite primary outcome in the intensive-therapy group, with rates of the primary outcome beginning to separate in the two study groups after 3 years (Table 4Table 4
Primary and Secondary Outcomes. and Figure 2AFigure 2Kaplan–Meier Curves for the Primary Outcome and Death from Any Cause.). This trend was not significant, with rates of 6.9% in the intensive-therapy group and 7.2% in the standard-therapy group (hazard ratio, 0.90; 95% confidence interval [CI], 0.78 to 1.04; P=0.16). In the intensive-therapy group, the rate of nonfatal myocardial infarction was lower than in the standard-therapy group (3.6% vs. 4.6%; hazard ratio, 0.76; 95% CI, 0.62 to 0.92; P=0.004), and the rate of death from cardiovascular causes was higher (2.6% vs. 1.8%; hazard ratio, 1.35; 95% CI, 1.04 to 1.76; P=0.02); there was no significant difference in the rate of nonfatal stroke (1.3% vs. 1.2%; hazard ratio, 1.06; 95% CI, 0.75 to 1.50; P=0.74).The rate of death from any cause was higher in the intensive-therapy group than in the standard-therapy group (5.0% vs. 4.0%; hazard ratio, 1.22; 95% CI, 1.01 to 1.46; P=0.04). In sensitivity analyses of the Cox model for death from any cause that included variables as stratifying factors rather than as covariates, the estimated hazard ratio for mortality in the intensive-therapy group, as compared with that in the standard-therapy group, was stable to the second decimal place. Rates of death in the two study groups began to separate after 1 year, and the differences persisted throughout the follow-up period (Figure 2B). The effect on mortality was consistent within the subgroups with no evidence of heterogeneity (Figure 3Figure 3
Hazard Ratios for the Primary Outcome and Death from Any Cause in Prespecified Subgroups.) and persisted in models adjusting for differences in the receipt of medications for blood pressure and lipids.For the primary outcome, there was some evidence of heterogeneity among prespecified subgroups, which suggested that patients in the intensive-therapy group who had not had a cardiovascular event before randomization (P for interaction=0.04) or whose baseline glycated hemoglobin level was 8.0% or less (P for interaction=0.03) may have had fewer fatal or nonfatal cardiovascular events than did patients in the standard-therapy group (Figure 3). Preliminary nonprespecified exploratory analyses of episodes of severe hypoglycemia after randomization and differences in the use of drugs (including rosiglitazone), weight change, and other factors did not identify an explanation for the mortality finding.
Discussion
We conducted this study because previous clinical trials had not established the effects of intensive glucose lowering on cardiovascular events or mortality in patients with type 2 diabetes mellitus. For example, in the United Kingdom Prospective Diabetes Study,15 an intensive glucose-lowering regimen significantly reduced a composite outcome of seven diabetes-related events, as compared with conventional therapy. However, the effects on cardiovascular events and mortality were not significant. Conversely, in the Veterans Affairs Diabetes Feasibility Trial,16 intensive glucose lowering was associated with a nonsignificant increase in cardiovascular events and no difference in mortality, and in the University Group Diabetes Program,17,18 the group that received a sulfonylurea (tolbutamide) had higher mortality.
Our findings indicate that a comprehensive, customized, therapeutic strategy targeting glycated hemoglobin levels below 6.0% increased the rate of death from any cause after a mean of 3.5 years, as compared with a strategy targeting levels of 7.0 to 7.9% in patients with a median glycated hemoglobin level of 8.1% and either previous cardiovascular events or multiple cardiovascular risk factors. Patients in both groups had lower mortality than reported in epidemiologic studies of similar patients.19,20 However, as compared with the standard-therapy group, the intensive-therapy group had a relative increase in mortality of 22% and an absolute increase of 1.0% during this follow-up period, with similar differences in death from cardiovascular causes. This increase in mortality is equivalent to one extra death for every 95 patients who were treated for 3.5 years.
This study was not designed to test the components of the intervention strategy. Analyses that we have performed to date have not identified any clear explanation for this higher mortality. In the intensive-therapy group, a median glycated hemoglobin level of 6.4% was rapidly achieved and maintained by a combination of behavioral and pharmacologic approaches. The standard-therapy group had fewer study visits and used fewer drugs and drug combinations. Thus, the higher rate of death in the intensive-therapy group may be related to factors associated with the various strategies. These factors include but are not limited to differences in the achieved glycated hemoglobin level of 6.4% in the intensive-therapy group, as compared with 7.5% in the standard-therapy group; in the magnitude of the reduction in glycated hemoglobin levels in the two study groups; in the speed of the reduction in glycated hemoglobin levels, with reductions of approximately 1.4% in the intensive-therapy group and 0.6% in the standard-therapy group within the first 4 months after randomization; in changes in drug regimens and in the rate of hypoglycemia; in adverse effects due to an undetected interaction of the various drug classes used at high doses; or in some combination of these or many other possibilities, perhaps in combination with the clinical characteristics of the patients in the study.
Differences in mortality emerged 1 year to 2 years after randomization. It is notable that after about 3 years, a nonsignificant decrease in the rate of the primary outcome emerged in the intensive-therapy group (Figure 2A), due to significantly fewer nonfatal myocardial infarctions, despite more deaths from cardiovascular causes and a similar number of strokes (Table 4). These patterns with respect to mortality and the primary outcome suggest that if there is any benefit associated with intensive glucose lowering, it may take several years to emerge, during which time there is an increased risk of death. This intriguing possibility can be answered only by further research.
The strengths of our study include the random assignment of patients to study groups and follow-up of a large number of high-risk patients according to a common protocol, a high rate of follow-up, achievement and maintenance of an absolute difference in glycated hemoglobin levels of 1.1% for 3.5 years, implementation within clinics that routinely treat patients in the community, adjudication of outcomes by a committee unaware of study-group assignment, a factorial design in which blood-pressure and lipid interventions continue to be tested, and safety auditing by an independent committee. However, our study did not address the risks and benefits of various approaches to lowering glycated hemoglobin levels (including what rate of glucose lowering is optimal), the prevention of increased glycated hemoglobin levels in patients with type 2 diabetes mellitus who have glycated hemoglobin levels below 7.5%, the prevention of diabetes altogether, and the lowering of glycated hemoglobin levels in people who do not have cardiovascular disease or additional cardiovascular risk factors. Indeed, the suggestion of a greater benefit in the primary outcome for patients with a lower glycated hemoglobin level or those without cardiovascular disease raises the possibility that certain subgroups of patients may benefit from intensive glucose lowering. However, our study was not designed to test these possibilities. Finally, glucose-lowering strategies were adjusted for each patient in an open fashion on the basis of their study-group assignment, their subsequent glycemic response to a drug or drug combination, and the development of clinical symptoms, such as hypoglycemia. This linkage of the study-group assignment to post-randomization exposures means that analyses to discern which aspects of the therapeutic strategy contributed to the observed outcomes were unlikely to clearly identify or exclude a cause. Thus, nonprespecified analyses of possible causes of the higher mortality in the intensive-therapy group can be only exploratory and require prospective testing.
Follow-up of the patients after they were switched from intensive therapy to standard therapy may provide crucial information regarding the long-term rates of death and cardiovascular events after a 3.5-year period of intensive therapy. Other trials investigating the long-term outcome of intensive glucose lowering21-25 will report the effect of a variety of therapeutic approaches on mortality and cardiovascular events in patients with type 2 diabetes mellitus and a range of clinical characteristics. Regardless of the results of these other trials, our study has identified a previously unrecognized harm of intensive glucose lowering in high-risk patients with type 2 diabetes mellitus and high glycated hemoglobin levels. This harm may be due either to the approach used for rapidly lowering glycated hemoglobin levels or to the levels that were achieved. Our findings highlight the importance of conducting trials with sufficient statistical power to assess commonly used approaches on clinically relevant outcomes.
Supported by grants (N01-HC-95178, N01-HC-95179, N01-HC-95180, N01-HC-95181, N01-HC-95182, N01-HC-95183, N01-HC-95184, IAA-Y1-HC-9035, and IAA-Y1-HC-1010) from the National Heart, Lung, and Blood Institute; by other components of the National Institutes of Health, including the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Aging, and the National Eye Institute; by the Centers for Disease Control and Prevention; and by General Clinical Research Centers. The following companies provided study medications, equipment, or supplies: Abbott Laboratories, Amylin Pharmaceutical, AstraZeneca, Bayer HealthCare, Closer Healthcare, GlaxoSmithKline, King Pharmaceuticals, Merck, Novartis, Novo Nordisk, Omron Healthcare, Sanofi-Aventis, and Schering-Plough.
Dr. Gerstein reports receiving consulting fees from Sanofi-Aventis, GlaxoSmithKline, Merck, Abbott, Novo Nordisk, Novartis, and Lilly, lecture fees from Sanofi-Aventis, GlaxoSmithKline, Merck, and Lilly, and grant support from Sanofi-Aventis, GlaxoSmithKline, King, and Merck and holding a patent that is completely assigned to Sanofi-Aventis, for which he receives no royalties or benefit; Dr. Goff, receiving grant support from Merck; Dr. Bigger, receiving grant support from McMaster University; Dr. Buse, having an equity interest in Insulet, MicroIslet, and dLife and receiving grant support from Bristol-Myers Squibb, Novartis, Pfizer, Novo Nordisk, Amylin, Eli Lilly, and Medtronic; Dr. Cushman, receiving consulting fees from Novartis, King, Takeda, and Sanofi-Aventis, lecture fees from Novartis, and grant support from Novartis, Hamilton Health, and Abbott; Dr. Genuth, receiving consulting fees from Merck, Mannkind, Sanofi-Aventis, and Novartis and lecture fees from Lilly and having an equity interest in Bristol-Myers Squibb; Dr. Grimm, receiving lecture fees from Merck, Pfizer, and Novartis; and Dr. Probstfield, receiving consulting fees from King and grant support from King and Sanofi-Aventis. No other potential conflict of interest relevant to this article was reported.
This article (10.1056/NEJMoa0802743) was published at www.nejm.org on June 6, 2008.
Source Information
The members of the writing group (Hertzel C. Gerstein, M.D., M.Sc., McMaster University and Hamilton Health Sciences, Population Health Research Institute, Hamilton, ON, Canada; Michael E. Miller, Ph.D., Robert P. Byington, Ph.D., and David C. Goff, Jr., M.D., Ph.D., Wake Forest University School of Medicine, Winston-Salem, NC; J. Thomas Bigger, M.D., Columbia University College of Physicians and Surgeons, New York; John B. Buse, M.D., Ph.D., University of North Carolina School of Medicine, Chapel Hill; William C. Cushman, M.D., Memphis Veterans Affairs Medical Center, Memphis, TN; Saul Genuth, M.D., and Faramarz Ismail-Beigi, M.D., Ph.D., Case Western Reserve University, Cleveland; Richard H. Grimm, Jr., M.D., Ph.D., Berman Center for Outcomes and Clinical Research, Minneapolis; Jeffrey L. Probstfield, M.D., University of Washington, Seattle; Denise G. Simons-Morton, M.D., Ph.D., National Heart, Lung, and Blood Institute, Bethesda, MD; and William T. Friedewald, M.D., Columbia University Mailman School of Public Health, New York) assume responsibility for the overall content and integrity of this article.
Address reprint requests to Dr. Byington at the Division of Public Health Sciences, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, or at bbyingto@wfubmc.edu.
Members of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group are listed in the Appendix.
Appendix
Members of the ACCORD data and safety monitoring committee were A.M. Gotto (chair), K. Bailey, D. Gohdes, S. Haffner, R. Hiss, K. Jamerson, K. Lee, D. Nathan, J. Sowers, L. Walters. Members of the ACCORD study group were as follows: Steering Committee: W.T. Friedewald (chair), J.B. Buse (vice chair), J.T. Bigger, R.P. Byington, W.C. Cushman, H.C. Gerstein, H.N. Ginsberg, D.C. Goff, Jr., R.H. Grimm, Jr., F. Ismail-Beigi, J.L. Probstfield, D.G. Simons-Morton. Asterisks denote persons who are no longer affiliated with the study unit, and daggers persons who are deceased. Clinical Center Networks and Clinical Sites — Canada: Population Health Research Institute, Hamilton General Hospital, Canadian Diabetes Outcome Researchers, Hamilton, ON: H.C. Gerstein, S. Yusuf, Z. Punthakee, R. Russo, S. Anand, B. Cracknell, T. Cukierman-Yaffe, A. Gafni, G. Guyatt,* S. Hall, J. Kaszyca, E. Lonn,* D. McLeod, K. Read,* V. Reiding, N. Shehadeh,* B. Tadeson,* K. Thompson,* M. Vallis, V. Vasudeva, I. Wilderman.* Canadian Clinical Sites: McMaster Medical Centre, Hamilton, ON: Z. Punthakee, A. Smith, I. Stanton, S. Capes,* S. Danby, W. Harper, P. Harvey, D. Hunt, P. Manjoo,* A. Moroso, R. Otto, A. Prebtani, T. Valla. Six Nations Health Services, Ohsweken, ON: Z. Punthakee, A. Davis, S. Capes,* K.L. Hill, V. McCarthy. Diabetes, Hypertension and Cholesterol Centre, University of Calgary, Calgary, AB: A.L. Edwards, D.J. Mitchell, M.A. Clearwaters, C. Dielissen, M. Gillam, B. Hammond,* H. Jensen,* A. Kherani, D. Lau, V. Pringle, D. Rabi, R. Sigal, C. Smith,* M. Walker,* G. Williams.* Memorial University of Newfoundland, St. John's: C. Joyce, M. Parsons, B. Rowe, J. Burton,* V. Chandurkar, S. Coady-McDonald,* D. Gibbons,* C. Kovacs, B. Murphy, R. Smart, S. Varghese. University of Alberta, Edmonton: L. Mereu, E. Ryan, P. Senior, P. Kirkland, J. Abe,* K. Dalton, W. Gendall, J. Germsheid,* D. Hartman,* A. Jeffrys,* C. MacDonald, N. Makhani, S. Mawani,* F. Morales, B. Paty,* M. Pick,* B. Schwanke, A. Stark, M. Tennant, S. Varma,* P. Werbiski-Wood, B. Woloschuk, W. Zimmerman.* Centre de Recherche Clinique de Laval, Laval, QC: A. Bélanger, S. Gauthier, G. Bahsali, C. Barbeau, E. Caponi, R. Duchesne,* R. Dumas, P. Gauthier, J. Girouard, N. Kandalaft, M. Labbé, J. Palardy, M. Pilon, J. Raymond, A. Schiffrin. St. Joseph's Health Care London, London, ON: I. Hramiak, S. Tereschyn, M. Driscoll, M. Gehring, J. Gonder, C. Lincoln, W. McBeth, C. McDonald, T. McDonald,* P. Pauli,* T. Paul, S. Powers,* N. Ronald, V. Trinh, L. Vancer, G. Walsh.* Ottawa Hospital, Division of Endocrinology and Metabolism, Ottawa: H. Lochnan, T.C. Ooi, J. Maranger, R. Bate,* L. Bradley,* R. Buhrmann, M. Cyr,* C. Gilchrist, B. Hanlon, M. Harley, K. Jay,* T. Leech, J. Malcolm, M. McLean,* E. Parker, R. Sigal,* K. Sullivan. Royal Victoria Hospital, Montreal: J.F. Yale, S.A. Segal, N. Renouf, N. Allaire,* M.A.M.A. Alawadhi,* B. Belfer,* D.W. Blank, F. Bouchard, S. Buoy-Phang,* J. Carter, L. Coppin,* D. Dalpe,* I. Delpech,* P.M. Doran, F. Emmian,* S. Fortin,* N. Garfield, M. Gosselin,* S. Horan,* M. Kalergis,* S. Koutelias,* C. Légaré, A. Lombardo, J.A. Morais, M. Quigley, N. Renouf, C. Riopel,* S. Riopel, J.A. Rivera, G. Rochon,* M. Roy, M. Salera,* M.H. Sherman, M. Shingler, H.E. Staples,* L. Ulyatt,* Z. Yared.* St. Michael's Hospital, Toronto: L.A. Leiter, G. Booth, L. Sparrow, H. Choi, D.C. Bedard, A. Berger, L.A. Berndl, A. Cheng,* V. Evalmplev,* J. Goguen, A. Hanna, R.G. Josse, J.A. Kalas, S. Perry, M. Pike.* Vancouver General Hospital, Vancouver, BC: T. Elliott, K. Dawson, J. Kong, M. Inducil, R. Al Amoudi,* T. Broughton,* L. Hall,* B. Harrison,* N. Hirvi,* R. Lee,* E. Norman,* B. Paty, M. Potter, D. Stevenson, A. Vafadaran. Health Sciences Centre Diabetes Research Group, Winnipeg, MB: V. Woo, L. Berard, T. Anderlic, K. Austman, A. Bernard, D. Catte,* P. Darvill, D. Hak, K. Hutchison, L. Janzen, T. Klopak, C. Mandock, M. Mathen, S. Mawani,* A. Mawani,* L. Murphy,* G. Nyomba, B. Penner, S. Pockett, S. Russell, F. Stockl, J. Studney,* R. Sukkau. Queen Elizabeth II Health Sciences Centre, Halifax, NS: C. Abbott, E. Ur, M. Yuille, M. Archibald,* A. Cruess, N. Davis, H. Fong,* S. Frizzell,* B. Hanway,* A. Hoskin-Mott, A. Imran, C. Ingraham,* G. McCarthy, H. Murdock,* T. Palmer, A.M. Patterson,* T. Ransom, D. Shu,* J. Tuttle. Western Clinical Center Network: University of Washington, Seattle: J.L. Probstfield, C. Kingry, A.S. Line, M.A. Corson, R. Knopp, E. Lipkin, M.D. Sullivan, J. Johnson, C. Griswold, K. Liebert, A. Brown,* D. Juliano,* E.M. Kurashige,* S. Moberg.* Western Clinical Sites: Northridge Hospital Medical Center, Cardiovascular Center, Northridge, CA: K. Ariani, K. Karunaratne, M. Azizad, C. Chow, H. Gutierrez, J. Partamian, J. Toven, J. Mular,* S. Sanders.* White Memorial Medical Center, Clinical Hypertension Services, Los Angeles: L.J. Haywood, V. Kamdar, D.L. DeQuattro, L. Wang, Z. Song, C. Miller, L. Becerra, A. Qi Cai, C. Pruitt, V. DeQuattro.† University of Washington Medical Center at Roosevelt, Family Medical Center, Seattle: R. Failor, A. Ellsworth, N. Jackson, C. Miller, D. Britt, S. Dobie, I. Hirsch, D. Khakpour, R. Quaempts, W. Stoffel, T. Wilcox, W. Neighbor,* K. Cappocia.* Idaho State University, Department of Family Medicine, Pocatello: R. Force, M. Macdonald, S. Lusk, C. Liday, E. Borzadek, S. Koester, T. Pettinger, R. Solbrig, C. Waldron, K. Pettingill,* W. Woodhouse,* B. Hoover.* Naval Medical Center San Diego, Cardiology Division, San Diego, CA: P.E. Linz, P.V. Pepper, J. Kozlowski, C. Chase, D. Samuelson, P. Gutierrez, C. Gonzales, M. Engle,* J. Coopersmith,* S. Griffin,* R. Lammers,* J. Leon.* Oregon Health & Science University, Section of Diabetes, Portland: M.C. Riddle, K.A. Hanavan, P.A. McDaniel, R. Swift, A.J. Ahmann, S.C. Gammell-Matthews, D.M. Karl, V. Burden, B. MacNeil, M. MacMurray, J. Weiss, C. Carlson,* S.K. DesRochers,* D. Negreanu,* E.A. Stephens.* Washington State University, Spokane: C. Wysham, D. Weeks, L. Kuntsmann, L. Maxwell, S. Yedinak, H. Pena,* J. White.* Kaiser Endocrine Clinic, San Diego, CA: J. Dudl, L. Lyons, B. House, M. Murray, P. Wu, A. Palma, S. Briere, T. Wilson, D. Becker,* K. Harden,* C. Hawley,* R. Stevenson.* Whittier Institute for Diabetes, Clinical Trials Department, La Jolla, CA: G. Dailey, M. Baron, A. Gianella, M. Jacobson, E. Farro, A. Philis-Tsimikas, A. Banares, A. Bravo-Medina, J. Horne,* E. Esquer,* R. Morrissey.* Minnesota–Iowa Clinical Center Network: Berman Center for Outcomes and Clinical Research, Minneapolis: R.H. Grimm, Jr., B.R. Kirpach, M.M. Bartkoske, C.M. Boyce,* N. Druckman,* A.M. Gillett,* J.A. Levin, G.J. Livingston, A.M. Murray, H. Wood,* HealthPartners Research Foundation, Minneapolis: K.L. Margolis. Minnesota–Iowa Clinical Sites: Berman Center Clinic, Minneapolis: S. Kempainen, M. Madden, M. Tariq Fareed,* K. Hall,* R. Moor, K. Wood. International Diabetes Center, Minneapolis: R. Bergenstal, R. Cuddihy, B. Davick, J. Hokanson,* M. Johnson, D. Kendall,* M. Lausch, S. List, A. Monk, R. Robinson,* K. Smith,* D. Whipple, G. Damberg, R. Hahn,* V. Koenig, M. Magadan, S. Sabin-Smith,* P. Stewart, E. Strock, D. Peremislov, K. Gunyou, R. Passi. University of Minnesota, Minneapolis: E.R. Seaquist, M.V. Mech, L.E. Benedict,* D.J. Demmon,* A.F. Kumar, S.M. Martinson,* S.A. Miller, C. Pease,* J.P. Rao,* J.B. Redmon, J.E. Swanson,† J.K. Wimmer.* University of Minnesota, Phalen Village Clinic, St. Paul: K. Peterson, L.A. Seaquist, C. Boese,* M. Cruciani, E. Dodds, F. Parenteau Ek,* J.L. Feldman, P. Fontaine, C.J. Lange, T.J. Mendenhall,* A.M. Peterson, A. Rudelt, T.M. Schrock,* D.P. Spielman,* S. Velasco,* J.C. Weinhandl. Riverside Health Partners Clinic, Department of Endocrinology, Minneapolis: J.M. Sperl-Hillen, P.J. O'Connor, M.E. Busch, A. Chung, B.K. Klein, N. Krugen, T. Bunkers-Lawson,* H.L. Ekstrom,* H.S. Gunderson,* B.M. Johnson,* J.H. MacIndoe,* D.J. Prewedo,* J.L. Rawl,* C.M. Roethke,* Mary Spencer. University of Iowa, Health Care Diabetes Clinical Research and Programs, Iowa City: W.I. Sivitz, S.M. Wayson, T.A. Lower,* L. Larson, L.A. Ahrens,* M. Bayless, S.E. Beck,* J. Chahal, C. Chenard, G.C. Doelle, V.M. Guzman, U.M. Kabadi,* K.A. Ochs,* A. Rahhal, R.G. Spanheimer,* L. Snetselaar,* K. Smith,* D. Wells. Ohio–Michigan Clinical Center Network: Case Western Reserve University, Division of Clinical and Molecular Endocrinology, Cleveland: F. Ismail-Beigi, S. Genuth, M. Thibonnier,* L. Vargo,* C. Kelly,* T. Bongorno,* A. Dolish,* L. Pavlik, M. Tiktin, S. Isteitieh. Ohio–Michigan Clinical Sites: University Hospitals of Cleveland, Division of Endocrinology, and University Hospitals Westlake Medical, Cleveland: F. Ismail-Beigi, A. Krikorian, L. Moore, L. Richardson, E. Coles-Herman, K. Yee, J. Frankino, M. Jing, A. Sood, L. Hustak,* M. Julius,* L. Pavlik,* T. Ross,* L. Long,* W. Schwing,* M. Tiktin,* M.K. Sullivan,* L. Strauss,* K. Behm,* F. Eskandari,* C. Hall,* D. Hayes,* K. Horowitz, S. Isteitieh,* Z. Madhun,* E. Seeholzer,* J. Shina,* H. Taylor,* A. Schnall,* S. Huang, M. Heeg, J. Tang, J. Belkin,* M.S. Lee,* T. Joly.* St. Vincent Charity Hospital, Lipid Research Center, Cleveland: L.S. Sadler, M. Griffith,* A. Hornsby,* K. Klyn, E. Ospelt, L. Long, M. DeSmit,* P. McCann, N.P. Schmidt,* C. Gottfried, T. Kulow, J. Zaletal, M.S. Kapadia. University Suburban Health Center, South Euclid, OH: A.M. Schnall, L. Dragmen, R. Ellert,* J. Smith, J. Leksan, T. Sussman, S. Huang, M. Heeg, J. Tang, J. Belkin,* M.S. Lee,* T. Joly.* Cleveland Veterans Affairs (VA) Medical Center, Department of Medicine, and Ravenna Community Based Outpatient Clinic, Cleveland: F. Ismail-Beigi, L. Hustak, M. Julius,* W. Schwing, M. Tiktin,* J. Anselmo,* F. Eskandari,* S. Daeumeyer,* C. Hall, D. Hayes,* K. Horowitz, S. Isteitieh,* C. Johnson,* E. Kern, M.A. Richmond,* L. Richardson, K. Roberts,* J. Shina,* A. Sood, P. Suhan,* H. Taylor, S. Watts,* J. Martin, L. Moore,* B. Burtch,* S. Ober, G.J. Strauss, A. Leone, J. Belkin,* S. Huang,* K. Frank,* D. Stephens,* M.S. Lee,* T. Joly.* The Cleveland Clinic Foundation, Cleveland: B.J. Hoogwerf, J. Brakeman, M. Matzinger,* J. Newsome,* J. Becker,* S. Bizjack,* B. Clingman,* S. Curtas, G. Depietro,* R. Ellert,* C. Horner, G. Bunae,* A. Hamrahian,* A. Hawkins, T. Head, S. Iannica, L. Jones, P. Kaiser, R. McCoy, A. Mehta, L. Olansky, A. Orasko, S. Reddy,* D. Ross,* L. Shockley,* E. Siraj,* M. Williams,* R. Zimmerman. Your Diabetes Endocrine Nutrition Group, Mentor, OH: D. Weiss, K.A. Fagan, T.M. Hanslik, J. Farrell, P. Brys, M. Oligny, K. Prokop, K. Lenardic, T. Karapanzcik, S. Huang, M. Heeg, J. Tang, J. Belkin,* M.S. Lee,* T. Joly.* Medical University of Ohio, Department of Medicine, Ruppert Health Center, Toledo: B. Akpunonu, R. Franco-Saenz,† J. Gilmore, M. Gilmore, L. Godfrey, P. Ross, B. Bauer, M. Chrisstie,* A. Lopez, P. Mulrow, C. Peters,* R. Pop-Busui,* J. Roman,* C. Smith,* J. Bick,* Z. Blust,* P.T. Nelsen, D. Marcus.* The Ohio State University Medical Center, Division of Endocrinology, Diabetes and Metabolism, Columbus: K. Osei, E.A. Dziengelewski,* H. Breedlove, D. Boland,* C. Casey Boyer, S. Cataland, P.A. Green, J.E. Irwin, D.P. Schuster, J.L. Varga-Spangler, T. Bowles, K. Weiland, K. Arnold, T. Evans,* J. Bouttamy, A. Letson, E. Craig, F. Davidorf. University of Cincinnati/VA Medical Center, Research Service, Cincinnati: R.M. Cohen, K. Burton, J. Craig, B. Carter,* J. Harrer,* R. Hurd,* D. Lopez-Stickney,* C. Pritchard,* A. Pfefferman,* B.A. Ramlo-Halsted,* C. McCormick, C. Riley, M. Strominger,* A. Knittel, G. Groff, C. Bailey, A. Howald, N. Anderson, J. Laver Bierschbach, M. Tyzinski,* B. Smith,* S. Krug, V. Hershberger,* R.K. Hutchins,* L.A. Raymond.* Henry Ford Health System–New Center One, Detroit: D.M. Kahkonen,* T. Cushman, M. Roman, A.M. Stys, A. Thomas, K. White, M. Austin,* C. Chatterton, J.K. Francis,* C. Jones,* D. Kruger, A. McLellan,* F. Whitehouse, E. Higgins,* S. Levy, A. Schoenherr,* P. Edwards. Grunberger Diabetes Institute, Bloomfield Hills, MI: G. Grunberger, L.C. Aman,* A.H. Bandagi,* K.M. Russell, C. Tucker, Y. Abidova, A. Amirikia. Northeastern Clinical Center Network: Columbia University College of Physicians and Surgeons, New York: J.T. Bigger, C.R. Lopez-Jimenez, R. Bornholdt, L. Busacca, H.N. Ginsberg, P. Gonzales, D. Gosh,* P. Love,† A. Kosok,* E. Robinson,* R. Steinman, C. Watson, G. Reyes. Northeastern Clinical Sites: Jacobi Medical Center, Bronx, NY: U.K. Schubart, M. Mendoza, G. Goswami, A. Laufer,* J. Russo, N. Vincenty. Albert Einstein General Clinical Research Center, Bronx, NY: M.H. Alderman, L. Carroll, M.J. Sanguily, J.U. Gorkin, A.C. Mayer, L. Ramos, V. Sessoms, A. Fritts Stewart.* Cornell Internal Medicine Associates, New York: D. Brillon, J. Cordero, M.A. Richardson, E. Wei, F. Ganz, B.R. Meyer, J. Paley,* S. Anderson,* C. Charles,* A. Dwoskin,* R. Chiong, K. Hyams. The Diabetes Care and Information Center of New York, Flushing: D.L. Lorber, T. Arenstein, P. Depree, A.A. Elmorsy,* J.M. Wendel, L.L. Zintl, P. August, M. Beck,* M.D. Goldberg, M.J. Hofacker,* M. Marotta-Kollarus,* E.J.L. Ocampo, C.A. Resta, J.M. Tibaldi. The Cooper Health System, Cherry Hill, NJ: A. Bastien,* S. Grudzinski, P. Niblack, L. Abreu, T. Brobyn, K. Brown,* M. Casale,* D. Dougherty,* G. Haddad, K. Heintz, M. Kelly,* D. Linneman,* C. Olivia, M.A. Salvador,* P. Zee,* D. Hyman. Great Lakes Medical Clinic Research, Westfield, NY: D.F. Brautigam, R. Fischer, J.M. Chiarot, D.M. Scharf, B. Nunn,* J. Carlson, C. Flanders,* M.R. Hagen, S. Newman, T.A. Gordon. Naomi Berrie Diabetes Center, New York: R. Goland, C.H. Tuck,† P. Kringas, J. Hey-Hadavi,* J. Montes,* J. Vargas-Jerez, J. Salas-Spiegel. Ambulatory Care Network at Columbia University, New York: A. Getaneh, J. Ramirez,* E.F. Vasquez,* G. Kranwinkel. Irving Diabetes Research Unit, New York: D.S. Donovan, G. Febres,* C. Hernandez,* M.A. Jonaitis, L. Mesa. State University of New York Downstate Medical Center, Brooklyn: M.A. Banerji, M. Norton, P. Patel, V. Daly, S. Hirsch, C. Jazmin, R. Khillan, D. Mendonca, A. Relingado, E. Sandoval, M. Tiewala. Kings County, Brooklyn, NY: M.A. Banerji, M. Norton, P. Patel, V. Daly, S. Hirsch, C. Jazmin, R. Khillan, D. Mendonca, A. Relingado, E. Sandoval, M. Tiewala. Southeastern Clinical Center Network: Wake Forest University School of Medicine, Department of Public Health Sciences, Winston-Salem, NC: D.C. Goff, Jr., J.H. Summerson, L. Crago, C.S. Blackwell,* A. Bertoni,* R.L. Blaine, J.K. Kirk, R.L. Spach, J. Williamson, J. Calles, J. Katula, D.B. Wishnietsky.* Southeastern Clinical Sites: Duke University Medical Center, Durham, NC: M.N. Feinglos, J. Jones, M.B. Mason, M.A. Furst, W.J. Bean,* G. Gedon-Lipscomb, J.B. Green, T. Parham,* B.M. Satterwhite,* C.R. Thacker. Constant Care, Inc., Valdosta, GA: D. Padhiar, R. Noel,* N. Padhiar, S. West,* J. Braden, A. Francis.* Wake Forest University School of Medicine, Department of Geriatrics/Gerontology, Winston-Salem, NC: H.H. Atkinson, M. Dibari,* J. Allen, J. Stanfield, T. Delvalle-Fagan, L.J. Gordineer, L. Gordon, M. Gordon,* S.L. Smith,* H. Yates.* Downtown Health Plaza, Winston-Salem, NC: C.F. Pedley, G. Zurek, M. Baird, B. Dunn,* W. Kinder,* S. Mauney. University of North Carolina, Diabetes Care Center, Chapel Hill: J.B. Buse, M.D. Duclos, R.E. Kirby,* J.F. Largay, N.M. McDermott,* A. Goley, S.S. Braithwaite, M. Busby, J.M. Dostou, E.A. Fasy,* D.C. Kelly,* B. MacIntosh, C.E. Metz,* J. Jeffries, D. Rubin.* Holston Medical Group, Kingsport, TN: J.L. Miller, S.M. Norton, J. Weatherly,* S. Bishop,* B. Cross, K. Nuss, M. Surgenor, Y. Wood. Carolinas Medical Center Family Practice, Charlotte, NC: K. Andrews,* T. Barringer, C. Hoffman,* J. Konen,* C. Morris, P. Tochiki,* G. Reinblatt, P. Bruner.* Robeson Health Care Corporation, Fairmont Clinic, Fairmont, NC: R. Peace, D.O. Stuart,* J. Strickland, L. Cummings, D. Craig,* J. Stanfield.* Robeson Health Care, Julian T. Pierce Clinic, Pembroke, NC: R. Peace, D.O. Stuart,* J. Strickland, L. Cummings, D. Craig,* J. Stanfield.* Wake Forest University School of Medicine, Departments of Internal Medicine and Endocrinology, Winston-Salem, NC: J.R. Crouse, L. Menon, S. Marion,* D. Davis,* B. Cabrera,* J. Calles, T. Chandler, J. Ellis, E. Kouba, P. Riddle, E. Myers.* Tulane University Health Science Center, New Orleans: V. Fonseca, R.H. McDuffie, N.O. Asafu-Adjaye, S.M. Leger, P. Reilly, G. Afner, F. Arrey,* S. Asnani, E. Borshard,* D. Boyd,* A. Cemo, S. Chennur,* P. Dupart, R. Garg,* G.P. Girindra,* B. Gouda,* W. Itoua-N'Ganongo,* I. Innocent-Ituah,* C. Johnson,* N. Kuhadiya, M. Kukreja,* I. Mangan-Mbondi,* S. Mason,* C. McLain, J. Naylyanya,* K. Nazereth,* S. Nazereth,* S. Singh, T. Thethi, K. Varnado,* R. Williams.* Kaiser Permanente, Clinic Atlanta Crescent Medical Center, Tucker, GA: J.I. Barzilay, M. Eley,* K. Bader, D. Curry-Ball, S. Goodman,* M. Stevens. Veterans Affairs (VA) Clinical Center Network: Memphis VA Medical Center, Memphis, TN: W.C. Cushman, T.S. Geraci, S.M. Walsh, L.G. Coley, M.B. Elam, C.M. Huff, D.I. Pickering,* P. Massimino.* VA Clinical Sites: Memphis VA Medical Center, Hypertension/Lipid Research Clinic, Memphis, TN: M.B. Elam, C.W. Thompson, L. Lichtermann, S. Peeples, J. Turner-Bates,* M. Heimberg, D. Childress, S. Solomon, J. Turner, J. Jasper, R. Pfeifer, J. Coley. Baltimore VA Medical Center, Baltimore: B.P. Hamilton, J. Hamilton, G. Kuzbida, D. Bannerman-Wood,* W. Hatten, Jr., A. Lancaster, H. Jang. Carl T. Hayden VA Medical Center, Phoenix, AZ: J. Felicetta, M. Bourne-Collo, M.E. Svoboda, D. Clothier, M. Deitz,† C. Flaugher,* P. Hayward,* T. Scheibe,* D. Heritage,* S. Velarde, S. Heritage, J.P. Nelson. Atlanta VA Medical Service, Decatur, GA: M.E. Sweeney, D. Harrelson, S. McConnell, C.R. Rice,* F. Watson, R. Johnson, L. Whittington, M. Nanes, M. Salles. Ralph H. Johnson VA Medical Center, Primary Care, Charleston, SC: J. Basile, D.B. Ham, B. North-Lee, H.A. Baig, S.U. Rehman, J. Mixson, D. Nelson.* G.V. Montgomery VA Medical Center, Research Department, Jackson, MS: K.A. Kirchner, B.S. Ross, M. Kazi,* J. Subauste,* L.A. Hinton, L. Mack, B. James,* A. Spencer, L. Henegar,* A. Jones. VA NY Harbor Healthcare System, New York: L. Katz, E.A. Richardson, A.G. Goldberg,* A. Nieves, J.E. Russo,* S.A. Sochalski, D. Hoffman. Washington VA Medical Center, Washington, DC: V. Papademetriou, P. Narayan,* D. Wojciechowski, B. Gregory, R. Alignay,* E. Nylen, B. Rajendran, R. Hodges, A. Ross,* A. Notargiacomo.* St. Louis VA Medical Center, St. Louis: S. Giddings, E. Clark, A. Pittler, R. Davis, P. Harris, T. Hofmeister. Central Arkansas Clinic Healthcare System, Little Rock: D.L. Simmons, J.J. Cooper,* K. Dishongh,* P. Choksi,* S. Elbein, F. Faas, Z. Hamid, J. Johnson, A. Mayo,* M.S. Moriarty, D. Rani,* N. Rasouli, K. Watson, A. Makdissi. ACCORD Steering Committee Chair: W.T. Friedewald, Mailman School of Public Health and Columbia University College of Physicians and Surgeons, New York. Coordinating Center: Wake Forest University School of Medicine, Winston-Salem, NC: R.P. Byington, W.T. Ambrosius, R.T. Anderson,* J. Barnes, J. Beal, C. Bell, D.E. Bonds, S. Burton,* C. Collins, D. Cook, B. Craven, T. Craven, D. Dunbar, G.W. Evans, P. Feeney, C.D. Furberg, C.M. Greven, J. Griffin, L. Harvin, J. Hepler, L. Howard,* L.T. Howard-Perdue, M. Hough, W. Hwang, A. Kimel, D. Lefkowitz, A. Lopina,* J. Lovato, L.C. Lovato, M.E. Miller, D. Reboussin,* S. Rushing, L. Sanders, L. Sims, C. Stowe, M. Walkup,* S. Wilmoth, K. Wilson, N. Woolard. Drug Distribution Center: Albuquerque VA Medical Center, Albuquerque, NM: D. Raisch, R. Ringer, M. Sather, B. DelCurto, D. Garnand. ECG Reading Center: Wake Forest University School of Medicine, Winston-Salem, NC: R. Prineas, C. Campbell, Z. Zhang, L. Selph, S. Hall,* S. Hensley, Y. Li, M. Mills. Central Chemistry Laboratory: Northwest Lipid Research Laboratories, Seattle: S. Marcovina, J. Chmielewski, K. Gadbois, V. Gaur, G. Strylewicz, M. Ramirez, S. Waddell, M. Mehan.* ACCORD–MIND MRI Reading Center: University of Pennsylvania, Philadelphia: R.N. Bryan, C. Davatzkios, G. Moonis, L. Desiderio, S. D'Arcy.* Fundus Photograph Reading Center: University of Wisconsin Medical School, Madison: M. Davis, R. Danis, S. Johnson,* N. Robinson, L. Hubbard, B. Esser, D. Thayer, M. Neider, K. Glader, M. Burger. Project Office: National Heart, Lung, and Blood Institute, Bethesda, MD: D.G. Simons-Morton, L. Cooper,* M. Domanski, C. Nwachuku,* Y. Rosenberg, M. Salive,* P. Savage, J.L. Fleg, J.A. Cutler, N. Geller, D. Follmann,* M. Proschan,* C. Jennings, E. Schaeffer,* P. Mills,* J. Bittner,* R. Kirby, P. Frommer,† L. Fine, J. Chan. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD: J. Fradkin, S. Malozowski, C. Meyers, T. Hostetter.* National Institute on Aging, Bethesda, MD: L. Launer. National Eye Institute, Bethesda, MD: E.Y. Chew. Centers for Disease Control and Prevention, Atlanta: A. Albright, K.M.V. Narayan, M. Engelgau,* P. Zhang.
- References
References
1
Goff DC Jr ,Gerstein HC ,Ginsberg HN , et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:4i-20i
Web of Science | Medline2
Selvin E ,Marinopoulos S ,Berkenblit G , et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421-431
Web of Science | Medline3
Gerstein HC ,Pogue J ,Mann JF , et al. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 2005;48:1749-1755
CrossRef | Web of Science | Medline4
Stratton IM ,Adler AI ,Neil HA , et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412
CrossRef | Web of Science | Medline5
American Diabetes Association
CrossRef | Web of Science | Medline6
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee 7
Ryden L ,Standl E ,Bartnik M , et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 2007;28:88-136
CrossRef | Web of Science | Medline8
AACE Diabetes Mellitus Clinical Practice Guidelines Task Force
Medline9
Buse JB ,Bigger JT ,Byington RP , et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007;99:21i-33i
CrossRef | Web of Science | Medline10
Gerstein HC ,Riddle MC ,Kendall DM , et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:34i-43i
CrossRef | Web of Science | Medline11
Ginsberg HN ,Bonds DE ,Lovato LC , et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:56i-67i
CrossRef | Web of Science | Medline12
Bonds DE ,Kurashige EM ,Bergenstal R , et al. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:80i-89i
CrossRef | Web of Science | Medline13
ACCORD Web site. (Accessed May 19, 2008, at http://www.accordtrial.org.)
14
Kingry C ,Bastien A ,Booth G , et al. Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:68i-79i
CrossRef | Web of Science | Medline15
UK Prospective Diabetes Study (UKPDS) Group
CrossRef | Web of Science | Medline16
Abraira C ,Colwell JA ,Nuttall F , et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial: Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med 1997;157:181-188
CrossRef | Web of Science | Medline17
Meinert CL ,Knatterud GL ,Prout TE ,Klimt CR . A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970;19:Suppl:789-830
Web of Science | Medline18
Genuth S . Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus. Ann Intern Med 1996;124:104-109
Web of Science | Medline19
Booth GL ,Kapral MK ,Fung K ,Tu JV . Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006;368:29-36
CrossRef | Web of Science | Medline20
Thomas RJ ,Palumbo PJ ,Melton LJ III , et al. Trends in the mortality burden associated with diabetes mellitus: a population-based study in Rochester, Minn, 1970-1994. Arch Intern Med 2003;163:445-451
CrossRef | Web of Science | Medline21
Abraira C ,Duckworth W ,McCarren M , et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. J Diabetes Complications 2003;17:314-322
CrossRef | Web of Science | Medline22
Study rationale and design of ADVANCE: action in diabetes and vascular disease -- preterax and diamicron MR controlled evaluation. Diabetologia 2001;44:1118-1120
CrossRef | Web of Science | Medline23
Milicevic Z ,Raz I ,Strojek K , et al. Hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with Type 2 diabetes mellitus (HEART2D) Study design. J Diabetes Complications 2005;19:80-87
CrossRef | Web of Science | Medline24
ORIGIN Trial Investigators, Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J
Web of Science | Medline25
Magee MF ,Isley WL . Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol 2006;97:20G-30G
CrossRef | Web of Science | Medline
- Citing Articles (980)
Citing Articles
1
Véronique Kerlan, Bruno Vergès, Camille Tawil, Nora Lahrichi, Jean Doucet. (2012) Insulin initiation in elderly patients with type 2 diabetes in France: a subpopulation of the LIGHT Study. Current Medical Research and Opinion1-38
CrossRef2
Sophia Zoungas, John Chalmers. (2012) Diabetes: Glycemic control and outcomes in people with diabetes and CKD. Nature Reviews Nephrology
CrossRef3
C. R. Mikus, D. J. Oberlin, J. Libla, L. J. Boyle, J. P. Thyfault. (2012) Glycaemic control is improved by 7 days of aerobic exercise training in patients with type 2 diabetes. Diabetologia
CrossRef4
Katherine Esposito, Dario Giugliano. (2012) Current insulin analogues in the treatment of diabetes: emphasis on type 2 diabetes. Expert Opinion on Biological Therapy 12:2, 209-221
CrossRef5
Soo Lim, Martin K. Rutter. (2012) Unfavorable Effects of Intensive Glucose Lowering on Mortality: Lessons from the 5-Year Follow-up of the ACCORD Trial. Current Cardiovascular Risk Reports 6:1, 1-3
CrossRef6
P. A. Senior. (2012) Type 2 diabetes, metformin and lactic acidosis-defining the risk and promoting safe practice. Diabetic Medicine 29:2, 161-163
CrossRef7
A. Vaag, S. Lund. (2012) THERAPY OF ENDOCRINE DISEASE: Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues. European Journal of Endocrinology 166:2, 159-170
CrossRef8
Assam El-Osta. (2012) Glycemic memory. Current Opinion in Lipidology 23:1, 24-29
CrossRef9
C. Barrett Bowling, Ann M. O'Hare. (2012) Managing Older Adults With CKD: Individualized Versus Disease-Based Approaches. American Journal of Kidney Diseases 59:2, 293-302
CrossRef10
Q. Zhang, S. Rajagopalan, E. Marrett, M. J. Davies, L. Radican, S. S. Engel. (2012) Time to treatment initiation with oral antihyperglycaemic therapy in US patients with newly diagnosed type 2 diabetes. Diabetes, Obesity and Metabolism 14:2, 149-154
CrossRef11
Leon I. Igel, Amanda G. Powell, Caroline M. Apovian, Louis J. Aronne. (2012) Advances in Medical Therapy for Weight Loss and the Weight-Centric Management of Type 2 Diabetes Mellitus. Current Atherosclerosis Reports 14:1, 60-69
CrossRef12
Shuqian Liu, Yingnan Zhao, James M Hempe, Vivian Fonseca, Lizheng Shi. (2012) Economic burden of hypoglycemia in patients with Type 2 diabetes. Expert Review of Pharmacoeconomics & Outcomes Research 12:1, 47-51
CrossRef13
S. Leucht, S. Hierl, W. Kissling, M. Dold, J. M. Davis. (2012) Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. The British Journal of Psychiatry 200:2, 97-106
CrossRef14
Raimund I. Herzog, Robert S. Sherwin. (2012) Diabetes: Can tight glycemic control in diabetes benefit cognition?. Nature Reviews Neurology
CrossRef15
Ann V. Schwartz. (2012) Clinical Aspects of Diabetic Bone Disease: An Update. Clinical Reviews in Bone and Mineral Metabolism
CrossRef16
(2012) Panretinal Photocoagulation for Diabetic Retinopathy. New England Journal of Medicine 366:3, 277-279
Full Text17
H.M. Fischer, A. Charrier, R. Dörr, S.G. Spitzer. (2012) Ambulante Rehabilitation nach Herzinfarkt und bei Herzinsuffizienz. Herz
CrossRef18
Bernhard Ludvik, Guntram Schernthaner. (2012) Diabetes Care Austria 2009: Register an allgemeinmedizinischen Ordinationen für PatientInnen mit Typ 2 Diabetes mellitus in Österreich. Wiener klinische Wochenschrift
CrossRef19
Antonio Ceriello, Marco Gallo, Vincenzo Armentano, Gabriele Perriello, Sandro Gentile, Alberto De Micheli. (2012) Personalizing Treatment in Type 2 Diabetes: A Self-Monitoring of Blood Glucose Inclusive Innovative Approach. Diabetes Technology & Therapeutics120104064720007
CrossRef20
Toyoaki Murohara. (2012) Dipeptidyl Peptidase-4 Inhibitor. Journal of the American College of Cardiology 59:3, 277-279
CrossRef21
A. Prescott, J.E. Bailey, K.J. Kelly, T. Munyombwe, A. Gray, L.K.M. Summers. (2012) The effectiveness and cost of single and multi-factorial cardiovascular risk factor modification to guideline targets in type 2 diabetes. Primary Care Diabetes
CrossRef22
Chaoyang Li, Earl S. Ford, Guixiang Zhao, James Tsai, Lina S. Balluz, Wayne H. Giles. (2012) Trends of insulin use among US adults with type 2 diabetes: the Behavioral Risk Factor Surveillance System, 1995–2007. Journal of Diabetes and its Complications
CrossRef23
Emily S. Brouwer, Suzanne L. West, Marianne Kluckman, Dennis Wallace, Andrew L. Masica, Edward Ewen, Rustam Kudyakov, Dunlei Cheng, James Bowen, Neil S. Fleming. (2012) Initial and subsequent therapy for newly diagnosed type 2 diabetes patients treated in primary care using data from a vendor-based electronic health record. Pharmacoepidemiology and Drug Safetyn/a-n/a
CrossRef24
Chris Degeling, Melanie Rock. (2012) Hemoglobin A1c as a Diagnostic Tool: Public Health Implications From an Actor–Network Perspective. American Journal of Public Health 102:1, 99-106
CrossRef25
R. R. Kalyani, E. J. Metter, R. Ramachandran, C. W. Chia, C. D. Saudek, L. Ferrucci. (2012) Glucose and Insulin Measurements From the Oral Glucose Tolerance Test and Relationship to Muscle Mass. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 67A:1, 74-81
CrossRef26
P. Hamet. (2012) What matters in ADVANCE and ADVANCE-ON. Diabetes, Obesity and Metabolism 14, 20-29
CrossRef27
B. Detournay, D. Simon, P.-J. Guillausseau, D. Joly, B. Verges, C. Attali, O. Clement, Y. Briand, O. Delaitre. (2012) Chronic kidney disease in type 2 diabetes patients in France: Prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes. Diabetes & Metabolism
CrossRef28
S. Colagiuri. (2012) Optimal management of type 2 diabetes: the evidence. Diabetes, Obesity and Metabolism 14, 3-8
CrossRef29
Wiebke K. Fenske, Dimitri J. Pournaras, Erlend T. Aasheim, Alexander D. Miras, Nicola Scopinaro, Samantha Scholtz, Carel W. Roux. (2012) Can a Protocol for Glycaemic Control Improve Type 2 Diabetes Outcomes After Gastric Bypass?. Obesity Surgery 22:1, 90-96
CrossRef30
Clement Lo, Sophia Zoungas. (2012) Reducing renal failure: how low do glucose levels need to go?. Diabetes Management 2:1, 25-32
CrossRef31
R. A. DeFronzo, J. A. Davidson, S. Del Prato. (2012) The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes, Obesity and Metabolism 14:1, 5-14
CrossRef32
Mei-Fang Zhong, Wei-Li Shen, Masaki Tabuchi, Kyoko Nakamura, Yi-Chen Chen, Cong-Zhen Qiao, Jin He, Jie Yang, Chuan Zhang, Zdravko Kamenov, Hideaki Higashino, Hong Chen. (2012) Differential Changes of Aorta and Carotid Vasodilation in Type 2 Diabetic GK and OLETF Rats: Paradoxical Roles of Hyperglycemia and Insulin. Experimental Diabetes Research 2012, 1-16
CrossRef33
Junichi Matsubara, Seigo Sugiyama, Koichi Sugamura, Taishi Nakamura, Yukio Fujiwara, Eiichi Akiyama, Hirofumi Kurokawa, Toshimitsu Nozaki, Keisuke Ohba, Masaaki Konishi, Hirofumi Maeda, Yasuhiro Izumiya, Koichi Kaikita, Hitoshi Sumida, Hideaki Jinnouchi, Kunihiko Matsui, Shokei Kim-Mitsuyama, Motohiro Takeya, Hisao Ogawa. (2012) A Dipeptidyl Peptidase-4 Inhibitor, Des-Fluoro-Sitagliptin, Improves Endothelial Function and Reduces Atherosclerotic Lesion Formation in Apolipoprotein E–Deficient Mice. Journal of the American College of Cardiology 59:3, 265-276
CrossRef34
J. Huang, J. Schmeidler, M. S. Beeri, C. Rosendorff, S. Bhatia, R. K. West, I. N. Bespalova, R. Mavris, J. M. Silverman. (2012) Haemoglobin A1c and cognitive function in very old, cognitively intact men. Age and Ageing 41:1, 125-128
CrossRef35
Bruce Bode. (2012) An overview of the pharmacokinetics, efficacy and safety of liraglutide. Diabetes Research and Clinical Practice
CrossRef36
Thomas Forst, Andreas Pfützner. (2012) Linagliptin , a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes. Expert Opinion on Pharmacotherapy 13:1, 101-110
CrossRef37
A. E. Pontiroli, L. Miele, A. Morabito. (2012) Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes, Obesity and Metabolismno-no
CrossRef38
Nikhil Tandon, Mohammed K. Ali, K.M. Venkat Narayan. (2012) Pharmacologic Prevention of Microvascular and Macrovascular Complications in Diabetes Mellitus. American Journal Cardiovascular Drugs1
CrossRef39
Ofelia Llamazares Iglesias, Julia Sastre Marcos, Virginia Peña Cortés, Alessandra Luque Pazos, Bárbara Cánovas Gaillemin, Almudena Vicente Delgado, Amparo Marco Martínez, José López López. (2012) Control metabólico y de factores de riesgo cardiovascular en una cohorte de pacientes con diabetes mellitus. Resultados a los 4 años. Endocrinología y Nutrición
CrossRef40
Min Goo Lee, Myung Ho Jeong, Dong Han Kim, Ki Hong Lee, Keun Ho Park, Doo Sun Sim, Hyun Ju Yoon, Nam Sik Yoon, Kye Hun Kim, Hyoung Wook Park, Young Joon Hong, Ju Han Kim, Youngkeun Ahn, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang. (2012) Predictive value of glycosylated hemoglobin for mortality of patients with acute myocardial infarction undergoing percutaneous coronary intervention. International Journal of Cardiology
CrossRef41
Robert M. Kaplan. (2012) Economic decision models: Can they inform child welfare policy?. Child Abuse & Neglect
CrossRef42
James S. Krinsley, Geert Meyfroidt, Greet van den Berghe, Mori Egi, Rinaldo Bellomo. (2012) The impact of premorbid diabetic status on the relationship between the three domains of glycemic control and mortality in critically ill patients. Current Opinion in Clinical Nutrition and Metabolic Care1
CrossRef43
S. van Dieren, S. Czernichow, J. Chalmers, A.P. Kengne, B.E. de Galan, N. Poulter, M. Woodward, J.W.J. Beulens, D.E. Grobbee, Y.T. van der Schouw, S. Zoungas. (2012) Weight changes and their predictors amongst 11,140 patients with type 2 diabetes in the ADVANCE trial. Diabetes, Obesity and Metabolismno-no
CrossRef44
Juan José Gorgojo Martínez. (2012) Glucocentricity or adipocentricity: A critical view of consensus and clinical guidelines for the treatment of type 2 diabetes mellitus. Endocrinología y Nutrición (English Edition)
CrossRef45
The DCCT/EDIC Research Group. (2011) Intensive Diabetes Therapy and Glomerular Filtration Rate in Type 1 Diabetes. New England Journal of Medicine 365:25, 2366-2376
Full Text46
Marina Scavini, Emanuele Bosi, Antonio Ceriello, Francesco Giorgino, Massimo Porta, Antonio Tiengo, Giacomo Vespasiani, Davide Bottalico, Raffaele Marino, Christopher Parkin, Erminio Bonizzoni, Domenico Cucinotta. (2011) Prospective, randomized trial on intensive SMBG management added value in non-insulin-treated T2DM patients (PRISMA): a study to determine the effect of a structured SMBG intervention. Acta Diabetologica
CrossRef47
, S. Zoungas, J. Chalmers, T. Ninomiya, Q. Li, M. E. Cooper, S. Colagiuri, G. Fulcher, B. E. Galan, S. Harrap, P. Hamet, S. Heller, S. MacMahon, M. Marre, N. Poulter, F. Travert, A. Patel, B. Neal, M. Woodward. (2011) Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia
CrossRef48
2011. Introduction to Staged Diabetes Management. , 5-16.
CrossRef49
2011. Type 2 Diabetes in Adults. , 77-137.
CrossRef50
2011. Glucose Management in the Hospital Setting. , 261-271.
CrossRef51
2011. Complications Associated with Diabetes. , 201-249.
CrossRef52
2011. Characterization of Glucose Metabolism. , 29-39.
CrossRef53
2011. Can We Lower Health Care Costs by Eliminating Waste?. , 41-56.
CrossRef54
Faramarz Ismail-Beigi, Timothy E Craven, Patrick J O'Connor, Diane Karl, Jorge Calles-Escandon, Irene Hramiak, Saul Genuth, William C Cushman, Hertzel C Gerstein, Jeffrey L Probstfield, Lois Katz, Ulrich Schubart. (2011) Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney International
CrossRef55
Benoit J. Arsenault, Emilie Pelletier Beaumont, Jean-Pierre Després, Eric Larose. (2011) Mapping body fat distribution: A key step towards the identification of the vulnerable patient?. Annals of Medicine1-15
CrossRef56
Yvonne Elliott-Kemp, Kathy Ahern, Remo Ostini. (2011) Glargine prescribing practices for Type 2 diabetes: is there room for improvement?. Journal of Nursing and Healthcare of Chronic Illness 3:4, 352-360
CrossRef57
Heidi Buysse, Georges De Moor, Pascal Coorevits, Georges Van Maele, Jean Kaufman, Johannes Ruige. (2011) Main characteristics of type 1 and type 2 diabetic patients interested in the use of a telemonitoring platform. Journal of Nursing and Healthcare of Chronic Illness 3:4, 456-468
CrossRef58
Juan José Gorgojo Martínez. (2011) Glucocentrismo o adipocentrismo: una visión crítica de los consensos y guías clínicas para el tratamiento de la diabetes mellitus tipo 2. Endocrinología y Nutrición 58:10, 541-549
CrossRef59
Kelly J. Hunt, Maria Elena Gonzalez, Ruy Lopez, Steve M. Haffner, Michael P. Stern, Clicerio Gonzalez-Villalpando. (2011) Diabetes is More Lethal in Mexicans and Mexican-Americans Compared to Non-Hispanic Whites. Annals of Epidemiology 21:12, 899-906
CrossRef60
V. Koivisto, S. Cleall, A. E. Pontiroli, D. Giugliano. (2011) Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial. Diabetes, Obesity and Metabolism 13:12, 1149-1157
CrossRef61
S. Zoungas, M. Lui, P. G. Kerr, H. J. Teede, J. J. McNeil, B. P. McGrath, K. R. Polkinghorne. (2011) Advanced chronic kidney disease, cardiovascular events and the effect of diabetes: data from the Atherosclerosis and Folic Acid Supplementation Trial. Internal Medicine Journal 41:12, 825-832
CrossRef62
Denise G. Feil, Mangala Rajan, Orysya Soroka, Chin-Lin Tseng, Donald R. Miller, Leonard M. Pogach. (2011) Risk of Hypoglycemia in Older Veterans with Dementia and Cognitive Impairment: Implications for Practice and Policy. Journal of the American Geriatrics Society 59:12, 2263-2272
CrossRef63
T. J. Quinn, J. Dawson, M. R. Walters. (2011) Sugar and Stroke: Cerebrovascular Disease and Blood Glucose Control. Cardiovascular Therapeutics 29:6, e31-e42
CrossRef64
Alejandro de la Sierra. (2011) Renin–angiotensin system blockade and reduction of cardiovascular risk: future perspectives. Expert Review of Cardiovascular Therapy 9:12, 1585-1591
CrossRef65
Andrew J. Krentz, Alan J. Sinclair. (2011) Choice of Long-Acting Insulin Therapy for Type 2 Diabetes. Drugs & Aging 28:12, 935-941
CrossRef66
Zachary Bloomgarden, Yehuda Handelsman, Daniel Einhorn. (2011) Comprehensive diabetes cardiovascular treatment = sugar + blood pressure + lipids. Journal of Diabetes 3:4, 257-260
CrossRef67
F. Wilford Germino. (2011) Noninsulin Treatment of Type 2 Diabetes Mellitus in Geriatric Patients: A Review. Clinical Therapeutics 33:12, 1868-1882
CrossRef68
F. E. Vos, J. B. Schollum, R. J. Walker. (2011) Glycated albumin is the preferred marker for assessing glycaemic control in advanced chronic kidney disease. NDT Plus 4:6, 368-375
CrossRef69
K. L. Rensing, A. Q. Reuwer, B. J. Arsenault, J. H. von der Thüsen, J. B. L. Hoekstra, J. J. P. Kastelein, Th. B. Twickler. (2011) Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing?. Diabetes, Obesity and Metabolism 13:12, 1073-1087
CrossRef70
D. Kerr, H. Partridge, J. Knott, P. W. Thomas. (2011) HbA1c 3 months after diagnosis predicts premature mortality in patients with new onset type 2 diabetes. Diabetic Medicine 28:12, 1520-1524
CrossRef71
Brita Roy, Pushkar P. Pawar, Ravi V. Desai, Gregg C. Fonarow, Marjan Mujib, Yan Zhang, Margaret A. Feller, Fernando Ovalle, Inmaculada B. Aban, Thomas E. Love, Ami E. Iskandrian, Prakash Deedwania, Ali Ahmed. (2011) A Propensity-Matched Study of the Association of Diabetes Mellitus With Incident Heart Failure and Mortality Among Community-Dwelling Older Adults. The American Journal of Cardiology 108:12, 1747-1753
CrossRef72
Trond Jenssen, Anders Hartmann. (2011) Prevention and management of transplant-associated diabetes. Expert Opinion on Pharmacotherapy 12:17, 2641-2655
CrossRef73
Anna Maria Buehler, Alexandre Biasi Cavalcanti, Otavio Berwanger, Mabel Figueiro, Lígia Nasi Laranjeira, Ana Denise Zazula, Bruno Kioshi, Diogo G. Bugano, Eliana Santucci, Grazielle Sbruzzi, Helio Penna Guimaraes, Vitor Oliveira Carvalho, Silvana Auxiliadora Bordin. (2011) Effect of Tight Blood Glucose Control Versus Conventional Control in Patients with Type 2 Diabetes Mellitus: A Systematic Review with Meta-Analysis of Randomized Controlled Trials. Cardiovascular Therapeuticsno-no
CrossRef74
Clare Bradley, Pedro de Pablos-Velasco, Klaus G. Parhofer, Eveline Eschwège, Linda Gönder-Frederick, Dominique Simon. (2011) PANORAMA: A European study to evaluate quality of life and treatment satisfaction in patients with type-2 diabetes mellitus—Study design. Primary Care Diabetes 5:4, 231-239
CrossRef75
Lei Yu, Xin Jin, Yang Yang, Ningren Cui, Chun Jiang. (2011) Rosiglitazone inhibits vascular KATP channels and coronary vasodilation produced by isoprenaline. British Journal of Pharmacology 164:8, 2064-2072
CrossRef76
Stephanie Neuhold, Michael Resl, Martin Huelsmann, Guido Strunk, Christopher Adlbrecht, Claus Rath, Rudolf Prager, Anton Luger, Martin Clodi, Richard Pacher. (2011) Repeat measurements of glycated haemoglobin A1c and N-terminal pro-B-type natriuretic peptide: divergent behaviour in diabetes mellitus. European Journal of Clinical Investigation 41:12, 1292-1298
CrossRef77
Achim Peters, Bruce S. McEwen. (2011) Editorial introduction. Physiology & Behavior
CrossRef78
M. Varroud-Vial. (2011) Le parcours de soin : Une solution ou une contrainte supplémentaire?. Médecine des Maladies Métaboliques 5, S81-S85
CrossRef79
S. Halimi, C. Attali. (2011) L’inertie thérapeutique dans le diabète de type 2 : la comprendre sans la banaliser. Médecine des Maladies Métaboliques 5, S62-S68
CrossRef80
C. Attali, J. Le Breton, S. Bercier, S. Chartier, E. Ferrat. (2011) « Arrêtez de tirer sur le pianiste ! » Le point de vue du médecin généraliste sur l’inertie thérapeutique. Médecine des Maladies Métaboliques 5, S69-S75
CrossRef81
D. Simon. (2011) L’inertie thérapeutique dans le traitement du diabète de type 2 : À propos de quelques données. Médecine des Maladies Métaboliques 5, S46-S51
CrossRef82
J.M. Cabezas Agrícola, F.F. Casanueva. (2011) Tratamiento de la hiperglucemia en la diabetes mellitus tipo 2: Hacia un tratamiento individualizado. Medicine - Programa de Formación Médica Continuada Acreditado 10:92, 6230-6239
CrossRef83
Neda Laiteerapong, Elbert S. Huang, Marshall H. Chin. (2011) Prioritization of care in adults with diabetes and comorbidity. Annals of the New York Academy of Sciences 1243:1, 69-87
CrossRef84
Ravichandran Ramasamy, Shi Fang Yan, Ann Marie Schmidt. (2011) Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Annals of the New York Academy of Sciences 1243:1, 88-102
CrossRef85
J F Marcinak, P Viswanathan, V Arora, L E Roebel, T R Strack, E Leifke. (2011) Shift From Surrogate End Point to Outcome Trials: Implications for Cardiovascular Safety Assessment in Development Programs for Antidiabetic Drugs. Clinical Pharmacology & Therapeutics
CrossRef86
N. Altemtam, J. Russell, M. El Nahas. (2011) A study of the natural history of diabetic kidney disease (DKD). Nephrology Dialysis Transplantation
CrossRef87
Barbara J. Messinger-Rapport, John E. Morley, David R. Thomas, Julie K. Gammack. (2011) Clinical Update on Nursing Home Medicine: 2011. Journal of the American Medical Directors Association 12:9, 615-626.e6
CrossRef88
Morris Mosseri, Deepak L Bhatt, Itamar Raz. (2011) Ask the Experts: Cardiovascular complications in diabetic patients. Diabetes Management 1:6, 565-570
CrossRef89
David Sullivan, Peta Forder, John Simes, Malcolm Whiting, Leonard Kritharides, Alistair Merrifield, Mark Donoghoe, Peter G. Colman, Neil Graham, Hannu Haapamäki, Anthony Keech. (2011) Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study. Diabetes Research and Clinical Practice 94:2, 284-290
CrossRef90
Ramit Ravona-Springer, Michal Schnaider-Beeri. (2011) The association of diabetes and dementia and possible implications for nondiabetic populations. Expert Review of Neurotherapeutics 11:11, 1609-1617
CrossRef91
Niki Katsiki, Nikolaos Papanas, Dimitri P. Mikhailidis, Vivian A. Fonseca. (2011) Glycated hemoglobin A 1c (HbA 1c ) and diabetes: a new era?. Current Medical Research and Opinion 27:S3, 7-11
CrossRef92
David Aguilar. (2011) Heart failure and diabetes: Time to pay attention. American Heart Journal 162:5, 795-797
CrossRef93
Janice M. Scheufler, Maryjo Prince-Paul. (2011) The Diabetic Hospice Patient. Journal of Hospice & Palliative Nursing 13:6, 356-365
CrossRef94
Philip E. Cryer. (2011) Death during Intensive Glycemic Therapy of Diabetes: Mechanisms and Implications. The American Journal of Medicine 124:11, 993-996
CrossRef95
Devindra Sehra, Sudhish Sehra, Shiv Tej Sehra. (2011) Sulfonylureas: do we need to introspect safety again?. Expert Opinion on Drug Safety 10:6, 851-861
CrossRef96
Wolfgang Rathmann, Klaus Strassburger, Teresa Tamayo, Karel Kostev. (2011) Longitudinal change in HbA1c after insulin initiation in primary care patients with type 2 diabetes: A database analysis in UK and Germany. Primary Care Diabetes
CrossRef97
Laura Boucai, William N. Southern, Joel Zonszein. (2011) Hypoglycemia-associated Mortality Is Not Drug-associated but Linked to Comorbidities. The American Journal of Medicine 124:11, 1028-1035
CrossRef98
S. Leucht, S. Heres, J. M. Davis. (2011) Überlegungen zur Wirksamkeit von Psychopharmaka. Der Nervenarzt 82:11, 1425-1430
CrossRef99
Louis Monnier, Claude Colette, David Owens. (2011) The glycemic triumvirate and diabetic complications: Is the whole greater than the sum of its component parts?. Diabetes Research and Clinical Practice
CrossRef100
Alexandria M. Dailey, Jennifer A. Gibert, Lisa R. Tannock. (2011) Durability of glycemic control using U-500 insulin. Diabetes Research and Clinical Practice
CrossRef101
Antonio Pérez, Josep Franch, Aleix Cases, José Ramón González Juanatey, Pedro Conthe, Eva Gimeno, Arantxa Matali. (2011) Relación del grado de control glucémico con las características de la diabetes y el tratamiento de la hiperglucemia en la diabetes tipo 2. Estudio DIABES. Medicina Clínica
CrossRef102
Brian K Irons. (2011) Diagnosis of diabetes mellitus as a cardiovascular risk equivalent or risk factor and implications in drug therapy management. Diabetes Management 1:6, 615-626
CrossRef103
Lenore J Launer, Michael E Miller, Jeff D Williamson, Ron M Lazar, Hertzel C Gerstein, Anne M Murray, Mark Sullivan, Karen R Horowitz, Jingzhong Ding, Santica Marcovina, Laura C Lovato, James Lovato, Karen L Margolis, Patrick O'Connor, Edward W Lipkin, Joy Hirsch, Laura Coker, Joseph Maldjian, Jeffrey L Sunshine, Charles Truwit, Christos Davatzikos, R Nick Bryan. (2011) Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. The Lancet Neurology 10:11, 969-977
CrossRef104
Mihriye Mete, Charlton Wilson, Elisa T. Lee, Angela Silverman, Marie Russell, Mario Stylianou, Jason G. Umans, Wenyu Wang, Wm. J. Howard, Robert E. Ratner, Barbara V. Howard, Jerome L. Fleg. (2011) Relationship of glycemia control to lipid and blood pressure lowering and atherosclerosis: the SANDS experience. Journal of Diabetes and its Complications 25:6, 362-367
CrossRef105
D. R. Owens, S. D. Luzio, C. Sert-Langeron, M. C. Riddle. (2011) Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month ‘proof-of-concept' study. Diabetes, Obesity and Metabolism 13:11, 1020-1027
CrossRef106
Wei-Jei Lee, Chih-Yen Chen, Keong Chong, Yi-Chih Lee, Shu-Chun Chen, Shou-Dong Lee. (2011) Changes in postprandial gut hormones after metabolic surgery: a comparison of gastric bypass and sleeve gastrectomy. Surgery for Obesity and Related Diseases 7:6, 683-690
CrossRef107
J. Tafel, M. Buerstell, C. Leippert, E. Benack, A. Stelling, C. Jaeger. (2011) Diabetesmanagement in der Klinik. Der Diabetologe 7:7, 472-479
CrossRef108
Richard S. Beaser, Eyiuche Okeke, James Neighbours, Julie Brown, Katie Ronk, Walter W. Wolyniec. (2011) Coordinated Primary and Specialty Care for Type 2 Diabetes Mellitus, Guidelines, and Systems: An Educational Needs Assessment. Endocrine Practice 17:6, 880-890
CrossRef109
Davide Castagno, Jonathan Baird-Gunning, Pardeep S. Jhund, Giuseppe Biondi-Zoccai, Michael R. MacDonald, Mark C. Petrie, Fiorenzo Gaita, John J.V. McMurray. (2011) Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: Evidence from a 37,229 patient meta-analysis. American Heart Journal 162:5, 938-948.e2
CrossRef110
Morali D. Sharma, John Alan Farmer, Alan Garber. (2011) Type 2 diabetes and cardiovascular risk factors. Current Medical Research and Opinion 27:S3, 1-5
CrossRef111
Geert Jan Biessels. (2011) Intensive glucose lowering and cognition in type 2 diabetes. The Lancet Neurology 10:11, 949-950
CrossRef112
William C. Duckworth, Carlos Abraira, Thomas E. Moritz, Stephen N. Davis, Nicholas Emanuele, Steven Goldman, Rodney Hayward, Grant D. Huang, Jennifer B. Marks, Peter D. Reaven, Domenic J. Reda, Stuart R. Warren, Franklin J. Zieve. (2011) The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. Journal of Diabetes and its Complications 25:6, 355-361
CrossRef113
Cheow Peng Ooi, Seng Cheong Loke, Cheow Peng Ooi. 2011. Colesevelam for type 2 diabetes mellitus. .
CrossRef114
Jennifer B. Christian, Nancy E. Bourgeois, Kimberly A. Lowe. (2011) Prevalence, clinical characteristics and treatment patterns of low high-density lipoprotein cholesterol in the US population. Journal of Cardiovascular Medicine 12:10, 714-722
CrossRef115
Addison K. May, Rondi M. Kauffmann, Bryan R. Collier. (2011) The Place for Glycemic Control in the Surgical Patient. Surgical Infections 12:5, 405-418
CrossRef116
Ramsey M. Dallal, Amanda Hatalski, Alfred Trang, Arthur Chernoff. (2011) Longitudinal analysis of cardiovascular parameters after gastric bypass surgery. Surgery for Obesity and Related Diseases
CrossRef117
Yoshifumi Saisho, Kumiko Tanaka, Takayuki Abe, Akira Shimada, Toshihide Kawai, Hiroshi Itoh. (2011) Glycated albumin to glycated hemoglobin ratio reflects postprandial glucose excursion and relates to beta cell function in both type 1 and type 2 diabetes. Diabetology International 2:3, 146-153
CrossRef118
Scott E. Nelson. (2011) Management of patients with type 2 diabetes. Current Medical Research and Opinion 27:10, 1931-1947
CrossRef119
Vincenza Spallone, Dan Ziegler, Roy Freeman, Luciano Bernardi, Simona Frontoni, Rodica Pop-Busui, Martin Stevens, Peter Kempler, Jannik Hilsted, Solomon Tesfaye, Phillip Low, Paul Valensi, . (2011) Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes/Metabolism Research and Reviews 27:7, 639-653
CrossRef120
Richard J. MacIsaac, George Jerums. (2011) Intensive Glucose Control and Cardiovascular Outcomes in Type 2 Diabetes. Heart, Lung and Circulation 20:10, 647-654
CrossRef121
L. S. Farhy, A. L. McCall. (2011) Optimizing reduction in basal hyperglucagonaemia to repair defective glucagon counterregulation in insulin deficiency. Diabetes, Obesity and Metabolism 13, 133-143
CrossRef122
Larry A. Allen. (2011) End-Point Selection for Acute Heart Failure Trials. Heart Failure Clinics 7:4, 481-495
CrossRef123
Urmimala Sarkar, Andrea López, Karen Black, Dean Schillinger. (2011) The Wrong Tool for the Job: Diabetes Public Health Programs and Practice Guidelines. American Journal of Public Health 101:10, 1871-1873
CrossRef124
Radzi M Noh, Alex J Graveling, Brian M Frier. (2011) Medically minimising the impact of hypoglycaemia in type 2 diabetes: a review. Expert Opinion on Pharmacotherapy 12:14, 2161-2175
CrossRef125
Michael Pfeiffer, Rüdiger Bauer, Peter P. Nawroth. (2011) The new puzzle about the treatment of type 2 diabetes after the ACCORD and Da Qing studies. Langenbeck's Archives of Surgery 396:7, 941-947
CrossRef126
Manfredi Rizzo, Gerald H Tomkin, Angelo Maria Patti, Ilenia Pepe, Maria Rosa Valerio, Salvatore Di Rosa, Giovam Battista Rini, Gaetana Di Fede. (2011) Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes. Clinical Lipidology 6:5, 539-547
CrossRef127
Kyaw Soe, Alan Sacerdote, Jocelyn Karam, Gül Bahtiyar. (2011) Management of type 2 diabetes mellitus in the elderly. Maturitas 70:2, 151-159
CrossRef128
Xanthia F. Samaropoulos, Laney Light, Walter T. Ambrosius, Santica M. Marcovina, Jeffrey Probstfield, David C. Goff Jr. (2011) The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. Diabetes Research and Clinical Practice
CrossRef129
Gregory A. Nichols, Suma Vupputuri, A. Gabriela Rosales. (2011) Change in High-Density Lipoprotein Cholesterol and Risk of Subsequent Hospitalization for Coronary Artery Disease or Stroke Among Patients With Type 2 Diabetes Mellitus. The American Journal of Cardiology 108:8, 1124-1128
CrossRef130
T Deakin. (2011) The diabetes pandemic: is structured education the solution or an unnecessary expense?. Practical Diabetes 28:8, 1-14
CrossRef131
J. I. Vidal Pardo, T. R. Pérez Castro, X. L. López Álvarez, F. J. García Soidán, M. I. Santiago Pérez, J. Muñiz. (2011) Quality of care of patients with type-2 diabetes in Galicia (NW Spain) [OBTEDIGA project]. International Journal of Clinical Practice 65:10, 1067-1075
CrossRef132
A. Chaudhuri, P. Dandona. (2011) Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes. Diabetes, Obesity and Metabolism 13:10, 869-879
CrossRef133
Ulf G. Bronas, Diane Treat-Jacobson. (2011) Peripheral Artery Disease in the Elderly: Prevalence, Clinical Implications, and Therapy. Current Cardiovascular Risk Reports 5:5, 457-466
CrossRef134
Kwame S. Amankwah. (2011) Is Hemoglobin A1c an Adequate Marker for Disease Severity and Outcome in Limb Threatening Ischemia?. Journal of Surgical Research
CrossRef135
, S. Gudbjörnsdottir, B. Eliasson, K. Eeg-Olofsson, B. Zethelius, J. Cederholm. (2011) Additive effects of glycaemia and dyslipidaemia on risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register. Diabetologia 54:10, 2544-2551
CrossRef136
Andre Pascal Kengne, Eugene Sobngwi, John Chalmers. (2011) Multiple risk factor interventions and inflammatory biomarkers in high risk individuals with type 2 diabetes. Diabetes Research and Clinical Practice
CrossRef137
Masaharu Ishihara, Ichiro Inoue, Takuji Kawagoe, Yuji Shimatani, Satoshi Kurisu, Yasuharu Nakama, Eisuke Kagawa, Kazuoki Dai, Takayuki Ootani, Hiroki Ikenaga, Yoshimasa Morimoto, Kentarou Ejiri, Nozomu Oda. (2011) Glucometabolic responses during Glucose Tolerance Test: A comparison between known diabetes and newly detected diabetes after acute myocardial infarction. International Journal of Cardiology 152:1, 78-82
CrossRef138
MW Savage, I Malik, CN Dang. (2011) The case for basal analogue insulins as first-line insulins: back to the future?. Practical Diabetes 28:8, 329-330
CrossRef139
Ross Milne, Seymour Brownstein. (2011) Advanced glycation end products and diabetic retinopathy. Amino Acids
CrossRef140
M. K. Rutter, R. W. Nesto. (2011) Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care. European Heart Journal 32:18, 2247-2255
CrossRef141
Baptist Gallwitz. (2011) Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus. Drugs 71:13, 1675-1688
CrossRef142
Elyse S. Rosenthal, Eran Bashan, William H. Herman, Israel Hodish. (2011) The effort required to achieve and maintain optimal glycemic control. Journal of Diabetes and its Complications 25:5, 283-288
CrossRef143
Evelyn P. Davila, Hermes Florez, Mary Jo Trepka, Lora E. Fleming, Theophile Niyonsenga, David J. Lee, Jai Parkash. (2011) Strict glycemic control and mortality risk among US adults with type 2 diabetes. Journal of Diabetes and its Complications 25:5, 289-291
CrossRef144
Jamie C. Barner. (2011) Adherence to Oral Antidiabetic Agents with Pioglitazone and Metformin: Comparison of Fixed-Dose Combination Therapy with Monotherapy and Loose-Dose Combination Therapy. Clinical Therapeutics 33:9, 1281-1288
CrossRef145
Scott V. Joy, Jeffrey S. Freeman, James R. LaSalle. (2011) Tailoring treatment for type 2 diabetes: Uncovering the HOW and NOW of GLP-1 receptor agonist therapy. Osteopathic Family Physician 3:5, 217-236
CrossRef146
Kirsten Salmeen, Marya Zlatnik. (2011) The Oldest Gravidas: A Review of Pregnancy Risks in Women Over 45. Obstetrical & Gynecological Survey 66:9, 580-590
CrossRef147
John J. Ricotta, Ali AbuRahma, Enrico Ascher, Mark Eskandari, Peter Faries, Brajesh K. Lal. (2011) Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. Journal of Vascular Surgery 54:3, e1-e31
CrossRef148
Riccardo Perfetti. (2011) Combining Basal Insulin Analogs with Glucagon-Like Peptide-1 Mimetics. Diabetes Technology & Therapeutics 13:9, 873-881
CrossRef149
Joseph G. Ibrahim, Ming-Hui Chen, H. Amy Xia, Thomas Liu. (2011) Bayesian Meta-Experimental Design: Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. Biometricsno-no
CrossRef150
Luca Busetto, Paolo Sbraccia, Lucia Frittitta, Antonio E. Pontiroli. (2011) The Growing Role of Bariatric Surgery in the Management of Type 2 Diabetes: Evidences and Open Questions. Obesity Surgery 21:9, 1451-1457
CrossRef151
Denise G. Feil, Revana Lukman, Barbara Simon, Amy Walston, Barbara Vickrey. (2011) Impact of dementia on caring for patients’ diabetes. Aging & Mental Health 15:7, 894-903
CrossRef152
Harold L. Lazar, Marie M. McDonnell, Stuart Chipkin, Carmel Fitzgerald, Caleb Bliss, Howard Cabral. (2011) Effects of Aggressive Versus Moderate Glycemic Control on Clinical Outcomes in Diabetic Coronary Artery Bypass Graft Patients. Annals of Surgery 254:3, 458-464
CrossRef153
B. Fuentes, J. Gállego, A. Gil-Nuñez, A. Morales, F. Purroy, J. Roquer, T. Segura, J. Tejada, A. Lago, E. Díez-Tejedor, M. Alonso de Leciñana, J. Álvarez-Sabin, J. Arenillas, S. Calleja, I. Casado, M. Castellanos, J. Castillo, A. Dávalos, F. Díaz-Otero, J.A. Egido, J.C. López-Fernández, M. Freijo, A. García Pastor, F. Gilo, P. Irimia, J. Maestre, J. Masjuan, J. Martí-Fábregas, P. Martínez-Sánchez, E. Martínez-Vila, C. Molina, F. Nombela, M. Ribó, M. Rodríguez-Yañez, F. Rubio, J. Serena, P. Simal, J. Vivancos. (2011) Guía para el tratamiento preventivo del ictus isquémico y AIT (I). Actuación sobre los factores de riesgo y estilo de vida. Neurología
CrossRef154
Mikko T. Honkasalo, Outi M. Elonheimo, Timo Sane. (2011) Severe hypoglycaemia in drug-treated diabetic patients needs attention: A population-based study. Scandinavian Journal of Primary Health Care 29:3, 165-170
CrossRef155
Vanita R. Aroda, Robert Ratner. (2011) The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes/Metabolism Research and Reviews 27:6, 528-542
CrossRef156
I. Banu, P. Valensi. (2011) Hypoglycémie et effets cardiovasculaires. Médecine des Maladies Métaboliques 5:4, 399-405
CrossRef157
M. Porta, P. Maldari, F. Mazzaglia. (2011) New approaches to the treatment of diabetic retinopathy. Diabetes, Obesity and Metabolism 13:9, 784-790
CrossRef158
Louis Kuritzky, George P. Samraj. (2011) Enhanced glycemic control with combination therapy for type 2 diabetes in primary care. Diabetes Therapy 2:3, 162-177
CrossRef159
Geremia B. Bolli, Larry C. Deeb, Satish K. Garg, John L. Leahy, Roger S. Mazze, David R. Owens, Matthew C. Riddle, Phil Southerland, Ellie S. Strock. (2011) International Forum for the Advancement of Diabetes Research and Care, April 29–30, 2011, Athens, Greece. Diabetes Technology & Therapeutics 13:9, 967-979
CrossRef160
R. S. Stack, R. A. Harrington. (2011) Biomedical Innovation: A Risky Business at Risk. Science Translational Medicine 3:96, 96cm23-96cm23
CrossRef161
Peter M. Nilsson. (2011) Target blood pressure in diabetes patients with hypertension —What is the accumulated evidence in 2011?. Journal of Zhejiang University SCIENCE B 12:8, 611-623
CrossRef162
Handrean Soran, Paul N. Durrington. (2011) Susceptibility of LDL and its subfractions to glycation. Current Opinion in Lipidology 22:4, 254-261
CrossRef163
R. Pfister, S. J. Sharp, R. Luben, K.-T. Khaw, N. J. Wareham. (2011) No evidence of an increased mortality risk associated with low levels of glycated haemoglobin in a non-diabetic UK population. Diabetologia 54:8, 2025-2032
CrossRef164
Louis Monnier, Anne Wojtusciszyn, Claude Colette, David Owens. (2011) The Contribution of Glucose Variability to Asymptomatic Hypoglycemia in Persons with Type 2 Diabetes. Diabetes Technology & Therapeutics 13:8, 813-818
CrossRef165
Gordon Goodall, María Costi, Louise Timlin, Jesús Reviriego, José Antonio Sacristán, Jayne Smith-Palmer, Tatiana Dilla. (2011) Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus. Endocrinología y Nutrición (English Edition) 58:7, 331-340
CrossRef166
T. K. Schramm, G. H. Gislason, A. Vaag, J. N. Rasmussen, F. Folke, M. L. Hansen, E. L. Fosbol, L. Kober, M. L. Norgaard, M. Madsen, P. R. Hansen, C. Torp-Pedersen. (2011) Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. European Heart Journal 32:15, 1900-1908
CrossRef167
Walter J. Pories, James H. Mehaffey, Kyle M. Staton. (2011) The Surgical Treatment of Type Two Diabetes Mellitus. Surgical Clinics of North America 91:4, 821-836
CrossRef168
Gordon Goodall, María Costi, Louise Timlin, Jesús Reviriego, José Antonio Sacristán, Jayne Smith-Palmer, Tatiana Dilla. (2011) Coste-efectividad de exenatida en comparación con insulina glargina en pacientes con obesidad y diabetes mellitus tipo 2 en España. Endocrinología y Nutrición 58:7, 331-340
CrossRef169
Maciej Banach, Marta Michalska, Sverre E Kjeldsen, Jolanta Małyszko, Dimitri P Mikhailidis, Jacek Rysz. (2011) What should be the optimal levels of blood pressure: does the J-curve phenomenon really exist?. Expert Opinion on Pharmacotherapy 12:12, 1835-1844
CrossRef170
Ralph A. DeFronzo, Muhammad Abdul-Ghani. (2011) Assessment and Treatment of Cardiovascular Risk in Prediabetes: Impaired Glucose Tolerance and Impaired Fasting Glucose. The American Journal of Cardiology 108:3, 3B-24B
CrossRef171
Esther S.H. Kim, Thomas P. Carrigan, Venu Menon. (2011) International Participation in Cardiovascular Randomized Controlled Trials Sponsored by the National Heart, Lung, and Blood Institute. Journal of the American College of Cardiology 58:7, 671-676
CrossRef172
Bijan Roshan. (2011) Does Therapy Targeting Normal SBP of Less than 120 mm Hg Reduce Major CV Events in T2DM Patients?. Current Diabetes Reports 11:4, 233-235
CrossRef173
M. O. Gore, D. K. McGuire. (2011) Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: more support for cardiovascular outcome assessments. European Heart Journal 32:15, 1832-1834
CrossRef174
Philip Joseph, Koon Teo. (2011) Optimal Medical Therapy, Lifestyle Intervention, and Secondary Prevention Strategies for Cardiovascular Event Reduction in Ischemic Heart Disease. Current Cardiology Reports 13:4, 287-295
CrossRef175
Esther Maissi, Katie Ridge, Janet Treasure, Trudie Chalder, Suzanne Roche, Jonathan Bartlett, Ulrike Schmidt, Stephen Thomas, Khalida Ismail. (2011) Nurse-led psychological interventions to improve diabetes control: Assessing competencies. Patient Education and Counseling 84:2, e37-e43
CrossRef176
Sherita Hill Golden. (2011) Emerging Therapeutic Approaches for the Management of Diabetes Mellitus and Macrovascular Complications. The American Journal of Cardiology 108:3, 59B-67B
CrossRef177
Klaus G Parhofer. (2011) Pathophysiology of diabetic dyslipidemia: implications for atherogenesis and treatment. Clinical Lipidology 6:4, 401-411
CrossRef178
Gillian M. Keating. (2011) Fenofibrate. American Journal Cardiovascular Drugs 11:4, 227-247
CrossRef179
Jorge Plutzky. (2011) Macrovascular Effects and Safety Issues of Therapies for Type 2 Diabetes. The American Journal of Cardiology 108:3, 25B-32B
CrossRef180
Michael H. Davidson. (2011) Cardiovascular Effects of Glucagonlike peptide–1 Agonists. The American Journal of Cardiology 108:3, 33B-41B
CrossRef181
Yehuda Handelsman, Paul S. Jellinger. (2011) Overcoming Obstacles in Risk Factor Management in Type 2 Diabetes Mellitus. The Journal of Clinical Hypertension 13:8, 613-620
CrossRef182
Daisuke Koya, Shin-ichi Araki, Masakazu Haneda. (2011) Therapeutic management of diabetic kidney disease. Journal of Diabetes Investigation 2:4, 248-254
CrossRef183
Vivian A. Fonseca. (2011) Ongoing Clinical Trials Evaluating the Cardiovascular Safety and Efficacy of Therapeutic Approaches to Diabetes Mellitus. The American Journal of Cardiology 108:3, 52B-58B
CrossRef184
G. P. Fadini, S. V. de Kreutzenberg, V. Mariano, E. Boscaro, F. Bertolini, P. Mancuso, J. Quarna, M. Marescotti, C. Agostini, A. Tiengo, A. Avogaro. (2011) Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine. Diabetes, Obesity and Metabolism 13:8, 718-725
CrossRef185
Kerstin Kempf, Reiner Füth, Wilfried Dinh, Lars Bansemir, Till Köhler, Alexander Bufe, Thomas Scheffold, Eberhard Standl, Stephan Martin, Mark Lankisch. (2011) Screening for overt diabetes by oral glucose tolerance test: Stratification by fasting blood glucose and patients' age improve practicability of guidelines in cardiological routine. International Journal of Cardiology 150:2, 201-205
CrossRef186
Charlie Tomson, Pippa Bailey. (2011) Management of chronic kidney disease. Medicine 39:7, 407-413
CrossRef187
Lu Luo, De-Zai Dai, Yu-Si Cheng, Qi Zhang, Wen-Jun Yuan, Yin Dai. (2011) Sildenafil improves diabetic vascular activity through suppressing endothelin receptor A, iNOS and NADPH oxidase which is comparable with the endothelin receptor antagonist CPU0213 in STZ-injected rats. Journal of Pharmacy and Pharmacology 63:7, 943-951
CrossRef188
Alice YY Cheng, Lawrence A Leiter. (2011) ACCORD microvascular and Eye substudy: should the results change our practice?. Diabetes Management 1:4, 389-396
CrossRef189
Maíra Viégas, Christiane Costa, Arthur Lopes, Luiz Griz, Maria Antonieta Medeiro, Francisco Bandeira. (2011) Prevalence of osteoporosis and vertebral fractures in postmenopausal women with type 2 diabetes mellitus and their relationship with duration of the disease and chronic complications. Journal of Diabetes and its Complications 25:4, 216-221
CrossRef190
Ryotaro Bouchi, Tetsuya Babazono, Michino Mugishima, Naoshi Yoshida, Izumi Nyumura, Kiwako Toya, Toshihide Hayashi, Ko Hanai, Nobue Tanaka, Akiko Ishii, Yasuhiko Iwamoto. (2011) Fluctuations in HbA1c are associated with a higher incidence of cardiovascular disease in Japanese patients with type 2 diabetes. Journal of Diabetes Investigationno-no
CrossRef191
B. T. Corley, C. Davenport, L. Delaney, M. Hatunic, D. Smith. (2011) Hypoglycaemia-induced myocardial infarction as a result of sulphonylurea misuse. Diabetic Medicine 28:7, 876-879
CrossRef192
Melinda B Davis, Claire S Duvernoy. (2011) How to stay heart healthy in 2011: considerations for the primary prevention of cardiovascular disease in women. Women's Health 7:4, 433-451
CrossRef193
Maria Flamm, Henrike Winkler, Sigrid Panisch, Peter Kowatsch, Gert Klima, Bernhard Fürthauer, Raimund Weitgasser, Andreas C. Sönnichsen. (2011) Quality of diabetes care in Austrian diabetic patients willing to participate in a DMP – at baseline. Wiener klinische Wochenschrift 123:13-14, 436-443
CrossRef194
S. H. Wild. (2011) Diabetes, treatments for diabetes and their effect on cancer incidence and mortality: attempts to disentangle the web of associations. Diabetologia 54:7, 1589-1592
CrossRef195
J. B. Echouffo-Tcheugui, M. K. Ali, S. J. Griffin, K. M. V. Narayan. (2011) Screening for Type 2 Diabetes and Dysglycemia. Epidemiologic Reviews 33:1, 63-87
CrossRef196
Ram Kela, Kamlesh Khunti, Melanie J Davies. (2011) Liraglutide for type 2 diabetes mellitus. Expert Opinion on Biological Therapy 11:7, 951-959
CrossRef197
Tomohiko Kanaoka, Kouichi Tamura, Tatsumi Moriya, Keiji Tanaka, Yusuke Konno, Satoshi Kondoh, Masao Toyoda, Tomoya Umezono, Tetsuya Fujikawa, Masato Ohsawa, Toru Dejima, Akinobu Maeda, Hiromichi Wakui, Sona Haku, Mai Yanagi, Hiroshi Mitsuhashi, Motoko Ozawa, Yasuko Okano, Nariaki Ogawa, Tadashi Yamakawa, Shunsaku Mizushima, Daisuke Suzuki, Satoshi Umemura. (2011) Effects of Multiple Factorial Intervention on Ambulatory BP Profile and Renal Function in Hypertensive Type 2 Diabetic Patients with Overt Nephropathy – A Pilot Study. Clinical and Experimental Hypertension 33:4, 255-263
CrossRef198
Sagit Zolotov, Dafna Ben Yosef, Naphtali D Rishe, Yelena Yesha, Eddy Karnieli. (2011) Metabolic profiling in personalized medicine: bridging the gap between knowledge and clinical practice in Type 2 diabetes. Personalized Medicine 8:4, 445-456
CrossRef199
Thomas Forst, Markolf Hanefeld, Andreas Pfützner. (2011) Review of approved pioglitazone combinations for type 2 diabetes. Expert Opinion on Pharmacotherapy 12:10, 1571-1584
CrossRef200
G. Nicholson, G. M. Hall. (2011) Diabetes mellitus: new drugs for a new epidemic. British Journal of Anaesthesia 107:1, 65-73
CrossRef201
G. Stefansdottir, S. Zoungas, J. Chalmers, A. P. Kengne, M. J. Knol, H. G. M. Leufkens, A. Patel, M. Woodward, D. E. Grobbee, M. L. Bruin. (2011) Intensive glucose control and risk of cancer in patients with type 2 diabetes. Diabetologia 54:7, 1608-1614
CrossRef202
George Dailey. (2011) Rapid-acting insulin glulisine: an update on clinical experience. Expert Review of Endocrinology & Metabolism 6:4, 527-542
CrossRef203
W. L. Jin, K. Azuma, T. Mita, H. Goto, A. Kanazawa, T. Shimizu, F. Ikeda, Y. Fujitani, T. Hirose, R. Kawamori, H. Watada. (2011) Repetitive hypoglycaemia increases serum adrenaline and induces monocyte adhesion to the endothelium in rat thoracic aorta. Diabetologia 54:7, 1921-1929
CrossRef204
Mohammad H. Murad, Nilay D. Shah, Holly K. Van Houten, Jeanette Y. Ziegenfuss, James R. Deming, Timothy J. Beebe, Steven A. Smith, Gordon H. Guyatt, Victor M. Montori. (2011) Individuals with diabetes preferred that future trials use patient-important outcomes and provide pragmatic inferences. Journal of Clinical Epidemiology 64:7, 743-748
CrossRef205
Garth J.S. Cooper. (2011) Therapeutic Potential of Copper Chelation with Triethylenetetramine in Managing Diabetes Mellitus and Alzheimerʼs Disease. Drugs 71:10, 1281-1320
CrossRef206
William J Elliott. (2011) What should be the blood pressure target for diabetic patients?. Current Opinion in Cardiology 26:4, 308-313
CrossRef207
Junya Aoki, Ken Uchino. (2011) Treatment of Risk Factors to Prevent Stroke. Neurotherapeutics 8:3, 463-474
CrossRef208
David J. O’Connor, Nicholas J. Gargiulo, Jennifer Jang. (2011) Hemoglobin A1c as a Measure of Disease Severity and Outcome in Limb Threatening Ischemia. Journal of Surgical Research
CrossRef209
Mark Thomas Hayes, Lynette Anne Hunt, Jonathan Foo, Yulia Tychinskaya, Richard Strawson Stubbs. (2011) A Model for Predicting the Resolution of Type 2 Diabetes in Severely Obese Subjects Following Roux-en Y Gastric Bypass Surgery. Obesity Surgery 21:7, 910-916
CrossRef210
S. W. Oh, Y. C. Kim, H. S. Koo, D. C. Jin, K. Y. Na, D. W. Chae, S. Kim, H. J. Chin. (2011) Glycated haemoglobin and the incidence of end-stage renal disease in diabetics. Nephrology Dialysis Transplantation 26:7, 2238-2244
CrossRef211
Jean-Louis Chiasson, Sophie Bernard. (2011) Reducing cardiovascular risk factors in patients with prediabetes. Diabetes Management 1:4, 423-438
CrossRef212
Stuart A. Ross, Grzegorz Dzida, Jiten Vora, Kamlesh Khunti, Marcel Kaiser, Robert J. Ligthelm. (2011) Impact of weight gain on outcomes in type 2 diabetes. Current Medical Research and Opinion 27:7, 1431-1438
CrossRef213
Wan-gen Li, Xin-lian He, Tong Zhang, Guang-da Xiang, Jian-min Ran, Cheng Peng, Hong Zhang. (2011) Hemoglobin A1c proportion, mortality rate, and risk factors for death in diabetic patients with severe hypoglycemia: A multicenter retrospective survey over ten years. Diabetes Research and Clinical Practice 93:1, 17-20
CrossRef214
Christopher J Nolan, Peter Damm, Marc Prentki. (2011) Type 2 diabetes across generations: from pathophysiology to prevention and management. The Lancet 378:9786, 169-181
CrossRef215
Michael C. Riddell, Jamie Burr. (2011) Evidence-based risk assessment and recommendations for physical activity clearance: diabetes mellitus and related comorbidities 1 1 This paper is one of a selection of papers published in this Special Issue, entitled Evidence-based risk assessment and recommendations for physical activity clearance, and has undergone the Journal’s usual peer review process.. Applied Physiology, Nutrition, and Metabolism 36:S1, S154-S189
CrossRef216
R.P. Donahue, J.M. Dorn, S. Stranges, M. Swanson, K. Hovey, M. Trevisan. (2011) Impaired fasting glucose and recurrent cardiovascular disease among survivors of a first acute myocardial infarction: Evidence of a sex difference? The Western New York experience. Nutrition, Metabolism and Cardiovascular Diseases 21:7, 504-511
CrossRef217
M. Levis. (2011) FLT3/ITD AML and the law of unintended consequences. Blood 117:26, 6987-6990
CrossRef218
Udi Nussinovitch, Amos Nussinovitch. 2011. Clinical Uses of Alginate. , 137-184.
CrossRef219
Tomohiro Nishizawa, Karin E. Bornfeldt. (2011) Diabetic vascular disease and the potential role of macrophage glucose metabolism. Annals of Medicine1-9
CrossRef220
Bianca Hemmingsen, Søren S Lund, Christian Gluud, Allan Vaag, Thomas Almdal, Christina Hemmingsen, Jørn Wetterslev, Bianca Hemmingsen. 2011. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. .
CrossRef221
Mitchell D. Weinberg, Joe F. Lau, Kenneth Rosenfield, Jeffrey W. Olin. (2011) Peripheral artery disease. Part 2: medical and endovascular treatment. Nature Reviews Cardiology 8:8, 429-441
CrossRef222
(2011) Intensive Glucose Lowering and Cardiovascular Outcomes. New England Journal of Medicine 364:23, 2263-2264
Full Text223
P. Seitz, T. Rosemann, J. Gensichen, C. A. Huber. (2011) Interventions in primary care to improve cardiovascular risk factors and glycated haemoglobin (HbA1c) levels in patients with diabetes: a systematic review. Diabetes, Obesity and Metabolism 13:6, 479-489
CrossRef224
A. I. Vinik, R. E. Maser, D. Ziegler. (2011) Autonomic imbalance: prophet of doom or scope for hope?. Diabetic Medicine 28:6, 643-651
CrossRef225
B. Bouhanick, F. Ah-Kang, B. Chamontin. (2011) Hypertension artérielle et diabète: nouvelles données apportées par l’étude ACCORD-Blood Pressure (ACCORD-BP). Médecine des Maladies Métaboliques 5:3, 312-316
CrossRef226
Roman Pfister, Richard Cairns, Erland Erdmann, Christian A. Schneider. (2011) A clinical risk score for heart failure in patients with type 2 diabetes and macrovascular disease: An analysis of the PROactive study. International Journal of Cardiology
CrossRef227
Christian Ukena, Felix Mahfoud, Hans-Ruprecht Neuberger, Michael Böhm. (2011) Variability of ventricular repolarization during hypoglycemia. International Journal of Cardiology 149:2, 285-286
CrossRef228
Gissette Reyes-Soffer, Carlos Rondon-Clavo, Henry N Ginsberg. (2011) Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 12:9, 1429-1438
CrossRef229
George Dailey. (2011) Overall Mortality in Diabetes Mellitus: Where Do We Stand Today?. Diabetes Technology & Therapeutics 13:S1, S-65-S-74
CrossRef230
Frank Lavernia. (2011) What Options Are Available When Considering Starting Insulin: Premix or Basal?. Diabetes Technology & Therapeutics 13:S1, S-85-S-92
CrossRef231
Steven G. Chrysant, George S. Chrysant. (2011) Current Status of Aggressive Blood Glucose and Blood Pressure Control in Diabetic Hypertensive Subjects. The American Journal of Cardiology 107:12, 1856-1861
CrossRef232
Lawrence J. Schneiderman. (2011) Defining Medical Futility and Improving Medical Care. Journal of Bioethical Inquiry 8:2, 123-131
CrossRef233
Lisa M Younk, Lisa Uhl, Stephen N Davis. (2011) Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk. Expert Opinion on Drug Metabolism & Toxicology 7:6, 753-763
CrossRef234
, José A. Luchsinger, Walter Palmas, J. A. Teresi, S. Silver, J. Kong, J. P. Eimicke, R. S. Weinstock, S. Shea. (2011) Improved diabetes control in the elderly delays global cognitive decline. The journal of nutrition, health & aging 15:6, 445-449
CrossRef235
Andreas Pfützner, Thomas Schöndorf, Diethelm Tschöpe, Ralf Lobmann, Jürgen Merke, Jürgen Müller, Ute Lehmann, Winfried Fuchs, Thomas Forst. (2011) PIOfix-Study: Effects of Pioglitazone/Metformin Fixed Combination in Comparison with a Combination of Metformin with Glimepiride on Diabetic Dyslipidemia. Diabetes Technology & Therapeutics 13:6, 637-643
CrossRef236
Melissa Y. Tjota, Benjamin M. Kozak, Eric M. Chang, Kelly L. Close. (2011) Journal of Diabetes NEWS. Journal of Diabetes 3:2, 95-102
CrossRef237
Juliana C. N. Chan, Wingyee So, Ronald C. W. Ma, Peter C. Y. Tong, Rebecca Wong, Xilin Yang. (2011) The Complexity of Vascular and Non-Vascular Complications of Diabetes: The Hong Kong Diabetes Registry. Current Cardiovascular Risk Reports 5:3, 230-239
CrossRef238
George Dailey. (2011) Early and Intensive Therapy for Management of Hyperglycemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes. Clinical Therapeutics 33:6, 665-678
CrossRef239
Marie Solignac. (2011) Critères de choix des analogues du GLP-1 dans le traitement du diabète de type 2. Médecine des Maladies Métaboliques 5:3, 348
CrossRef240
, L. G. Mellbin, K. Malmberg, A. Norhammar, H. Wedel, L. Rydén. (2011) Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin–Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study. Diabetologia 54:6, 1308-1317
CrossRef241
Monika Lechleitner. (2011) Oral antidiabetic drug therapy in type 2 diabetes mellitus – focus on elderly patients. Wiener Medizinische Wochenschrift 161:11-12, 297-299
CrossRef242
Louis Monnier, Claude Colette, David Owens. (2011) Postprandial and Basal Glucose in Type 2 Diabetes: Assessment and Respective Impacts. Diabetes Technology & Therapeutics 13:S1, S-25-S-32
CrossRef243
Aya Morimoto, Rimei Nishimura, Daisuke Tsujino, Kentaro Taki, Naoko Tajima, Kazunori Utsunomiya. (2011) Relationship Among A1C, Hypoglycemia, and Hyperglycemia in Japanese with Type 2 Diabetes—Results from Continuous Glucose Monitoring Data. Diabetes Technology & Therapeutics 13:6, 667-670
CrossRef244
Sophia Zoungas, Mark Woodward. (2011) Diabetes: Insights from the extended follow-up of the ACCORD trial. Nature Reviews Cardiology 8:6, 308-310
CrossRef245
Peter Libby, Paul M Ridker, Göran K. Hansson. (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473:7347, 317-325
CrossRef246
P. RaviKumar, A. Bhansali, R. Walia, G. Shanmugasundar, M. Ravikiran. (2011) Alterations in HbA1c with advancing age in subjects with normal glucose tolerance: Chandigarh Urban Diabetes Study (CUDS). Diabetic Medicine 28:5, 590-594
CrossRef247
A. Virkamäki, J. Saltevo. (2011) Finnish Current Care Guideline for Diabetes: interactive approach to improve individualised treatment. Diabetologia 54:5, 1264-1265
CrossRef248
W.C. Lee, C. Conner, M. Hammer. (2011) Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US. Current Medical Research and Opinion 27:5, 897-906
CrossRef249
K. Kröger, H. Böhner, M. Aleksic, K. Balzer, U. Klemp, T. Nowak, M. Pillny, S. Pourhassan. (2011) Sekundärprävention bei Patienten mit peripherer arterieller Verschlusskrankheit. Gefässchirurgie 16:3, 211-220
CrossRef250
Israel F. Charo, Rebecca Taub. (2011) Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nature Reviews Drug Discovery 10:5, 365-376
CrossRef251
Amparo B. Gonzalez, Daniela Salas, Guillermo E. Umpierrez. (2011) Special considerations on the management of Latino patients with type 2 diabetes mellitus. Current Medical Research and Opinion 27:5, 969-979
CrossRef252
Andreas Liebl, Stephen Jones, Marian Benroubi, Conxa Castell, Albert Goday, Marie Aline Charles, Helen T. Smith, Claudia Nicolay, Alexander Simpson. (2011) Clinical outcomes after insulin initiation in patients with type 2 diabetes: 6-month data from the INSTIGATE observational study in five European countries. Current Medical Research and Opinion 27:5, 887-895
CrossRef253
George L. Bakris. (2011) Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus. Mayo Clinic Proceedings 86:5, 444-456
CrossRef254
Louis Monnier, Claude Colette, Françoise Michel, Jean-Paul Cristol, David R. Owens. (2011) Insulin therapy has a complex relationship with measure of oxidative stress in type 2 diabetes: a case for further study. Diabetes/Metabolism Research and Reviews 27:4, 348-353
CrossRef255
J. Joya-Galeana, M. Fernandez, A. Cervera, S. Reyna, S. Ghosh, C. Triplitt, N. Musi, R. A. DeFronzo, E. Cersosimo. (2011) Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects. Diabetes/Metabolism Research and Reviews 27:4, 373-382
CrossRef256
W. Motz, W. Kerner. (2011) Kardiale Endorganschäden bei Diabetes. Der Internist 52:5, 505-517
CrossRef257
Katrien Benhalima, Eberhard Standl, Chantal Mathieu. (2011) The importance of glycemic control: how low should we go with HbA1c? Start early, go safe, go low. Journal of Diabetes and its Complications 25:3, 202-207
CrossRef258
Ignacio Conget, Marga Giménez. (2011) Hypoglycemia, diabetes and atherosclerosis: is there a link?. Diabetes Management 1:3, 291-297
CrossRef259
Karen N Eggleston, Nilay D Shah, Steven A Smith, Ernst R Berndt, Joseph P Newhouse. (2011) Quality Adjustment for Health Care Spending on Chronic Disease: Evidence from Diabetes Treatment, 1999–2009. American Economic Review 101:3, 206-211
CrossRef260
H.-P. Hammes. (2011) Diabetische Retinopathie und Makulopathie. Der Internist 52:5, 518-532
CrossRef261
Andreas Holstein, Michael Hahn, Olaf Patzer, Angela Seeringer, Peter Kovacs, Julia Stingl. (2011) Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. European Journal of Clinical Pharmacology 67:5, 471-476
CrossRef262
S. Lim, M. K. Moon, H. Shin, T. H. Kim, B. J. Cho, M. Kim, H. S. Park, S. H. Choi, S.-H. Ko, M. H. Chung, I. K. Lee, H. C. Jang, Y.-B. Kim, K. S. Park. (2011) Effect of S-adenosylmethionine on neointimal formation after balloon injury in obese diabetic rats. Cardiovascular Research 90:2, 383-393
CrossRef263
Adie Viljoen, Alan J. Sinclair. (2011) Diabetes and Insulin Resistance in Older People. Medical Clinics of North America 95:3, 615-629
CrossRef264
Giovanni Musso, Roberto Gambino, Maurizio Cassader, Gianfranco Pagano. (2011) A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. Annals of Medicine1-19
CrossRef265
-Wei Du Hong, -Yue Li Jia, He Yao. (2011) Glycemic and blood pressure control in older patients with hypertension and diabetes: association with carotid atherosclerosis. Journal of Geriatric Cardiology 8:1, 24-30
CrossRef266
A White, M Fisher. (2011) Making sense of outcomes in the ACCORD trial. Practical Diabetes International 28:3, 102-103
CrossRef267
David Siegel, Arthur L.M. Swislocki. (2011) The ACCORD Study: The Devil Is in the Details. Metabolic Syndrome and Related Disorders 9:2, 81-84
CrossRef268
Amir Aziz, Stephen Wheatcroft. (2011) Insulin resistance in Type 2 diabetes and obesity: implications for endothelial function. Expert Review of Cardiovascular Therapy 9:4, 403-407
CrossRef269
Fernando Ovalle. (2011) Cardiovascular Implications of Antihyperglycemic Therapies for Type 2 Diabetes. Clinical Therapeutics 33:4, 393-407
CrossRef270
Edelmiro Menéndez Torre, Francisco Javier Lafita Tejedor, Sara Artola Menéndez, Jesús Millán Núñez-Cortés, Ángeles Alonso García, Manuel Puig Domingo, José Ramón García Solans, Fernando Álvarez Guisasola, Javier García Alegría, Javier Mediavilla Bravo, Carlos Miranda Fernández-Santos, Ramón Romero González. (2011) Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. Atención Primaria 43:4, 202.e1-202.e9
CrossRef271
A J Rennings, F G Russel, Y Li, P M Deen, R Masereeuw, C J Tack, P Smits. (2011) Preserved Response to Diuretics in Rosiglitazone-Treated Subjects With Insulin Resistance: A Randomized Double-Blind Placebo-Controlled Crossover Study. Clinical Pharmacology & Therapeutics 89:4, 587-594
CrossRef272
Amanda N. Long, Samuel Dagogo-Jack. (2011) Comorbidities of Diabetes and Hypertension: Mechanisms and Approach to Target Organ Protection. The Journal of Clinical Hypertension 13:4, 244-251
CrossRef273
K. J. J. van Hateren, G. W. D. Landman, N. Kleefstra, I. Drion, K. H. Groenier, S. T. Houweling, H. J. G. Bilo. (2011) Glycaemic control and the risk of mortality in elderly type 2 diabetic patients (ZODIAC-20). International Journal of Clinical Practice 65:4, 415-419
CrossRef274
Gianpaolo Reboldi, Giorgio Gentile, Fabio Angeli, Paolo Verdecchia. (2011) Optimal Therapy in Hypertensive Subjects with Diabetes Mellitus. Current Atherosclerosis Reports 13:2, 176-185
CrossRef275
Anthony L. McCall. (2011) What’s Wrong with Too Low? Is Hypoglycemia a Marker or a Cause of CVD and Mortality Risk?. Current Diabetes Reports 11:2, 71-74
CrossRef276
M. Schütt, H.H. Klein. (2011) Neue Möglichkeiten der Differenzialtherapie des Typ-2-Diabetes. Der Internist 52:4, 395-404
CrossRef277
Sei J. Lee, W. John Boscardin, Irena Stijacic Cenzer, Elbert S. Huang, Kathy Rice-Trumble, Catherine Eng. (2011) The Risks and Benefits of Implementing Glycemic Control Guidelines in Frail Older Adults with Diabetes Mellitus. Journal of the American Geriatrics Society 59:4, 666-672
CrossRef278
Manuel Monreal. (2011) Factores de riesgo de complicaciones vasculares en extremidades inferiores en pacientes diabéticos. Medicina Clínica 136:9, 386-387
CrossRef279
Bo Ahrén. (2011) Are Sulfonylureas Less Desirable Than DPP-4 Inhibitors as Add-on to Metformin in the Treatment of Type 2 Diabetes?. Current Diabetes Reports 11:2, 83-90
CrossRef280
Shin Kadota, Mitsuo Matsuda, Masayasu Izuhara, Osamu Baba, Hirokazu Mitsuoka, Keisuke Shioji, Takashi Uegaito. (2011) The association between post-load low insulin level and high mortality rates in patients with no previous diagnosis of diabetes mellitus. International Journal of Cardiology 148:1, 59-63
CrossRef281
Daniel Addison, David Aguilar. (2011) Diabetes and Cardiovascular Disease: The Potential Benefit of Incretin-Based Therapies. Current Atherosclerosis Reports 13:2, 115-122
CrossRef282
Matthew C Riddle. (2011) Glycemic control and cardiovascular mortality. Current Opinion in Endocrinology, Diabetes and Obesity 18:2, 104-109
CrossRef283
P. Anagnostis, V. G. Athyros, F. Adamidou, A. Panagiotou, M. Kita, A. Karagiannis, D. P. Mikhailidis. (2011) Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes, Obesity and Metabolism 13:4, 302-312
CrossRef284
Kathryn A. Britton, Vikas Aggarwal, Anita Y. Chen, Karen P. Alexander, Ezra Amsterdam, Elizabeth Fraulo, Paul Muntner, Laine Thomas, Darren K. McGuire, Stephen D. Wiviott, Matthew T. Roe, Ulrich K. Schubart, Caroline S. Fox. (2011) No association between hemoglobin A1c and in-hospital mortality in patients with diabetes and acute myocardial infarction. American Heart Journal 161:4, 657-663.e1
CrossRef285
Robert J. Richards, L. Yvonne Melendez-Ramirez, William T. Cefalu. 2011. Insulin Sensitizers Versus Secretagogues as First-Line Therapy for Diabetes: Rationale for Clinical Choice. , 71-78.
CrossRef286
Steven A. Smith. 2011. HbA1c: Is it the Most Important Therapeutic Target in outPatient Management of Diabetes?. , 96-104.
CrossRef287
Rami Almokayyad, Robert Cuddihy. 2011. What is the Role of Self-Monitoring in Diabetes? Is there a Role for Postprandial Glucose Monitoring? How does Continuous Glucose Monitoring Integrate into Clinical Practice?. , 41-55.
CrossRef288
The ACCORD Study Group. (2011) Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes. New England Journal of Medicine 364:9, 818-828
Full Text289
J. H. DeVries. (2011) Intensified glucose lowering in type 2 diabetes: don’t throw the baby out with the bathwater. Diabetologia 54:3, 705-706
CrossRef290
M. J. Davies, R. Kela, K. Khunti. (2011) Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes, Obesity and Metabolism 13:3, 207-220
CrossRef291
James B. Seward. (2011) Physiological Aging: Window of Opportunity
Editorials published in JACC: Cardiovascular Imaging reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Imaging or the American College of Cardiology.. JACC: Cardiovascular Imaging 4:3, 243-245
CrossRef292
L. Czupryniak, E. Szymańska-Garbacz, M. Pawłowski, M. Saryusz-Wolska, J. Loba. (2011) Intensified glucose lowering in type 2 diabetes: time for a bolder reappraisal. Diabetologia 54:3, 701-702
CrossRef293
DJ Galloway. (2011) Provision of laparoscopic bariatric surgery. Practical Diabetes International 28:2, 56-57
CrossRef294
Diana Muačević-Katanec, Željko Reiner. (2011) Diabetic dyslipidemia or ‘diabetes lipidus’?. Expert Review of Cardiovascular Therapy 9:3, 341-348
CrossRef295
Sofiya Milman, Jill P. Crandall. (2011) Mechanisms of Vascular Complications in Prediabetes. Medical Clinics of North America 95:2, 309-325
CrossRef296
J. S. Yudkin, B. Richter, E. A. M. Gale. (2011) Intensified glucose lowering in type 2 diabetes. Reply to Czupryniak L, Szymańska-Garbacz E, Pawłowski M et al. [letter], Aizawa T and Funase Y [letter] and DeVries JH [letter]. Diabetologia 54:3, 707-708
CrossRef297
Susan A. Marsh, Louis J. Dell’Italia, John C. Chatham. (2011) Activation of the hexosamine biosynthesis pathway and protein O-GlcNAcylation modulate hypertrophic and cell signaling pathways in cardiomyocytes from diabetic mice. Amino Acids 40:3, 819-828
CrossRef298
Zafar H Israili. (2011) Advances in the Treatment of Type 2 Diabetes Mellitus. American Journal of Therapeutics 18:2, 117-152
CrossRef299
J T Cross, D L Veenstra, J S Gardner, L P Garrison. (2011) Can Modeling of Health Outcomes Facilitate Regulatory Decision Making?: The Benefit–Risk Tradeoff for Rosiglitazone in 1999 vs. 2007. Clinical Pharmacology & Therapeutics 89:3, 429-436
CrossRef300
A. de la Sierra. (2011) Prevención de la progresión y regresión de la lesión orgánica. Estrategias de futuro. Revista Clínica Española 211, 8-14
CrossRef301
Barbara J. Zarowitz. (2011) The ADA Focus on Diabetes 2011. Geriatric Nursing 32:2, 119-122
CrossRef302
Yogish C Kudva, Ananda Basu. (2011) Ultra-long-acting insulins for a lifestyle-related pandemic. The Lancet 377:9769, 880-881
CrossRef303
Hana Rosolova, Barbora Nussbaumerova. (2011) Cardio-metabolic risk prediction should be superior to cardiovascular risk assessment in primary prevention of cardiovascular diseases. The EPMA Journal 2:1, 15-26
CrossRef304
Filippos Triposkiadis, Gregory Giamouzis, Javed Butler. (2011) The importance of managing diabetes correctly to prevent heart failure. Expert Review of Cardiovascular Therapy 9:3, 257-259
CrossRef305
(2011) The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: Baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH) trial. American Heart Journal 161:3, 538-543
CrossRef306
Ignacio Conget. (2011) Hypoglycaemia and cardiovascular disease. The fatal linkage. Avances en Diabetología 27:2, 39-41
CrossRef307
Todd R. Marcy, Mark L. Britton, Don Harrison. (2011) Identification of barriers to appropriate dietary behavior in low-income patients with type 2 diabetes mellitus. Diabetes Therapy 2:1, 9-19
CrossRef308
C. J. Bailey, M. Kodack. (2011) Patient adherence to medication requirements for therapy of type 2 diabetes. International Journal of Clinical Practice 65:3, 314-322
CrossRef309
Francisco Arrieta, Miguel Salinero, Marbella Piñera, José Ignacio Botella-Carretero, Pedro Iglesias, Juan Carlos Abanades, Enrique Carrillo, Pedro Nogales, José Antonio Balsa, Isabel Zamarrón, Adela Rovira, Clotilde Vázquez. (2011) Estudio descriptivo de la evolución clínico-asistencial de la población con diabetes tipo 2 en la Comunidad de Madrid. Estudio de seguimiento diabético tipo 2 (ESD-2). Avances en Diabetología 27:2, 53-60
CrossRef310
E. Menéndez Torre, J. Lafita Tejedor, S. Artola Menéndez, J. Millán Núñez-Cortés, Á. Alonso García, M. Puig Domingo, J.R. García Solans, F. Álvarez Guisasola, J. García Alegría, J. Mediavilla Bravo, C. Miranda Fernández-Santos, R. Romero González. (2011) Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. Revista Clínica Española 211:3, 147-155
CrossRef311
C. Lamanna, M. Monami, N. Marchionni, E. Mannucci. (2011) Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism 13:3, 221-228
CrossRef312
Harold E. Lebovitz. (2011) Type 2 diabetes mellitus—current therapies and the emergence of surgical options. Nature Reviews Endocrinology 7:7, 408-419
CrossRef313
Thomas G. Brott, Jonathan L. Halperin, Suhny Abbara, J. Michael Bacharach, John D. Barr, Ruth L. Bush, Christopher U. Cates, Mark A. Creager, Susan B. Fowler, Gary Friday, Vicki S. Hertzberg, E. Bruce McIff, Wesley S. Moore, Peter D. Panagos, Thomas S. Riles, Robert H. Rosenwasser, Allen J. Taylor. (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary. Journal of the American College of Cardiology 57:8, 1002-1044
CrossRef314
Marshall Elam, Laura C Lovato, Henry Ginsberg. (2011) Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective. Current Opinion in Lipidology 22:1, 55-61
CrossRef315
A. H. Barnett. (2011) Tight glycaemic control-caution in high risk groups. International Journal of Clinical Practice 65:2, 226-226
CrossRef316
Salo Haratz, David Tanne. (2011) Diabetes, hyperglycemia and the management of cerebrovascular disease. Current Opinion in Neurology 24:1, 81-88
CrossRef317
Marshall Elam, Laura Lovato, Henry Ginsberg. (2011) The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus. Clinical Lipidology 6:1, 9-20
CrossRef318
S. Aldasouqi, V. Gossain. (2011) Preventing diabetes complications and the “glucocentric” dilemma: a word of caution. International Journal of Clinical Practice 65:2, 225-225
CrossRef319
Eisuke Yasunari, Kageumi Takeno, Hideaki Funayama, Setsuko Tomioka, Motoyuki Tamaki, Yoshio Fujitani, Ryuzo Kawamori, Hirotaka Watada, Takahisa Hirose. (2011) Efficacy of pioglitazone on glycemic control and carotid intima-media thickness in type 2 diabetes patients with inadequate insulin therapy. Journal of Diabetes Investigation 2:1, 56-62
CrossRef320
M. W. J. Strachan. (2011) R D Lawrence Lecture 2010^. The brain as a target organ in Type 2 diabetes: exploring the links with cognitive impairment and dementia. Diabetic Medicine 28:2, 141-147
CrossRef321
Mariel M Finucane, Gretchen A Stevens, Melanie J Cowan, Goodarz Danaei, John K Lin, Christopher J Paciorek, Gitanjali M Singh, Hialy R Gutierrez, Yuan Lu, Adil N Bahalim, Farshad Farzadfar, Leanne M Riley, Majid Ezzati. (2011) National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. The Lancet 377:9765, 557-567
CrossRef322
Giuseppe Mancia, Enrico Agabiti Rosei, Ettore Ambrosioni, Francesco Avino, Antonio Carolei, Maurizio Daccò, Giovanni Di Giacomo, Claudio Ferri, Irene Grazioli, Gabriella Melzi, Giuseppe Nappi, Lorenzo Pinessi, Giorgio Sandrini, Bruno Trimarco, Giorgio Zanchin. (2011) Hypertension and migraine comorbidity: prevalence and risk of cerebrovascular events: evidence from a large, multicenter, cross-sectional survey in Italy (MIRACLES study). Journal of Hypertension 29:2, 309-318
CrossRef323
Thomas G. Brott, Jonathan L. Halperin, Suhny Abbara, J. Michael Bacharach, John D. Barr, Ruth L. Bush, Christopher U. Cates, Mark A. Creager, Susan B. Fowler, Gary Friday, Vicki S. Hertzberg, E. Bruce McIff, Wesley S. Moore, Peter D. Panagos, Thomas S. Riles, Robert H. Rosenwasser, Allen J. Taylor. (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease. Journal of the American College of Cardiology 57:8, e16-e94
CrossRef324
Mark W. J. Strachan, Rebecca M. Reynolds, Riccardo E. Marioni, Jacqueline F. Price. (2011) Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nature Reviews Endocrinology 7:2, 108-114
CrossRef325
Meng Lee, Bruce Ovbiagele. (2011) Reno-cerebrovascular disease: linking the nephron and neuron. Expert Review of Neurotherapeutics 11:2, 241-249
CrossRef326
Lal K. Tanwani. (2011) Insulin Therapy in the Elderly Patient With Diabetes. The American Journal of Geriatric Pharmacotherapy 9:1, 24-36
CrossRef327
Juliana CN Chan. (2011) What can we learn from the recent blood glucose lowering megatrials?. Journal of Diabetes Investigation 2:1, 1-5
CrossRef328
Ashley Dickinson, Motaz Qadan, Clayton Weller, Sarah Gardner, Hiram C. Polk. (2011) In Vitro Study of Variables Relevant to Perioperative Care of the Surgical Patient: Glucose, Osmolarity, and Rewarming. Journal of the American College of Surgeons 212:2, 180-186
CrossRef329
P. Valensi, S. Picard. (2011) Lipids, lipid-lowering therapy and diabetes complications. Diabetes & Metabolism 37:1, 15-24
CrossRef330
Daniel M Tessier. (2011) Optimal glycemic control in the elderly: where is the evidence and who should be targeted?. Aging Health 7:1, 89-96
CrossRef331
Eiichi Araki, Hideo Fukushima, Hideki Kishikawa. (2011) HbA1c: The lower the better?. Journal of Diabetes Investigation 2:1, 45-47
CrossRef332
Hisako Hirai, Rie Kanaya, Morihiko Maeda, Ding qungfang, Koichiro Ina, Toshio Hayashi. (2011) The role of insulin growth factor on atherosclerosis and endothelial function: The effect on hyperlipidemia and aging. Life Sciences 88:9-10, 425-431
CrossRef333
P. Chamnan, R. K. Simmons, R. Jackson, K. T. Khaw, N. J. Wareham, S. J. Griffin. (2011) Non-diabetic hyperglycaemia and cardiovascular risk: moving beyond categorisation to individual interpretation of absolute risk. Diabetologia 54:2, 291-299
CrossRef334
Mark S Kipnes. (2011) Sodium–glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: a review of Phase II and III trials. Clinical Investigation 1:1, 145-156
CrossRef335
Edelmiro Menéndez Torre, Francisco Javier Lafita Tejedor, Sara Artola Menéndez, Jesús Millán Núñez-Cortés, Ángeles Alonso García, Manuel Puig Domingo, José Ramón García Solans, Fernando Álvarez Guisasola, Javier García Alegría, Javier Mediavilla Bravo, Carlos Miranda Fernández-Santos, Ramón Romero González. (2011) Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. Clínica e Investigación en Arteriosclerosis 23:1, 40-48
CrossRef336
Carrie McAdam-Marx, Jonathan Bouchard, Mark Aagren, Chris Conner, Diana I. Brixner. (2011) Concurrent Control of Blood Glucose, Body Mass, and Blood Pressure in Patients With Type 2 Diabetes: An Analysis of Data From Electronic Medical Records. Clinical Therapeutics 33:1, 110-120
CrossRef337
Jin Taek Kim, Tae Jung Oh, Ye An Lee, Jun Ho Bae, Hyo Jeong Kim, Hye Seung Jung, Young Min Cho, Kyong Soo Park, Soo Lim, Hak Chul Jang, Hong Kyu Lee. (2011) Increasing Trend in the Number of Severe Hypoglycemia Patients in Korea. Diabetes & Metabolism Journal 35:2, 166
CrossRef338
Larry B. Goldstein, Ralph L. Sacco. 2011. Primary Prevention of Stroke. , 242-251.
CrossRef339
Viduranga Y. Waisundara, Sing Yung Siu, Annie Hsu, Dejian Huang, Benny K.H. Tan. (2011) Baicalin upregulates the genetic expression of antioxidant enzymes in Type-2 diabetic Goto-Kakizaki rats. Life Sciences
CrossRef340
Thomas G. Brott, Jonathan L. Halperin, Suhny Abbara, J. Michael Bacharach, John D. Barr, Ruth L. Bush, Christopher U. Cates, Mark A. Creager, Susan B. Fowler, Gary Friday, Vicki S. Hertzberg, E. Bruce McIff, Wesley S. Moore, Peter D. Panagos, Thomas S. Riles, Robert H. Rosenwasser, Allen J. Taylor, Alice K. Jacobs, Sidney C. Smith, Jeffery L. Anderson, Cynthia D. Adams, Nancy Albert, Christopher E. Buller, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Sharon Ann Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick A. Nishimura, E. Magnus Ohman, Richard L. Page, Barbara Riegel, William G. Stevenson, Lynn G. Tarkington, Clyde W. Yancy. (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive summary. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef341
Christoph Wanner, Vera Krane. (2011) Recent Advances in the Treatment of Atherogenic Dyslipidemia in Type 2 Diabetes Mellitus. Kidney and Blood Pressure Research 34:4, 209-217
CrossRef342
Lisa M Younk, Maia Mikeladze, Donna Tate, Stephen N Davis. (2011) Exercise-related hypoglycemia in diabetes mellitus. Expert Review of Endocrinology & Metabolism 6:1, 93-108
CrossRef343
Ah Young Kang, Su Kyung Park, So Young Park, Hye Jeong Lee, Ying Han, Sa Ra Lee, Sung Hwan Suh, Duk Kyu Kim, Mi Kyoung Park. (2011) Therapeutic Target Achievement in Type 2 Diabetic Patients after Hyperglycemia, Hypertension, Dyslipidemia Management. Diabetes & Metabolism Journal 35:3, 264
CrossRef344
Susie Yim-Yeh, Shilpa Rahangdale, Anh Tu Duy Nguyen, Karen E. Stevenson, Victor Novack, Aristidis Veves, Atul Malhotra. (2011) Vascular Dysfunction in Obstructive Sleep Apnea and Type 2 Diabetes Mellitus. Obesity 19:1, 17-22
CrossRef345
Ju-Young Shin, Nam-Kyong Choi, Sun-Young Jung, Ye-Jee Kim, Jong-Mi Seong, Byung-Joo Park. (2011) Overlapping Medication Associated with Healthcare Switching among Korean Elderly Diabetic Patients. Journal of Korean Medical Science 26:11, 1461
CrossRef346
Henry Punzi, Ali Shojaee, William F. Waverczak, Jen-Fue Maa. (2011) Efficacy of Amlodipine and Olmesartan Medoxomil in Hypertensive Patients With Diabetes and Obesity. Journal of Clinical Hypertensionno
CrossRef347
Mário Raimundo, José António Lopes. (2011) Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease: A Dynamic and Life-Threatening Triad. Cardiology Research and Practice 2011, 1-16
CrossRef348
Arthur J. Chu. (2011) Tissue Factor, Blood Coagulation, and Beyond: An Overview. International Journal of Inflammation 2011, 1-30
CrossRef349
Stavros Stavrakis, Julie A. Stoner, Madona Azar, Siddharth Wayangankar, Udho Thadani. (2011) Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis. The American Journal of the Medical Sciences 341:1, 1-9
CrossRef350
Hideo Fujita, Ryozo Nagai. (2011) Glycemic Control Is Another Target of PCI in Diabetic Patients. Circulation Journal 75:4, 773-774
CrossRef351
Stephen J. Nicholls, E. Murat Tuzcu, Kathy Wolski, Ozgur Bayturan, Andrea Lavoie, Kiyoko Uno, Stuart Kupfer, Alfonso Perez, Richard Nesto, Steven E. Nissen. (2011) Lowering the Triglyceride/High-Density Lipoprotein Cholesterol Ratio Is Associated With the Beneficial Impact of Pioglitazone on Progression of Coronary Atherosclerosis in Diabetic Patients. Journal of the American College of Cardiology 57:2, 153-159
CrossRef352
Ulrich M. Vischer. (2011) Glycemic Targets for Elderly Diabetic Patients Need Reappraisal. Journal of the American Medical Directors Association 12:1, 9-11
CrossRef353
Mark S. MacGregor, Maarten W. Taal. (2011) Renal Association Clinical Practice Guideline on Detection, Monitoring and Management of Patients with CKD. Nephron Clinical Practice 118:s1, c71-c100
CrossRef354
J. A. Johnson, S. L. Bowker. (2011) Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 54:1, 25-31
CrossRef355
Brent C. Taylor, Timothy J. Wilt, H. Gilbert Welch. (2011) Impact of Diastolic and Systolic Blood Pressure on Mortality: Implications for the Definition of “Normal”. Journal of General Internal Medicine
CrossRef356
Ingrid Mühlhauser, Matthias Lenz, Gabriele Meyer. (2011) Entwicklung, Bewertung und Synthese von komplexen Interventionen – eine methodische Herausforderung. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 105:10, 751-761
CrossRef357
Wendy A Davis. (2011) Predicting severe hypoglycemia in the community: a review of recent evidence. Diabetes Management 1:1, 109-128
CrossRef358
M. Camafort, L. R. Álvarez-Rodríguez, J. F. S. Muñoz-Torrero, J. C. Sahuquillo, L. López-Jiménez, R. Coll, M. Monreal, . (2011) Glucose control and outcome in patients with stable diabetes and previous coronary, cerebrovascular or peripheral artery disease. Findings from the FRENA Registry. Diabetic Medicine 28:1, 73-80
CrossRef359
Hyun Jeong Jeon, Tae Keun Oh. (2011) Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients. Diabetes & Metabolism Journal 35:5, 529
CrossRef360
Vicky Cheng, Sangeeta R. Kashyap. (2011) Weight Considerations in Pharmacotherapy for Type 2 Diabetes. Journal of Obesity 2011, 1-9
CrossRef361
Sara M. Alexanian, Marie E. McDonnell, Shamsuddin Akhtar. (2011) Creating a Perioperative Glycemic Control Program. Anesthesiology Research and Practice 2011, 1-9
CrossRef362
Hiroshi Ito. (2011) Optimal treatment for coronary artery disease in patients with diabetes: percutaneous coronary intervention, coronary artery bypass graft, and medications. General Thoracic and Cardiovascular Surgery 59:1, 6-13
CrossRef363
Eran Bashan, William H. Herman, Israel Hodish. (2011) Are Glucose Readings Sufficient to Adjust Insulin Dosage?. Diabetes Technology & Therapeutics 13:1, 85-92
CrossRef364
Bruno Rodrigues, Kaleizu T Rosa, Alessandra Medeiros, Beatriz D Schaan, Patricia C Brum, Kátia De Angelis, Maria Irigoyen. (2011) Hyperglycemia can delay left ventricular dysfunction but not autonomic damage after myocardial infarction in rodents. Cardiovascular Diabetology 10:1, 26
CrossRef365
Jerzy W. Kolaczynski. (2011) Concept paper: antihyperglycemic therapy and the diabetic heart—do we really know enough?. Journal of Diabetes and its Complications 25:1, 63-72
CrossRef366
Jung Hee Kim, Dae Jung Kim, Hak Chul Jang, Sung Hee Choi. (2011) Epidemiology of Micro- and Macrovascular Complications of Type 2 Diabetes in Korea. Diabetes & Metabolism Journal 35:6, 571
CrossRef367
Ebenezer A. Nyenwe, Terri W. Jerkins, Guillermo E. Umpierrez, Abbas E. Kitabchi. (2011) Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism 60:1, 1-23
CrossRef368
Michael J. Satlin, Donald R. Hoover, Marshall J. Glesby. (2011) Glycemic Control in HIV-Infected Patients with Diabetes Mellitus and Rates of Meeting American Diabetes Association Management Guidelines. AIDS Patient Care and STDs 25:1, 5-12
CrossRef369
Masahiko Kato, Naoya Matsumoto, Yoshimochi Nakano, Yasuyuki Suzuki, Shunichi Yoda, Yuichi Sato, Shu Kasama, Ken Nagao, Atsushi Hirayama. (2011) Combined Assessment of Myocardial Perfusion and Function by ECG-Gated Myocardial Perfusion Single-Photon Emission Computed Tomography for the Prediction of Future Cardiac Events in Patients With Type 2 Diabetes Mellitus. Circulation Journal 75:2, 376-382
CrossRef370
Jerry Yee. (2011) CKD and Hypertension: Pogo and Pragmatism. Advances in Chronic Kidney Disease 18:1, 1-2
CrossRef371
Moritoki Egi, Rinaldo Bellomo, Edward Stachowski, Craig J. French, Graeme K. Hart, Gopal Taori, Colin Hegarty, Michael Bailey. (2011) The interaction of chronic and acute glycemia with mortality in critically ill patients with diabetes*. Critical Care Medicine 39:1, 105-111
CrossRef372
M.G. Hennerici. (2011) Report of the 20th European Stroke Conference, Hamburg, May 24–27, 2011. Cerebrovascular Diseases 32:6, 589-613
CrossRef373
Aureo L. DePaula, Alessandro Stival, Alfredo Halpern, Sergio Vencio. (2011) Thirty-Day Morbidity and Mortality of the Laparoscopic Ileal Interposition Associated with Sleeve Gastrectomy for the Treatment of Type 2 Diabetic Patients with BMI <35: An Analysis of 454 Consecutive Patients. World Journal of Surgery 35:1, 102-108
CrossRef374
Robert Ratner, Jenny Han, Dawn Nicewarner, Irina Yushmanova, Byron J Hoogwerf, Larry Shen. (2011) Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovascular Diabetology 10:1, 22
CrossRef375
Henry H Fischer, Sheri L Eisert, M Josh Durfee, Susan L Moore, Andrew W Steele, Kevin McCullen, Katherine Anderson, Lara Penny, Thomas D Mackenzie. (2011) The impact of tailored diabetes registry report cards on measures of disease control: a nested randomized trial. BMC Medical Informatics and Decision Making 11:1, 12
CrossRef376
Vianda S. Stel, Friedo W. Dekker, Giovanni Tripepi, Carmine Zoccali, Kitty J. Jager. (2011) Survival Analysis I: The Kaplan-Meier Method. Nephron Clinical Practice 119:1, c83-c88
CrossRef377
Keun-Hwa Jung, Kon Chu, Soon-Tae Lee, Jae-Jun Bahn, Jin-Hee Kim, Manho Kim, Sang Kun Lee, Jae-Kyu Roh. (2011) Risk of Macrovascular Complications in Type 2 Diabetes Mellitus: Endothelial Microparticle Profiles. Cerebrovascular Diseases 31:5, 485-493
CrossRef378
Edelmiro Menéndez Torre, Francisco Javier Lafita Tejedor, Sara Artola Menéndez, Jesús Millán Núñez-Cortés, Ángeles Alonso García, Manuel Puig Domingo, José Ramón García Solans, Fernando Álvarez Guisasola, Javier García Alegría, Javier Mediavilla Bravo, Carlos Miranda Fernández-Santos, Ramón Romero González. (2011) Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes. Endocrinología y Nutrición (English Edition) 58:3, 112-120
CrossRef379
Shih-Hung Tsai, Yen-Yue Lin, Chin-Wang Hsu, Chien-Sheng Cheng, Der-Ming Chu. (2011) Hypoglycemia Revisited in the Acute Care Setting. Yonsei Medical Journal 52:6, 898
CrossRef380
Vladimir Vuksan, John Sievenpipper, Elena Jovanovski, Alexandra L. Jenkins. (2010) Current Clinical Evidence for Korean Red Ginseng in Management of Diabetes and Vascular Disease: A Toronto's Ginseng Clinical Testing Program. Journal of Ginseng Research 34:4, 264-273
CrossRef381
Andrew Siebel, Ana Fernandez, Assam El-Osta. 2010. Glycemic Memory and Epigenetic Changes. , 215-227.
CrossRef382
Om P. Ganda. (2010) The Role of Bile Acid Sequestrants in the Management of Type 2 Diabetes Mellitus. Metabolic Syndrome and Related Disorders 8:S1, S-15-S-21
CrossRef383
Luciano Pirola, Aneta Balcerczyk, Jun Okabe, Assam El-Osta. (2010) Epigenetic phenomena linked to diabetic complications. Nature Reviews Endocrinology 6:12, 665-675
CrossRef384
Eric M. Chang, Benjamin M. Kozak, Kelly L. Close. (2010) Journal of Diabetes NEWS. Journal of Diabetes 2:4, 227-232
CrossRef385
Zachary Bloomgarden, Yehuda Handelsman. (2010) The Avandia debate: An unhappy conclusion. Journal of Diabetes 2:4, 221-222
CrossRef386
Alfonso Perez, Randal Jacks, Vipin Arora, Robert Spanheimer. (2010) Effects of Pioglitazone and Metformin Fixed-Dose Combination Therapy on Cardiovascular Risk Markers of Inflammation and Lipid Profile Compared With Pioglitazone and Metformin Monotherapy in Patients With Type 2 Diabetes. The Journal of Clinical Hypertension 12:12, 973-982
CrossRef387
Michel P Hermans, Jean-Charles Fruchart. (2010) Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here?. Clinical Lipidology 5:6, 811-826
CrossRef388
David C. Klonoff. (2010) Incretin therapy for type 2 diabetes mellitus. Advances in Therapy 27:12, 881-894
CrossRef389
Khaled I. Khalaf, Heinrich Taegtmeyer. (2010) Insulin Sensitizers and Heart Failure: An Engine Flooded with Fuel. Current Hypertension Reports 12:6, 399-401
CrossRef390
María Costi, Tatiana Dilla, Jesús Reviriego, Conxa Castell, Albert Goday. (2010) Clinical characteristics of patients with type 2 diabetes mellitus at the time of insulin initiation: INSTIGATE observational study in Spain. Acta Diabetologica 47:S1, 169-175
CrossRef391
Laura Pala, Matteo Monami, Caterina Lamanna, Barbara Cresci, Claudia Colombi, Gianluca Bardini, Jolanda Sposato, Niccolò Marchionni, Carlo M. Rotella, Edoardo Mannucci. (2010) Failure to metformin and insulin secretagogue monotherapy: an observational cohort study. Acta Diabetologica 47:S1, 7-11
CrossRef392
José A. Luchsinger. (2010) Diabetes, related conditions, and dementia. Journal of the Neurological Sciences 299:1-2, 35-38
CrossRef393
Philip Greenland, Joseph S. Alpert, George A. Beller, Emelia J. Benjamin, Matthew J. Budoff, Zahi A. Fayad, Elyse Foster, Mark A. Hlatky, John McB. Hodgson, Frederick G. Kushner, Michael S. Lauer, Leslee J. Shaw, Sidney C. Smith, Allen J. Taylor, William S. Weintraub, Nanette K. Wenger. (2010) 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults. Journal of the American College of Cardiology 56:25, e50-e103
CrossRef394
Barbara Ludwig, Stefan Ludwig, Anja Steffen, Hans-Detlev Saeger, Stefan R. Bornstein. (2010) Islet Versus Pancreas Transplantation in Type 1 Diabetes: Competitive or Complementary?. Current Diabetes Reports 10:6, 506-511
CrossRef395
M Brito-Sanfiel, J Diago-Cabezudo, A Calderon. (2010) Economic impact of hypoglycemia on healthcare in Spain. Expert Review of Pharmacoeconomics & Outcomes Research 10:6, 649-660
CrossRef396
Taina K. Mattila, Anthonius de Boer. (2010) Influence of Intensive versus Conventional Glucose Control on Microvascular and Macrovascular Complications in Type 1 and 2 Diabetes Mellitus. Drugs 70:17, 2229-2245
CrossRef397
S. Jacqueminet, O. Barthelemy, F. Rouzet, R. Isnard, M. Halbron, A. Bouzamondo, D. Le Guludec, A. Grimaldi, J.-P. Metzger, C. Le Feuvre. (2010) A randomized study comparing isotope and echocardiography stress testing in the screening of silent myocardial ischaemia in type 2 diabetic patients. Diabetes & Metabolism 36:6, 463-469
CrossRef398
M. O’Reilly, E. P. O’Sullivan, C. Davenport, D. Smith. (2010) “Dead in bed”: a tragic complication of type 1 diabetes mellitus. Irish Journal of Medical Science 179:4, 585-587
CrossRef399
(2010) Retinopathy Progression in Type 2 Diabetes. New England Journal of Medicine 363:22, 2171-2174
Full Text400
Paul J. Beisswenger. (2010) Glycation and biomarkers of vascular complications of diabetes. Amino Acids
CrossRef401
Bas Houweling, Martin Willink, Lex Goudswaard, Guy Rutten en Henk Bilo. (2010) Verwarring rond scherp instellen DM2. Huisarts en wetenschap
CrossRef402
Ralf Paschke, Florian Gerhard Wuthe, Katja Kühn, Claudia Jochmann, Peter Wiedemann. (2010) Vergleich der Risikoparameter der diabetischen Retinopathie und der leitliniengerechten Prävention für Patienten einer diabetischen Schwerpunktambulanz und eines Lasertherapiezentrums. Medizinische Klinik 105:11, 772-778
CrossRef403
J. Wernecke, A. Friedl. (2010) Therapieziele beim geriatrischen Patienten. Der Diabetologe 6:7, 551-559
CrossRef404
R. Kahn. (2010) Guidelines: we’ll always need them, we sometimes dislike them, and we have to make them better. Diabetologia 53:11, 2280-2284
CrossRef405
E. E. Wright, A. H. Stonehouse, R. M. Cuddihy. (2010) In support of an early polypharmacy approach to the treatment of type 2 diabetes. Diabetes, Obesity and Metabolism 12:11, 929-940
CrossRef406
Claudia Ruth Pischke, Steven Frenda, Dean Ornish, Gerdi Weidner. (2010) Lifestyle changes are related to reductions in depression in persons with elevated coronary risk factors. Psychology & Health 25:9, 1077-1100
CrossRef407
Deborah Meyer, Monica Wirrig, Victor Heh, Jay Shubrook. (2010) Comanagement of elderly patients with type 2 diabetes: better adherence to ADA guidelines?. Osteopathic Family Physician 2:6, 160-164
CrossRef408
T. Siegmund, P.M. Schumm-Draeger. (2010) Therapie mit oralen Antidiabetika und/oder Insulin im höheren Alter?. Der Diabetologe 6:7, 560-569
CrossRef409
Francesco Boscia. (2010) Current Approaches to the Management of Diabetic Retinopathy and Diabetic Macular Oedema. Drugs 70:16, 2171-2200
CrossRef410
A. Ceriello. (2010) The glucose triad and its role in comprehensive glycaemic control: current status, future management. International Journal of Clinical Practice 64:12, 1705-1711
CrossRef411
Toyoyoshi Uchida, Junko Kawai, Yoshio Fujitani, Ryuzo Kawamori, Hirotaka Watada, Takahisa Hirose. (2010) Efficacy and adverse effects of low-dose nateglinide in early type 2 diabetes: comparison with acarbose in a crossover study. Diabetology International 1:1, 35-41
CrossRef412
Mary Margaret Huizinga, Christianne L. Roumie, Robert A. Greevy, Xulei Liu, Harvey J. Murff, Adriana M. Hung, Carlos G. Grijalva, Marie R. Griffin. (2010) Glycemic and weight changes after persistent use of incident oral diabetes therapy: a veterans administration retrospective cohort study. Pharmacoepidemiology and Drug Safety 19:11, 1108-1112
CrossRef413
M. O. Gore, F. A. Masoudi, D. K. McGuire. (2010) Diabetes mellitus in patients with myocardial infarction complicated by heart failure: a 'low ejection fraction' equivalent?. European Journal of Heart Failure 12:11, 1156-1158
CrossRef414
Tomás Romero, Camila X. Romero. (2010) Prevención cardiovascular estancada: tendencias alarmantes y barreras socioeconómicas persistentes. Revista Española de Cardiología 63:11, 1340-1348
CrossRef415
Sophia Zoungas, Anushka Patel. (2010) Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies. Annals of the New York Academy of Sciences 1212:1, 29-40
CrossRef416
K. Eeg-Olofsson, J. Cederholm, P. M. Nilsson, B. Zethelius, A.-M. Svensson, S. Gudbjörnsdóttir, B. Eliasson. (2010) New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Journal of Internal Medicine 268:5, 471-482
CrossRef417
J. S. Skyler. (2010) Glycemia and cardiovascular diseases in type 2 diabetes. Journal of Internal Medicine 268:5, 468-470
CrossRef418
Nebojsa M. Lalic, Bernhard Landers. (2010) 3rd Annual Symposium on Self Monitoring of Blood Glucose (SMBG) Applications and Beyond, May 7–8, 2010, London, UK. Diabetes Technology & Therapeutics 12:11, 859-872
CrossRef419
David G. Sutin. (2010) DIABETES MELLITUS IN OLDER ADULTS: TIME FOR AN OVERTREATMENT QUALITY INDICATOR. Journal of the American Geriatrics Society 58:11, 2244-2245
CrossRef420
Patrick Murray, Gary W. Chune, Vasudevan A. Raghavan. (2010) Legacy Effects from DCCT and UKPDS: What They Mean and Implications for Future Diabetes Trials. Current Atherosclerosis Reports 12:6, 432-439
CrossRef421
John Gerich. (2010) DPP-4 inhibitors: What may be the clinical differentiators?. Diabetes Research and Clinical Practice 90:2, 131-140
CrossRef422
G. K. Adler, I. Bonyhay, V. Curren, E. Waring, R. Freeman. (2010) Hypoglycaemia increases aldosterone in a dose-dependent fashion. Diabetic Medicine 27:11, 1250-1255
CrossRef423
Zoungas, Sophia, Patel, Anushka, Chalmers, John, de Galan, Bastiaan E., Li, Qiang, Billot, Laurent, Woodward, Mark, Ninomiya, Toshiharu, Neal, Bruce, MacMahon, Stephen, Grobbee, Diederick E., Kengne, Andre Pascal, Marre, Michel, Heller, Simon, . (2010) Severe Hypoglycemia and Risks of Vascular Events and Death. New England Journal of Medicine 363:15, 1410-1418
Full Text424
Yael Dinur Schejter, Elliot Turvall, Zvi Ackerman. (2010) Characteristics of Patients With Sulphonurea-Induced Hypoglycemia. Journal of the American Medical Directors Association
CrossRef425
S. Halimi. (2010) Acute consequences of hypoglycaemia in diabetic patients. Diabetes & Metabolism 36, S75-S83
CrossRef426
R. K. Simmons, J. B. Echouffo-Tcheugui, S. J. Griffin. (2010) Screening for type 2 diabetes: an update of the evidence. Diabetes, Obesity and Metabolism 12:10, 838-844
CrossRef427
Stephan Jacob, Manuel Serrano-Gil. (2010) Engaging and empowering patients to manage their type 2 diabetes, Part II: Initiatives for success. Advances in Therapy 27:10, 665-680
CrossRef428
S. C. Bain, J. McKenna. (2010) Clinical experience with liraglutide. International Journal of Clinical Practice 64, 44-48
CrossRef429
Xiao-min Chen, Yan Zhang, Xing-ping Shen, Qun Huang, Hong Ma, Yang-Ling Huang, Wen-Qiang Zhang, Hao-Jie Wu. (2010) Correlation between glucose fluctuations and carotid intima-media thickness in type 2 diabetes. Diabetes Research and Clinical Practice 90:1, 95-99
CrossRef430
Alethea N. Hill, Susan J. Appel. (2010) Diagnosing Diabetes with A1C. The Nurse Practitioner 35:10, 16-23
CrossRef431
I. Rustenbeck, S. Baltrusch, M. Tiedge. (2010) Do insulinotropic glucose-lowering drugs do more harm than good? The hypersecretion hypothesis revisited. Diabetologia 53:10, 2105-2111
CrossRef432
Lesley J. Scott. (2010) Alogliptin. Drugs 70:15, 2051-2072
CrossRef433
J. S. Yudkin, B. Richter, E. A. M. Gale. (2010) Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia 53:10, 2079-2085
CrossRef434
George Bakris, Joseph Vassalotti, Eberhard Ritz, Christoph Wanner, George Stergiou, Mark Molitch, Richard Nesto, George A Kaysen, James R Sowers. (2010) National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney International 78:8, 726-736
CrossRef435
V. Owen, I. Seetho, I. Idris. (2010) Predictors of responders to insulin therapy at 1 year among adults with type 2 diabetes. Diabetes, Obesity and Metabolism 12:10, 865-870
CrossRef436
Jefferson Tilley, Joseph Grimsby, Shawn Erickson, Steven Berthel. 2010. Diabetes Drugs: Present and Emerging. .
CrossRef437
R. E. Ratner, J. Rosenstock, G. Boka, . (2010) Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabetic Medicine 27:9, 1024-1032
CrossRef438
Jean-Pierre Grégoire, Caroline Sirois, Guillaume Blanc, Paul Poirier, Jocelyne Moisan. (2010) Persistence Patterns with Oral Antidiabetes Drug Treatment in Newly Treated Patients—A Population-Based Study. Value in Health 13:6, 820-828
CrossRef439
Jesse Foote, Jennifer Giuseffi, Medha N. Munshi. (2010) Diabetes in the Elderly. Current Cardiovascular Risk Reports 4:5, 347-353
CrossRef440
Amulya T. Siram, Robert Yanagisawa, Maria Skamagas. (2010) Weight Management in Type 2 Diabetes Mellitus. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 77:5, 533-548
CrossRef441
Hussein H. Karnib, Fuad N. Ziyadeh. (2010) The cardiorenal syndrome in diabetes mellitus. Diabetes Research and Clinical Practice 89:3, 201-208
CrossRef442
A. J. Rennings, P. Smits, M. W. Stewart, C. J. Tack. (2010) Autonomic neuropathy predisposes to rosiglitazone-induced vascular leakage in insulin-treated patients with type 2 diabetes: a randomised, controlled trial on thiazolidinedione-induced vascular leakage. Diabetologia 53:9, 1856-1866
CrossRef443
P.P. Casado, J. Szymaniec, P. Conthe. (2010) ¿Qué ha cambiado en la estrategia terapéutica de la diabetes mellitus tipo 2?. Revista Clínica Española 210, 18-25
CrossRef444
Marie T Brown, Derek LeRoith. (2010) Overcoming challenges in Type 2 diabetes management to improve patient outcomes. Expert Review of Endocrinology & Metabolism 5:5, 741-751
CrossRef445
Arjang Djamali, Carolynn E Pietrangeli, Robert D Gordon, Christophe Legendre. (2010) Potential of emerging immunosuppressive strategies to improve the posttransplant cardiovascular risk profile. Kidney International 78, S15-S21
CrossRef446
Urmimala Sarkar, Andrew J. Karter, Jennifer Y. Liu, Howard H. Moffet, Nancy E. Adler, Dean Schillinger. (2010) Hypoglycemia is More Common Among Type 2 Diabetes Patients with Limited Health Literacy: The Diabetes Study of Northern California (DISTANCE). Journal of General Internal Medicine 25:9, 962-968
CrossRef447
Volker Vallon, Kumar Sharma. (2010) Sodium–glucose transport: role in diabetes mellitus and potential clinical implications. Current Opinion in Nephrology and Hypertension 19:5, 425-431
CrossRef448
Gissette Reyes-Soffer, Steve Holleran, Marco R. Di Tullio, Shunichi Homma, Bernadette Boden-Albala, Rajasekhar Ramakrishnan, Mitchell S. Elkind, Ralph L. Sacco, Henry N. Ginsberg. (2010) Endothelial function in individuals with coronary artery disease with and without type 2 diabetes mellitus. Metabolism 59:9, 1365-1371
CrossRef449
Javier Díez Espino. (2010) Diagnóstico y control de la diabetes mellitus tipo 2. Atención Primaria 42, 2-8
CrossRef450
José Miguel González Clemente, Gemma Llauradó Cabot. (2010) Parámetros de control glucémico: nuevas perspectivas en la evaluación del diabético. Medicina Clínica 135, 15-19
CrossRef451
David S.H. Bell. (2010) Goals for HbA1c Need To Be Individualized Based on Clinical Judgment, Instead of Third Party Recommendations. Southern Medical Journal 103:9, 854-855
CrossRef452
Grant C. Fowler, Deepa A. Vasudevan. (2010) Type 2 Diabetes Mellitus: Managing Hemoglobin A1c and Beyond. Southern Medical Journal 103:9, 911-916
CrossRef453
Pablo B. Pedrianes Martín, Pedro L. de Pablos Velasco. (2010) Seguridad y tolerabilidad de los antidiabéticos orales en el tratamiento de la diabetes mellitus tipo 2. Medicina Clínica 135, 20-26
CrossRef454
Dídac Mauricio, Ferran Rius. (2010) Controversias actuales en los objetivos de control glucémico. ¿Qué reflexiones exigen los resultados de los últimos estudios para abordar la diabetes mellitus tipo 2?. Medicina Clínica 135, 2-5
CrossRef455
E. S. Kilpatrick, A. S. Rigby, S. L. Atkin. (2010) For debate.Glucose variability and diabetes complication risk: we need to know the answer. Diabetic Medicine 27:8, 868-871
CrossRef456
P Sanwald-Ducray, X Liogier D'ardhuy, C Jamois, L Banken. (2010) Pharmacokinetics, Pharmacodynamics, and Tolerability of Aleglitazar in Patients With Type 2 Diabetes: Results From a Randomized, Placebo-Controlled Clinical Study. Clinical Pharmacology & Therapeutics 88:2, 197-203
CrossRef457
Faramarz Ismail-Beigi, Timothy Craven, Mary Ann Banerji, Jan Basile, Jorge Calles, Robert M Cohen, Robert Cuddihy, William C Cushman, Saul Genuth, Richard H Grimm, Bruce P Hamilton, Byron Hoogwerf, Diane Karl, Lois Katz, Armand Krikorian, Patrick O'Connor, Rodica Pop-Busui, Ulrich Schubart, Debra Simmons, Harris Taylor, Abraham Thomas, Daniel Weiss, Irene Hramiak. (2010) Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. The Lancet 376:9739, 419-430
CrossRef458
J.C. Fruchart, F.M. Sacks, M.P. Hermans. (2010) Implications of the ACCORD Lipid study: perspective from the Residual Risk Reduction Initiative (R 3 i). Current Medical Research and Opinion 26:8, 1793-1797
CrossRef459
Steven V. Edelman, Bruce W. Bode, Timothy S. Bailey, Mark S. Kipnes, Rocco Brunelle, Xiaojing Chen, Juan P. Frias. (2010) Insulin Pump Therapy in Patients with Type 2 Diabetes Safely Improved Glycemic Control Using a Simple Insulin Dosing Regimen. Diabetes Technology & Therapeutics 12:8, 627-633
CrossRef460
James D. Marsh, Salah G. Keyrouz. (2010) Stroke Prevention and Treatment. Journal of the American College of Cardiology 56:9, 683-691
CrossRef461
Billal Patel, Michael Fisher. (2010) Therapeutic advances in myocardial microvascular resistance: Unravelling the enigma. Pharmacology & Therapeutics 127:2, 131-147
CrossRef462
N. Danchin, É. Eschwège, S. Bekka, M. Krempf. (2010) Variations pondérales, risque cardiométabolique et impact des médicaments antidiabétiques chez le diabétique de type 2. Annales de Cardiologie et d'Angéiologie 59:4, 214-220
CrossRef463
Cyril W. C. Kendall, Andrea R. Josse, Amin Esfahani, David J. A. Jenkins. (2010) Nuts, metabolic syndrome and diabetes. British Journal of Nutrition 104:04, 465-473
CrossRef464
Paresh Dandona, Ajay Chaudhuri, Husam Ghanim. (2010) Rosiglitazone, thiazolidinediones and atherosclerosis. Atherosclerosis 211:2, 384-385
CrossRef465
Jean A. Ballweg. (2010) Hyperglycemia and neurodevelopmental outcomes in infants with congenital heart disease. Progress in Pediatric Cardiology 29:2, 107-111
CrossRef466
S. Zoungas, J. Chalmers, A.P. Kengne, A. Pillai, L. Billot, B. de Galan, M. Marre, B. Neal, S. Harrap, N. Poulter, A. Patel. (2010) The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. Diabetes Research and Clinical Practice 89:2, 126-133
CrossRef467
Louis Kuritzky. (2010) Managing Type 2 Diabetes in the Primary Care Setting: Beyond Glucocentricity. The American Journal of the Medical Sciences 340:2, 133-143
CrossRef468
M. L. Norgaard, S. S. Andersen, T. K. Schramm, F. Folke, C. H. Jørgensen, M. L. Hansen, C. Andersson, D. M. Bretler, A. Vaag, L. Køber, C. Torp-Pedersen, G. H. Gislason. (2010) Changes in short- and long-term cardiovascular risk of incident diabetes and incident myocardial infarction—a nationwide study. Diabetologia 53:8, 1612-1619
CrossRef469
D. Hill, M. Fisher. (2010) The effect of intensive glycaemic control on cardiovascular outcomes. Diabetes, Obesity and Metabolism 12:8, 641-647
CrossRef470
Matthew A. Cavender, A. Michael Lincoff. (2010) Therapeutic Potential of Aleglitazar, a New Dual PPAR-α/γ Agonist. American Journal Cardiovascular Drugs 10:4, 209-216
CrossRef471
C. Nordin. (2010) The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. Diabetologia 53:8, 1552-1561
CrossRef472
2010. Management of Type 2 Diabetes. , 79-86.
CrossRef473
2010. Macrovascular Disease in Diabetes. , 152-160.
CrossRef474
The ACCORD Study Group and ACCORD Eye Study Group. (2010) Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. New England Journal of Medicine 363:3, 233-244
Full Text475
Clifford J. Bailey, Andrew J. Krentz. 2010. Oral Antidiabetic Agents. , 452-477.
CrossRef476
Jane Overland, Margaret McGill, Dennis K. Yue. 2010. The Role of Community and Specialist Services. , 957-968.
CrossRef477
Richard I. G. Holt, Barry J. Goldstein. 2010. The Aims of Diabetes Care. , 323-333.
CrossRef478
Inga S. Thrainsdottir, Lars Rydén. 2010. Congestive Heart Failure. , 684-697.
CrossRef479
Philip E. Cryer. 2010. Hypoglycemia in Diabetes. , 528-545.
CrossRef480
Peter M. Nilsson, Adie Viljoen, Anthony S. Wierzbicki. 2010. Cardiovascular Risk Factors. , 657-683.
CrossRef481
Alan J. Sinclair. 2010. Diabetes in Old Age. , 922-939.
CrossRef482
Mohammed K. Ali, Mary Beth Weber, K. M. Venkat Narayan. 2010. The Global Burden of Diabetes. , 69-84.
CrossRef483
Riccardo Candido, Mark E. Cooper, Karin A. M. Jandeleit-Dahm. 2010. The Pathogenesis of Macrovascular Complications Including Atherosclerosis in Diabetes. , 635-656.
CrossRef484
Joseph A. Aloi, Anthony L. McCall. 2010. How to use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies. , 494-513.
CrossRef485
M. Stramba-Badiale. (2010) Women and research on cardiovascular diseases in Europe: a report from the European Heart Health Strategy (EuroHeart) project. European Heart Journal 31:14, 1677-1681
CrossRef486
Shamsa Ali, Vivian A. Fonseca. (2010) Diabetes: Low HbA1c levels and mortality in type 2 diabetes mellitus. Nature Reviews Endocrinology 6:7, 359-360
CrossRef487
A. H. Barnett, S. Cradock, M. Fisher, G. Hall, E. Hughes, A. Middleton. (2010) Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. International Journal of Clinical Practice 64:8, 1121-1129
CrossRef488
D. M. Mann, M. Woodward, P. Muntner. (2010) Preventing diabetes complications: are we too glucocentric?. International Journal of Clinical Practice 64:8, 1024-1027
CrossRef489
Ning Cheung, Paul Mitchell, Tien Yin Wong. (2010) Diabetic retinopathy. The Lancet 376:9735, 124-136
CrossRef490
Jose M. Miguel-Yanes, James B. Meigs. (2010) Intensive-Therapy Glycemic Control Fails to Prevent Vascular Complications in Veterans with Type 2 Diabetes Mellitus. Current Cardiovascular Risk Reports 4:4, 248-250
CrossRef491
Pan Chang Yu, Zsolt Bosnyak, Antonio Ceriello. (2010) The importance of glycated haemoglobin (HbA1c) and postprandial glucose (PPG) control on cardiovascular outcomes in patients with type 2 diabetes. Diabetes Research and Clinical Practice 89:1, 1-9
CrossRef492
S. Halimi, D. Raccah, A. Schweizer, S. Dejager. (2010) Role of vildagliptin in managing type 2 diabetes mellitus in the elderly. Current Medical Research and Opinion 26:7, 1647-1656
CrossRef493
G. Schernthaner, E. Ritz, G.-H. Schernthaner. (2010) Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly?. Nephrology Dialysis Transplantation 25:7, 2044-2047
CrossRef494
Marta Letizia Hribal, Giorgio Sesti. (2010) Liraglutide, the once-daily human GLP-1 analog, in the treatment of Type 2 diabetes. Expert Review of Endocrinology & Metabolism 5:4, 495-505
CrossRef495
Jesús Millán Nú˜ez-Cortés, Juan Pedro-Botet Montoya, Xavier Pintó Sala. (2010) Riesgo vascular residual: recomendaciones de la Iniciativa Espa˜ola para la Reducción del Riesgo Residual. Medicina Clínica 135:4, 165-171
CrossRef496
Aparna Brown, L. Raymond Reynolds, Dennis Bruemmer. (2010) Intensive glycemic control and cardiovascular disease: an update. Nature Reviews Cardiology 7:7, 369-375
CrossRef497
Gerald H Tomkin. (2010) Atherosclerosis, diabetes and lipoproteins. Expert Review of Cardiovascular Therapy 8:7, 1015-1029
CrossRef498
Gaurav Gupta, Mark L. Unruh, Thomas D. Nolin, Peggy B. Hasley. (2010) Primary Care of the Renal Transplant Patient. Journal of General Internal Medicine 25:7, 731-740
CrossRef499
J. Hsia. (2010) Managing cardiovascular risk factors: Trial evidence in women. Nutrition, Metabolism and Cardiovascular Diseases 20:6, 445-450
CrossRef500
Dena E. Rifkin, Wolfgang C. Winkelmayer. (2010) Medication Issues in Older Individuals With CKD. Advances in Chronic Kidney Disease 17:4, 320-328
CrossRef501
Baptist Gallwitz. (2010) The evolving place of incretin-based therapies in type 2 diabetes. Pediatric Nephrology 25:7, 1207-1217
CrossRef502
J. Reckless, A. Robinson. (2010) Benefits and risks around glycaemic control in diabetes: where are we now?. International Journal of Clinical Practice 64:8, 1001-1003
CrossRef503
H. Sourij, C. H. Saely, F. Schmid, R. Zweiker, T. Marte, T. C. Wascher, H. Drexel. (2010) Post-challenge hyperglycaemia is strongly associated with future macrovascular events and total mortality in angiographied coronary patients. European Heart Journal 31:13, 1583-1590
CrossRef504
E. Lukich, Z. Matas, M. Boaz, M. Shargorodsky. (2010) Increasing derangement of glucose homeostasis is associated with increased arterial stiffness in patients with diabetes, impaired fasting glucose and normal controls. Diabetes/Metabolism Research and Reviews 26:5, 365-370
CrossRef505
Jesús Millán Núñez-Cortés, Juan Pedro Botet Montoya, Xavier Pintó Sala. (2010) Dislipemia aterogénica: una llamada de atención sobre su papel en el riesgo residual. Clínica e Investigación en Arteriosclerosis 22:4, 162-166
CrossRef506
G. Schernthaner, A. H. Barnett, D. J. Betteridge, R. Carmena, A. Ceriello, B. Charbonnel, M. Hanefeld, R. Lehmann, M. T. Malecki, R. Nesto, V. Pirags, A. Scheen, J. Seufert, A. Sjohölm, A. Tsatsoulis, R. DeFronzo. (2010) Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 53:7, 1258-1269
CrossRef507
Ryuzo Kawamori, Paul Valensi. (2010) IMPROVE™ observational study of biphasic insulin aspart 30/70 in patients with Type 2 diabetes mellitus. Expert Review of Endocrinology & Metabolism 5:4, 507-516
CrossRef508
Mikko Honkasalo, Outi Elonheimo, Timo Sane. (2010) Many Diabetic Patients With Recurrent Severe Hypoglycemias Hold a Valid Driving License. A Community-Based Study in Insulin-Treated Patients With Diabetes. Traffic Injury Prevention 11:3, 258-262
CrossRef509
Leonard E. Egede, Martina Mueller, Carrae L. Echols, Mulugeta Gebregziabher. (2010) Longitudinal Differences in Glycemic Control by Race/Ethnicity Among Veterans With Type 2 Diabetes. Medical Care 48:6, 527-533
CrossRef510
HELEN L PILMORE. (2010) Review: Metformin: Potential benefits and use in chronic kidney disease. Nephrology 15:4, 412-418
CrossRef511
Motaz Qadan, E. Brooks Weller, Sarah A. Gardner, Claudio Maldonado, Donald E. Fry, Hiram C. Polk. (2010) Glucose and Surgical Sepsis: A Study of Underlying Immunologic Mechanisms. Journal of the American College of Surgeons 210:6, 966-974
CrossRef512
J. H. Martin, M. F. Fay. (2010) Surrogate end-points in clinical practice: are we providing worse care?. Internal Medicine Journal 40:6, 395-398
CrossRef513
C. Jacobshagen, D. Westermann, C. Holubarsch, M. Böhm. (2010) Hotline update of clinical trials and registries presented at the American College of Cardiology Congress 2010: ACCORD, INVEST, NAVIGATOR, RACE II, SORT OUT III, CSP-474, DOSE, ASPIRE and more. Clinical Research in Cardiology 99:6, 337-344
CrossRef514
A. Schweizer, S. Dejager, J. E. Foley, A. Couturier, M. Ligueros-Saylan, W. Kothny. (2010) Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes, Obesity and Metabolism 12:6, 485-494
CrossRef515
Massimo Volpe, Claudio Borghi, Paolo Cavallo Perin, Massimo Chiariello, Enzo Manzato, Roberto Miccoli, Maria Grazia Modena, Gabriele Riccardi, Giorgio Sesti, Antonio Tiengo, Bruno Trimarco, Diego Vanuzzo, Paolo Verdecchia, Augusto Zaninelli, Stefano Del Prato. (2010) Cardiovascular Prevention in Subjects with Impaired Fasting Glucose or Impaired Glucose Tolerance. High Blood Pressure & Cardiovascular Prevention 17:2, 73-102
CrossRef516
Carrie McAdam-Marx, Julia A Gaebler, Brandon K Bellows, Diana I Brixner. (2010) Contemporary management of patients with Type 2 diabetes. Expert Review of Cardiovascular Therapy 8:6, 767-770
CrossRef517
Manuel Serrano-Gil, Stephan Jacob. (2010) Engaging and empowering patients to manage their type 2 diabetes, Part I: a knowledge, attitude, and practice gap?. Advances in Therapy 27:6, 321-333
CrossRef518
Vikas Bhalla, Andreas Kalogeropoulos, Vasiliki Georgiopoulou, Javed Butler. (2010) Serum resistin: physiology, pathophysiology and implications for heart failure. Biomarkers in Medicine 4:3, 445-452
CrossRef519
Donald K. Zettervall, Laura Shane-McWhorter, Curtis Triplitt. (2010) Diabetes in the Elderly: Exercising Your Clinical Skills. The Consultant Pharmacist 25:0, 1-37
CrossRef520
M Fisher. (2010) Half full, half empty, or negative? Results of recent clinical trials. Practical Diabetes International 27:5, 174-175
CrossRef521
Angelo Scuteri, Manfredi Tesauro. (2010) Management of Global Cardiovascular Risk in Older Subjects with Diabetes Mellitus. High Blood Pressure & Cardiovascular Prevention 17:2, 53-58
CrossRef522
K. Khunti, M. Davies. (2010) Glycaemic goals in patients with type 2 diabetes: current status, challenges and recent advances. Diabetes, Obesity and Metabolism 12:6, 474-484
CrossRef523
Sherrie H. Kaplan, John Billimek, Dara H. Sorkin, Quyen Ngo-Metzger, Sheldon Greenfield. (2010) Who Can Respond to Treatment?. Medical Care 48, S9-S16
CrossRef524
D. R. Webb, K. Khunti, R. Silverman, L. J. Gray, B. Srinivasan, P. S. Lacy, B. Williams, M. J. Davies. (2010) Impact of metabolic indices on central artery stiffness: independent association of insulin resistance and glucose with aortic pulse wave velocity. Diabetologia 53:6, 1190-1198
CrossRef525
Stephen Tonna, Assam El-Osta, Mark E. Cooper, Chris Tikellis. (2010) Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms. Nature Reviews Nephrology 6:6, 332-341
CrossRef526
M. Gebregziabher, L. E. Egede, C. P. Lynch, C. Echols, Y. Zhao. (2010) Effect of Trajectories of Glycemic Control on Mortality in Type 2 Diabetes: A Semiparametric Joint Modeling Approach. American Journal of Epidemiology 171:10, 1090-1098
CrossRef527
Sally E. Blank, Emily Carolyn Johnson, Debra K. Weeks, Carol H. Wysham. (2010) Circulating dendritic cell number and intracellular TNF-α production in women with type 2 diabetes. Acta Diabetologica
CrossRef528
(2010) Reevaluating Erythropoiesis-Stimulating Agents. New England Journal of Medicine 362:18, 1742-1744
Full Text529
Chun-Yu Zhang, Ai-Jun Sun, Shu-Ning Zhang, Chao-neng Wu, Ming-Qiang Fu, Guang Xia, Ke-Qiang Wang, Yun-Zeng Zou, Jun-Bo Ge. (2010) Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: A meta-analysis. Annals of Medicine 42:4, 305-315
CrossRef530
Ippei Shimizu, Tohru Minamino, Haruhiro Toko, Sho Okada, Hiroyuki Ikeda, Noritaka Yasuda, Kaoru Tateno, Junji Moriya, Masataka Yokoyama, Aika Nojima, Gou Young Koh, Hiroshi Akazawa, Ichiro Shiojima, C. Ronald Kahn, E. Dale Abel, Issei Komuro. (2010) Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. Journal of Clinical Investigation 120:5, 1506-1514
CrossRef531
R. De Caterina, R. Madonna. (2010) Impaired fasting plasma glucose and long-term cardiovascular risk: still a foggy relationship. European Heart Journal 31:10, 1159-1162
CrossRef532
Cristina Bianchi, Giuseppe Penno, Roberto Miccoli, Stefano Prato. (2010) Blood Glucose Control and Coronary Heart Disease. Herz 35:3, 148-159
CrossRef533
Vivian A. Fonseca, Yehuda Handelsman, Bart Staels. (2010) Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes, Obesity and Metabolism 12:5, 384-392
CrossRef534
S. Dietrich. (2010) Intensivierte Blutdruckeinstellung bei Typ-II-Diabetes. Der Nephrologe 5:3, 236-238
CrossRef535
Irene M. Van Der Meer, Piero Ruggenenti, Giuseppe Remuzzi. (2010) THE DIABETIC CKD PATIENT-A MAJOR CARDIOVASCULAR CHALLENGE. Journal of Renal Care 36, 34-46
CrossRef536
Alice Y.Y. Cheng, Lawrence A. Leiter. (2010) Glucose lowering and cardiovascular disease: what do we know and what should we do?. European Journal of Cardiovascular Prevention & Rehabilitation 17, S25-S31
CrossRef537
Yannis S. Guerra, Krishna Das, Pete Antonopoulos, Shane Borkowsky, Leon Fogelfeld, Melanie J. Gordon, Betsy M. Palal, Joanne C. Witsil, Evelyn A. Lacuesta. (2010) Computerized Physician Order Entry-Based Hyperglycemia Inpatient Protocol and Glycemic Outcomes: The CPOE-HIP Study. Endocrine Practice 16:3, 389-397
CrossRef538
Hong Ding, Chris R. Triggle. (2010) Endothelial dysfunction in diabetes: multiple targets for treatment. Pflügers Archiv - European Journal of Physiology 459:6, 977-994
CrossRef539
Ángeles Alonso-García, Francisco J. García-Soidán, Arturo Lisbona-Gil. (2010) Tratamiento hipoglucemiante en pacientes con diabetes mellitus tipo 2 con insuficiencia cardiaca estable o cardiopatía isquémica sin insuficiencia cardiaca. Medicina Clínica 134:13, 596-599
CrossRef540
A. I. Adler, S. Erqou, T. A. S. Lima, A. H. N. Robinson. (2010) Association between glycated haemoglobin and the risk of lower extremity amputation in patients with diabetes mellitus—review and meta-analysis. Diabetologia 53:5, 840-849
CrossRef541
Sabin Shurraw, Sumit R. Majumdar, Ravi Thadhani, Natasha Wiebe, Marcello Tonelli. (2010) Glycemic Control and the Risk of Death in 1,484 Patients Receiving Maintenance Hemodialysis. American Journal of Kidney Diseases 55:5, 875-884
CrossRef542
Matthew A. Cavender, Stephen J. Nicholls, A. Michael Lincoff. (2010) Strategies for the development of new PPAR agonists in diabetes. European Journal of Cardiovascular Prevention & Rehabilitation 17, S32-S37
CrossRef543
P. McEwan, M. Evans, H. Kan, K. Bergenheim. (2010) Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model. Diabetes, Obesity and Metabolism 12:5, 431-436
CrossRef544
Bernd Stratmann, Thomas Gawlowski, Diethelm Tschoepe. (2010) Diabetic Cardiomyopathy – to Take a Long Story Serious. Herz 35:3, 161-168
CrossRef545
Paolo Pozzilli, R. David Leslie, Juliana Chan, Ralph De Fronzo, Louis Monnier, Itamar Raz, Stefano Del Prato. (2010) The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes/Metabolism Research and Reviews 26:4, 239-244
CrossRef546
Ryu Miyagawa, Takefumi Asakura, Tomomi Nakamura, Hiromi Okada, Soichiro Iwaki, Burton E. Sobel, Satoshi Fujii. (2010) Increased expression of plasminogen activator inhibitor type-1 (PAI-1) in HEPG2 cells induced by insulin mediated by the 3′-untranslated region of the PAI-1 gene and its pharmacologic implications. Coronary Artery Disease 21:3, 144-150
CrossRef547
Nilsson, Peter M., . (2010) ACCORD and Risk-Factor Control in Type 2 Diabetes. New England Journal of Medicine 362:17, 1628-1630
Full Text548
The ACCORD Study Group. (2010) Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. New England Journal of Medicine 362:17, 1575-1585
Full Text549
The ACCORD Study Group. (2010) Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. New England Journal of Medicine 362:17, 1563-1574
Full Text550
MI Hasan, MA Elrishi, A Kilvert, C Fox. (2010) Recurrent atrial fibrillation and prolonged QTc interval precipitated by severe hypoglycaemia. Practical Diabetes International 27:3, 120-121
CrossRef551
John Richard, Ildiko Lingvay. (2010) Is insulin treatment a first-line defense against Type 2 diabetes?. Expert Review of Cardiovascular Therapy 8:4, 483-485
CrossRef552
Caroline S. Fox. (2010) Cardiovascular Disease Risk Factors, Type 2 Diabetes Mellitus, and the Framingham Heart Study. Trends in Cardiovascular Medicine 20:3, 90-95
CrossRef553
Sherman J. Bigornia, Melanie M. Mott, Donald T. Hess, Caroline M. Apovian, Marie E. McDonnell, Mai-Ann Duess, Matthew A. Kluge, Antonino J. Fiscale, Joseph A. Vita, Noyan Gokce. (2010) Long-term Successful Weight Loss Improves Vascular Endothelial Function in Severely Obese Individuals. Obesity 18:4, 754-759
CrossRef554
E. Erdmann, R. Wilcox. (2010) Pioglitazone and mechanisms of CV protection. QJM 103:4, 213-228
CrossRef555
Natsuhiko Ehara, Takeshi Morimoto, Yutaka Furukawa, Satoshi Shizuta, Ryoji Taniguchi, Yoshihisa Nakagawa, Kozo Hoshino, Naritatsu Saito, Takahiro Doi, Yoshisumi Haruna, Neiko Ozasa, Yukiko Imai, Satoshi Teramukai, Masanori Fukushima, Toru Kita, Takeshi Kimura. (2010) Effect of Baseline Glycemic Level on Long-Term Cardiovascular Outcomes After Coronary Revascularization Therapy in Patients With Type 2 Diabetes Mellitus Treated With Hypoglycemic Agents. The American Journal of Cardiology 105:7, 960-966
CrossRef556
Richard Kahn, Peter Alperin, David Eddy, Knut Borch-Johnsen, John Buse, Justin Feigelman, Edward Gregg, Rury R Holman, M Sue Kirkman, Michael Stern, Jaakko Tuomilehto, Nick J Wareham. (2010) Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. The Lancet 375:9723, 1365-1374
CrossRef557
Juan J. Gagliardino, Line Kleinebreil, Stephen Colagiuri, Jeff Flack, Joaquín E. Caporale, Fernando Siri, Charles Clark. (2010) Comparison of clinical-metabolic monitoring and outcomes and coronary risk status in people with type 2 diabetes from Australia, France and Latin America. Diabetes Research and Clinical Practice 88:1, 7-13
CrossRef558
Joshua M. Stolker, Dazhong Sun, Darcy G. Conaway, Philip G. Jones, Frederick A. Masoudi, Pamela N. Peterson, Harlan M. Krumholz, Mikhail Kosiborod, John A. Spertus. (2010) Importance of Measuring Glycosylated Hemoglobin in Patients With Myocardial Infarction and Known Diabetes Mellitus. The American Journal of Cardiology 105:8, 1090-1094
CrossRef559
W. A. Davis, M. W. Knuiman, T. M. E. Davis. (2010) An Australian cardiovascular risk equation for type 2 diabetes: the Fremantle Diabetes Study. Internal Medicine Journal 40:4, 286-292
CrossRef560
Sanjay Kaul, Ann F. Bolger, David Herrington, Robert P. Giugliano, Robert H. Eckel. (2010) Thiazolidinedione Drugs and Cardiovascular Risks. Journal of the American College of Cardiology 55:17, 1885-1894
CrossRef561
P. Valensi, E. Cosson. (2010) It is not yet the time to stop screening diabetic patients for silent myocardial ischaemia. Diabetes & Metabolism 36:2, 91-96
CrossRef562
Maria M. Wanitschek, Otmar Pachinger, Hannes F. Alber. (2010) Ein „gefährliches Duo“. Wiener klinisches Magazin 13:2, 32-43
CrossRef563
Benjamin R. McClintic, Jedediah I. McClintic, John D. Bisognano, Robert C. Block. (2010) The Relationship between Retinal Microvascular Abnormalities and Coronary Heart Disease: A Review. The American Journal of Medicine 123:4, 374.e1-374.e7
CrossRef564
Richard M. Bergenstal, Clifford J. Bailey, David M. Kendall. (2010) Type 2 Diabetes: Assessing the Relative Risks and Benefits of Glucose-lowering Medications. The American Journal of Medicine 123:4, 374.e9-374.e18
CrossRef565
Kevin Niswender. (2010) Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay. Diabetes, Obesity and Metabolism 12:4, 267-287
CrossRef566
Friedrich C. Luft. (2010) The time has come for incretins, a long time coming. Journal of Molecular Medicine 88:4, 319-321
CrossRef567
(2010) Insulin Regimens in Type 2 Diabetes. New England Journal of Medicine 362:10, 959-960
Full Text568
Selvin, Elizabeth, Steffes, Michael W., Zhu, Hong, Matsushita, Kunihiro, Wagenknecht, Lynne, Pankow, James, Coresh, Josef, Brancati, Frederick L., . (2010) Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic Adults. New England Journal of Medicine 362:9, 800-811
Full Text569
Robert G. Nelson, Katherine R. Tuttle. (2010) Prevention of Diabetic Kidney Disease: Negative Clinical Trials With Renin-Angiotensin System Inhibitors. American Journal of Kidney Diseases 55:3, 426-430
CrossRef570
Radica Z. Alicic, Katherine R. Tuttle. (2010) Management of the Diabetic Patient with Advanced Chronic Kidney Disease. Seminars in Dialysis 23:2, 140-147
CrossRef571
L. Venskutonyte, K. Malmberg, A. Norhammar, H. Wedel, L. Rydén. (2010) Effect of gender on prognosis in patients with myocardial infarction and type 2 diabetes. Journal of Internal Medicine
CrossRef572
Gerald W. Smetana, Jane S. Sillman. (2010) Update in New Medications for Primary Care. Journal of General Internal Medicine 25:3, 261-269
CrossRef573
H. K. Berthold, K. P. Bestehorn, W. Krone, I. Gouni-Berthold. (2010) Atherosclerotic disease location and disparities in the control and treatment of cardiovascular risk factors in patients with Type 2 diabetes. Diabetic Medicine 27:3, 303-308
CrossRef574
Franz Wiesbauer, Georg Heinze, Heinz Regele, Walter H. Hörl, Gerit H. Schernthaner, Christoph Schwarz, Alexander Kainz, Reinhard Kramar, Rainer Oberbauer. (2010) Glucose Control is Associated With Patient Survival in Diabetic Patients After Renal Transplantation. Transplantation 89:5, 612-619
CrossRef575
Asmir I. Syed, Itsik Ben-Dor, Yanlin Li, Sara D. Collins, Manuel A. Gonzalez, Michael A. Gaglia, Gabriel Maluenda, Cedric Delhaye, Kohei Wakabayashi, Laurant Bonello, Axel De Labriolle, Loic Belle, Rebecca Torguson, Zhenyi Xue, Kimberly Kaneshige, Nelson Bernardo, Lowell F. Satler, Kenneth M. Kent, William O. Suddath, Augusto D. Pichard, Joseph Lindsay, Ron Waksman. (2010) Outcomes in Diabetic Versus Nondiabetic Patients Who Present With Acute Myocardial Infarction and Are Treated With Drug-Eluting Stents. The American Journal of Cardiology 105:6, 819-825
CrossRef576
Kirsten Howard, Sarah White, Glenn Salkeld, Stephen McDonald, Jonathan C. Craig, Steven Chadban, Alan Cass. (2010) Cost-Effectiveness of Screening and Optimal Management for Diabetes, Hypertension, and Chronic Kidney Disease: A Modeled Analysis. Value in Health 13:2, 196-208
CrossRef577
Eli A. Friedman. (2010) Continuously Evolving Management Concepts for Diabetic CKD and ESRD. Seminars in Dialysis 23:2, 134-139
CrossRef578
Jamshid Shirani, Vasken Dilsizian. (2010) Screening Asymptomatic Patients with Type 2 Diabetes Mellitus for Coronary Artery Disease: Does It Improve Patient Outcome?. Current Cardiology Reports 12:2, 140-146
CrossRef579
Doron Aronson, Elazer R. Edelman. (2010) Revascularization for coronary artery disease in diabetes mellitus: Angioplasty, stents and coronary artery bypass grafting. Reviews in Endocrine and Metabolic Disorders 11:1, 75-86
CrossRef580
David J. Maron, William E. Boden, Robert A. O'Rourke, Pamela M. Hartigan, Karen J. Calfas, G.B. John Mancini, John A. Spertus, Marcin Dada, William J. Kostuk, Merril Knudtson, Crystal L. Harris, Steven P. Sedlis, Robert G. Zoble, Lawrence M. Title, Gilbert Gosselin, Shah Nawaz, Gerald T. Gau, Alvin S. Blaustein, Eric R. Bates, Leslee J. Shaw, Daniel S. Berman, Bernard R. Chaitman, William S. Weintraub, Koon K. Teo. (2010) Intensive Multifactorial Intervention for Stable Coronary Artery Disease. Journal of the American College of Cardiology 55:13, 1348-1358
CrossRef581
Csaba P. Kovesdy, Jong C. Park, Kamyar Kalantar-Zadeh. (2010) Glycemic Control and Burnt-Out Diabetes in ESRD. Seminars in Dialysis 23:2, 148-156
CrossRef582
Baptist Gallwitz. (2010) DPP-4-Inhibitoren in der Klinik. Therapie ohne Hypoglykämie-Gefahr. Pharmazie in unserer Zeit 39:2, 114-118
CrossRef583
Matteo Anselmino, Klas Malmberg, Linda Mellbin, Lars Rydén. (2010) Overview of the importance of glycaemic control for cardiovascular events in the in-and out-patient setting. Reviews in Endocrine and Metabolic Disorders 11:1, 87-94
CrossRef584
Thomas D Aicher, Steven A Boyd, Maralee McVean, Anthony Celeste. (2010) Novel therapeutics and targets for the treatment of diabetes. Expert Review of Clinical Pharmacology 3:2, 209-229
CrossRef585
John P. Sheehan. (2010) Bad Medicine: There Is a Lot Wrong with Diabetes Care in the United States. Culture, Medicine, and Psychiatry 34:1, 2-12
CrossRef586
Christina L Aquilante. (2010) Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Review of Cardiovascular Therapy 8:3, 359-372
CrossRef587
Jean-Paul Chapelle, Jelda Teixeira, Diane Maisin, Hans Assink, Gerhard Barla, An K. Stroobants, Barend Delzenne, Wouter van den Eshof. (2010) Multicentre evaluation of the Tosoh HbA1c G8 analyser. Clinical Chemistry and Laboratory Medicine 48:3, 365-371
CrossRef588
Vivian A. Fonseca. (2010) Effects of β-blockers on glucose and lipid metabolism. Current Medical Research and Opinion 26:3, 615-629
CrossRef589
PS Sharp. (2010) Glycaemic outcomes following discharge from an intermediate care diabetes clinic. Practical Diabetes International 27:2, 53-54
CrossRef590
John P. D. Reckless. (2010) How much will Incretin Mimetics contribute to hyperglycaemia management?. International Journal of Clinical Practice 64:4, 418-420
CrossRef591
Ken Fujioka. (2010) Benefits of moderate weight loss in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 12:3, 186-194
CrossRef592
Hylton V. Joffe, Mary H. Parks, Robert Temple. (2010) Impact of cardiovascular outcomes on the development and approval of medications for the treatment of diabetes mellitus. Reviews in Endocrine and Metabolic Disorders 11:1, 21-30
CrossRef593
I. Oluwatowoju, E. Abu, S. H. Wild, C. D. Byrne. (2010) Improvements in glycaemic control and cholesterol concentrations associated with the Quality and Outcomes Framework: a regional 2-year audit of diabetes care in the UK. Diabetic Medicine 27:3, 354-359
CrossRef594
Corey E. Tabit, William B. Chung, Naomi M. Hamburg, Joseph A. Vita. (2010) Endothelial dysfunction in diabetes mellitus: Molecular mechanisms and clinical implications. Reviews in Endocrine and Metabolic Disorders 11:1, 61-74
CrossRef595
Harish Iyer, Anand Khedkar, Manish Verma. (2010) Oral insulin - a review of current status. Diabetes, Obesity and Metabolism 12:3, 179-185
CrossRef596
Diana Hortensia Barbonta, Christopher William Loughlan, JE Claire Dickerson, Diana Hortensia Barbonta. 2010. Pramlintide for diabetes mellitus. .
CrossRef597
Charlotte Andersson, Peter Weeke, Redi Pecini, Jesper Kjaergaard, Christian Hassager, Lars Køber, Christian Torp-Pedersen. (2010) Long-term impact of diabetes in patients hospitalized with ischemic and non-ischemic heart failure. Scandinavian Cardiovascular Journal 44:1, 37-44
CrossRef598
Beverley Balkau, Dominique Simon. (2010) Survival in people with type 2 diabetes as a function of HbA1c. The Lancet 375:9713, 438-440
CrossRef599
H. W. Cohen, C. Shmukler, R. Ullman, C. M. Rivera, E. A. Walker. (2010) Measurements of medication adherence in diabetic patients with poorly controlled HbA 1c. Diabetic Medicine 27:2, 210-216
CrossRef600
D. R. Webb, M. J. Davies, L. J. Gray, K. R. Abrams, B. Srinivasan, S. Das, N. Taub, I. Lawrence, S. Sutton, K. Khunti. (2010) Searching for the right outcome? A systematic review and meta-analysis of controlled trials using carotid intima-media thickness or pulse wave velocity to infer antiatherogenic properties of thiazolidinediones. Diabetes, Obesity and Metabolism 12:2, 124-132
CrossRef601
M. Hanefeld, C. Koehler, C. Hoffmann, K. Wilhelm, W. Kamke, H. Gerstein. (2010) Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes. Diabetic Medicine 27:2, 175-180
CrossRef602
Swapnil N. Rajpathak, Vikas Aggarwal, Frank B. Hu. (2010) Multifactorial Intervention to Reduce Cardiovascular Events in Type 2 Diabetes. Current Diabetes Reports 10:1, 16-23
CrossRef603
Kenichi Shikata, Masakazu Haneda, Daisuke Koya, Yoshiki Suzuki, Yasuhiko Tomino, Kenichi Yamada, Shiro Maeda, Norito Kawakami, Takashi Uzu, Motonobu Nishimura, Chikage Sato, Daisuke Ogawa, Hirofumi Makino. (2010) Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan): Rationale and study design. Diabetes Research and Clinical Practice 87:2, 228-232
CrossRef604
C. Studer, W. Sankou, A. Penfornis, S. Pili-Floury, M. Puyraveau, A. Cordier, J.-P. Etievent, E. Samain. (2010) Efficacy and safety of an insulin infusion protocol during and after cardiac surgery. Diabetes & Metabolism 36:1, 71-78
CrossRef605
Björn Meijers, Pieter Evenepoel. (2010) Targeting hyperphosphatemia: truth or dare. Kidney International 77:3, 256-257
CrossRef606
S. Del Prato, J. LaSalle, S. Matthaei, C. J. Bailey, . (2010) Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management. International Journal of Clinical Practice 64:3, 295-304
CrossRef607
Stuart W. Zarich. (2010) Does Choice of Antidiabetes Therapy Influence Macrovascular Outcomes?. Current Diabetes Reports 10:1, 24-31
CrossRef608
Stuart W. Zarich. (2010) Relationship of Coronary Angiographic Findings to Choice of Antidiabetic Medication. Current Diabetes Reports 10:1, 1-3
CrossRef609
R. Roussel, E. Cosson. (2010) Hypoglycaemia? Not guilty! Decreased HbA1c? Not guilty!. Diabetes & Metabolism 36:1, 86-87
CrossRef610
Lee Park, Deborah Wexler. (2010) Update in diabetes and cardiovascular disease: synthesizing the evidence from recent trials of glycemic control to prevent cardiovascular disease. Current Opinion in Lipidology 21:1, 8-14
CrossRef611
Elbert S. Huang, Andrew J. Karter, Kirstie K. Danielson, E. Margaret Warton, Ameena T. Ahmed. (2010) The Association Between the Number of Prescription Medications and Incident Falls in a Multi-ethnic Population of Adult Type-2 Diabetes Patients: The Diabetes and Aging Study. Journal of General Internal Medicine 25:2, 141-146
CrossRef612
J. K. Cruickshank. (2010) Low-dose thiazide diuretics in and around diabetes-definitely yes, and how do they compare with other interventions?. Diabetic Medicine 27:2, 127-129
CrossRef613
Abd A. Tahrani, Milan K. Piya, Amy Kennedy, Anthony H. Barnett. (2010) Glycaemic control in type 2 diabetes: Targets and new therapies. Pharmacology & Therapeutics 125:2, 328-361
CrossRef614
Craig J Currie, John R Peters, Aodán Tynan, Marc Evans, Robert J Heine, Oswaldo L Bracco, Tony Zagar, Chris D Poole. (2010) Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. The Lancet 375:9713, 481-489
CrossRef615
Siobhan HM Brown, Ahmed H Abdelhafiz. (2010) Hypoglycemia, intensive glycemic control and diabetes care in care home residents with Type 2 diabetes. Aging Health 6:1, 31-40
CrossRef616
Sung Hyuk Heo, Seung-Hoon Lee, Beom Joon Kim, Bong Su Kang, Byung Woo Yoon. (2010) Does glycated hemoglobin have clinical significance in ischemic stroke patients?. Clinical Neurology and Neurosurgery 112:2, 98-102
CrossRef617
Edward S. Horton. (2010) Challenges and Approaches to Managing Type 2 Diabetes Mellitus. Current Diabetes Reports 10:1, 7-9
CrossRef618
S. Garg, I. B. Hirsch. (2010) Self-monitoring of blood glucose. International Journal of Clinical Practice 64, 1-10
CrossRef619
Scott L. Charland, Daniel C. Malone. (2010) Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy. Current Medical Research and Opinion 26:2, 365-375
CrossRef620
A. Fritsche, M. Larbig, D. Owens, H.-U. Häring, . (2010) Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. Diabetes, Obesity and Metabolism 12:2, 115-123
CrossRef621
Carl J. Pepine. (2010) Residual risk for secondary ischemic events in patients with atherothrombotic disease: Opportunity for future improvements in patient care. Annals of Medicine 42:1, 19-35
CrossRef622
Tomonari Okada, Tamami Yamanaka, Ryo Tomaru, Tokiyo Tamekuni, Shinga Esaki, Tomoka Nango, Yoshitaka Miyaoka, Toshiyuki Nakao, Katsusuke Ikeda. (2010) Relationship among glycated albumin, hemoglobin A1c, and daily blood glucose profile in diabetic patients on chronic hemodialysis. Nihon Toseki Igakkai Zasshi 43:5, 433-441
CrossRef623
Victor S. Issa, Alexandre F. Amaral, Fátima D. Cruz, Silvia M. Ayub-Ferreira, Guilherme V. Guimarães, Paulo R. Chizzola, Germano E.C. Souza, Edimar A. Bocchi. (2010) Glycemia and prognosis of patients with chronic heart failure—Subanalysis of the Long-term Prospective Randomized Controlled Study Using Repetitive Education at Six-Month Intervals and Monitoring for Adherence in Heart Failure Outpatients (REMADHE) trial. American Heart Journal 159:1, 90-97
CrossRef624
Guntram Schernthaner. (2010) Diabetes and Cardiovascular Disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. Wiener Medizinische Wochenschrift 160:1-2, 8-19
CrossRef625
Torgeir Søvik, Babak Irandoust, Kåre Birkeland, Erlend Aasheim, Carl Schou, Jon Kristinsson, Tom Mala. (2010) Type 2-diabetes og metabolsk syndrom før og etter gastrisk bypass. Tidsskrift for Den norske legeforening 130:13, 1347-1350
CrossRef626
N. V. Emanuele. (2010) Duration of diabetes, glucose control and cardiovascular risk. Diabetologia 53:1, 214-215
CrossRef627
J. S. Yudkin, B. Richter. (2010) Using individual patient data in meta-analyses of glucose-lowering studies. Diabetologia 53:1, 216-217
CrossRef628
M. Halbron. (2010) Gestione terapeutica del diabete di tipo 2. EMC - AKOS - Trattato di Medicina 12:4, 1-7
CrossRef629
Barry Greenberg. (2010) Pre-Clinical Diastolic Dysfunction in Diabetic Patients. Journal of the American College of Cardiology 55:4, 306-308
CrossRef630
Kouichiro Aihara, Katsumi Miyauchi, Takatoshi Kasai, Naozumi Kubota, Kan Kajimoto, Hiroshi Tamura, Takahiko Kojima, Ken Yokoyama, Takeshi Kurata, Atsushi Amano, Hiroyuki Daida. (2010) Long-Term Efficacy of Pravastatin Therapy in Diabetic Patients Undergoing Complete Coronary Revascularization. Journal of Atherosclerosis and Thrombosis 17:4, 350-355
CrossRef631
Junji Koizumi. (2010) Diabetes in the elderly. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 47:5, 415-418
CrossRef632
Kenzo Oba, Hiroshi Nakano, Yoshimasa Igari. (2010) Clinical guidelines for elderly patients with diabetes mellitus. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 47:6, 517-521
CrossRef633
Tomoko Nakagami, Naoko Tajima, Toshihide Oizumi, Shigeru Karasawa, Kiriko Wada, Wataru Kameda, Shinji Susa, Takeo Kato, Makoto Daimon. (2010) Hemoglobin A1c in predicting progression to diabetes. Diabetes Research and Clinical Practice 87:1, 126-131
CrossRef634
G. Paolisso, A. J. Sinclair. (2010) Effective clinical practice for older people with type 2 diabetes. Glucose regulation is important but other strategies also need to be included. The journal of nutrition, health & aging 14:1, 3-4
CrossRef635
Jennifer C. Hirsch, John R. Charpie, Richard G. Ohye, James G. Gurney. (2010) Near Infrared Spectroscopy (NIRS) Should Not Be Standard of Care for Postoperative Management. Seminars in Thoracic and Cardiovascular Surgery: Pediatric Cardiac Surgery Annual 13:1, 51-54
CrossRef636
R. I. G. Holt. (2010) Insulin initiation in Type 2 diabetes: the implications of the 4-T study. Diabetic Medicine 27:1, 1-3
CrossRef637
Jeong-Taek Woo, Kyung Soo Park, Dong-Won Byun, Kyung Soo Ko, Yoon-Sok Chung, Doo Man Kim, Tae Sun Park, Bong Soo Cha, In Kyu Lee, Joong Yeol Park, Hyun Shik Son, Moon-Kyu Lee, Kwang Won Kim, Ho Young Son. (2010) Regulation of Glucose Control in People with Type 2 Diabetes: A Review and Consensus. Korean Diabetes Journal 34:1, 16
CrossRef638
Shepard D. Weiner, LeRoy E. Rabbani. (2010) Secondary prevention strategies for coronary heart disease. Journal of Thrombosis and Thrombolysis 29:1, 8-24
CrossRef639
A D Wright, P M Dodson. (2010) Diabetic retinopathy and blockade of the renin–angiotensin system: new data from the DIRECT study programme. Eye 24:1, 1-6
CrossRef640
Tamara B. Horwich, Gregg C. Fonarow. (2010) Glucose, Obesity, Metabolic Syndrome, and Diabetes. Journal of the American College of Cardiology 55:4, 283-293
CrossRef641
J.-M. Gamble, S. H. Simpson, D. T. Eurich, S. R. Majumdar, J. A. Johnson. (2010) Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes, Obesity and Metabolism 12:1, 47-53
CrossRef642
Neale Cohen. (2010) Diabetes: Intensive glucose-lowering therapy—weighing up the evidence. Nature Reviews Endocrinology 6:1, 9-10
CrossRef643
Kenro Nishida, Seiya Shimoda, Kenshi Ichinose. (2010) Glucose control in critically ill patients and clinical application of bedside-type artificial endocrine pancreas. Nihon Shuchu Chiryo Igakukai zasshi 17:4, 464-467
CrossRef644
Shinichiro UEDA. (2010) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 41:3, 90-94
CrossRef645
Sandra L. Tunis, William D. Willis, Volker Foos. (2010) Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain. Current Medical Research and Opinion 26:1, 163-175
CrossRef646
Alberto Cordero, Lorenzo Fácila, Enrique Galve, Pilar Mazón. (2010) Novedades en hipertensión arterial y diabetes mellitus. Revista Española de Cardiología 63, 101-115
CrossRef647
Masafumi NAKAYAMA. (2010) S14-4. Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 41:3, 99S-100s
CrossRef648
B. Gallwitz, H.-U. Häring. (2010) Future perspectives for insulinotropic agents in the treatment of type 2 diabetesâDPP-4 inhibitors and sulphonylureas. Diabetes, Obesity and Metabolism 12:1, 1-11
CrossRef649
Taiji Yamashita, Morihiro Matsuda, Orie Nishimoto, Kei Nakamoto, Hirohiko Nishiyama, Kengo Matsumoto, Ritsu Tamura, Toshiharu Kawamoto. (2010) Combination of Serum Adiponectin Level and Metabolic Syndrome is Closely Associated with Coronary Artery Disease in Japanese Subjects with Good Glycemic Control. Internal Medicine 49:8, 721-727
CrossRef650
(2010) Añadir insulina de acción lenta. Dr. J.A. Martin Oterino. Revista Clínica Española 210:1, 26-27
CrossRef651
Gregory A. Nichols, Shravanthi R. Gandra, Chiun-Fang Chiou, Mary S. Anthony, Maria Alexander-Bridges, Jonathan B. Brown. (2010) Successes and challenges of insulin therapy for type 2 diabetes in a managed-care setting. Current Medical Research and Opinion 26:1, 9-15
CrossRef652
Ichiro NIKI, Shigeki TANIGUCHI, Toshihide KIMURA. (2010) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 41:2, 55S-56S
CrossRef653
Sunao Kojima, Tomohiro Sakamoto, Hisao Ogawa, Akira Kitagawa, Kunihiko Matsui, Hideki Shimomura, Kazuo Kimura, Yasuhiro Ogata, Naritsugu Sakaino, The Multicenter Study for Aggressiv. (2010) Standard-Dose Statin Therapy Provides Incremental Clinical Benefits in Normocholesterolemic Diabetic Patients. Circulation Journal 74:4, 779-785
CrossRef654
Satish K. Garg. (2010) The Role of Basal Insulin and Glucagon-Like Peptide-1 Agonists in the Therapeutic Management of Type 2 Diabetes—A Comprehensive Review. Diabetes Technology & Therapeutics 12:1, 11-24
CrossRef655
Paola Fioretto, Paul M. Dodson, Dan Ziegler, Robert S. Rosenson. (2010) Residual microvascular risk in diabetes: unmet needs and future directions. Nature Reviews Endocrinology 6:1, 19-25
CrossRef656
Shari S. Bassuk, JoAnn E. Manson. 2010. Gender-Specific Aspects of Selected Coronary Heart Disease Risk FactorsA Summary of the Epidemiologic Evidence. , 162-174.
CrossRef657
Peter J. Veazie, Paul E. Johnson, Patrick J. O'Connor. (2009) Is there a downside to customizing care? Implications of general and patient-specific treatment strategies. Journal of Evaluation in Clinical Practice 15:6, 1171-1176
CrossRef658
F. Follath. (2009) Ethical considerations in cardiovascular prevention. Fundamental & Clinical Pharmacology 23:6, 669-673
CrossRef659
B. Guthrie, A. Emslie-Smith, A. D. Morris. (2009) Which people with Type 2 diabetes achieve good control of intermediate outcomes? Population database study in a UK region. Diabetic Medicine 26:12, 1269-1276
CrossRef660
Giuseppe Mancia, Stéphane Laurent, Enrico Agabiti-Rosei, Ettore Ambrosioni, Michel Burnier, Mark J. Caulfield, Renata Cifkova, Denis Clément, Antonio Coca, Anna Dominiczak, Serap Erdine, Robert Fagard, Csaba Farsang, Guido Grassi, Hermann Haller, Antony Heagerty, Sverre E. Kjeldsen, Wolfgang Kiowski, Jean Michel Mallion, Athanasios Manolis, Krzysztof Narkiewicz, Peter Nilsson, Michael H. Olsen, Karl Heinz Rahn, Josep Redon, José Rodicio, Luis Ruilope, Roland E. Schmieder, Harry A.J. Struijker-Boudier, Pieter A. Van Zwieten, Margus Viigimaa, Alberto Zanchetti. (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Pressure 18:6, 308-347
CrossRef661
Domenico Fusco, Fabrizia Lattanzio, Matteo Tosato, Andrea Corsonello, Antonio Cherubini, Stefano Volpato, Cinzia Maraldi, Carmelinda Ruggiero, Graziano Onder. (2009) Development of CRIteria to Assess Appropriate Medication Use among Elderly Complex Patients (CRIME) Project. Drugs & Aging 26:Supplement 1, 3-13
CrossRef662
Leszek Czupryniak. (2009) Guidelines for the management of type 2 diabetes: is ADA and EASD consensus more clinically relevant than the IDF recommendations?. Diabetes Research and Clinical Practice 86, S22-S25
CrossRef663
I. Salti, . (2009) Efficacy and safety of insulin glargine and glimepiride in subjects with Type 2 diabetes before, during and after the period of fasting in Ramadan. Diabetic Medicine 26:12, 1255-1261
CrossRef664
Adam Whaley-Connell, L. Romayne Kurukulasuriya, James R. Sowers. (2009) Renin-Angiotensin-Aldosterone System Inhibition and Improvement in Glucose Tolerance. The Journal of Clinical Hypertension 11, S40-S47
CrossRef665
D. Sander, K. Sander. (2009) Schlaganfall-Primärprävention bei Diabetespatienten. Der Diabetologe 5:8, 611-619
CrossRef666
Thomas R. Lux, Heinrich Taegtmeyer. (2009) All things considered-including glucose control in the ICU. Current Hypertension Reports 11:6, 383-384
CrossRef667
Stephan F. E. Praet, Luc J. C. Loon. (2009) Exercise therapy in Type 2 diabetes. Acta Diabetologica 46:4, 263-278
CrossRef668
Mahamood Edavalath, Alan Rees. (2009) Therapy and clinical trials: glycaemic control and cardiovascular disease. Current Opinion in Lipidology 20:6, 530-531
CrossRef669
R. Weber, K. Busch, H.C. Diener. (2009) Schlaganfallsekundärprävention bei Diabetespatienten. Der Diabetologe 5:8, 620-627
CrossRef670
M. J. Davies, R. Donnelly, A. H. Barnett, S. Jones, C. Nicolay, A. Kilcoyne. (2009) Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes, Obesity and Metabolism 11:12, 1153-1162
CrossRef671
Zachary Bloomgarden. (2009) Recent cardiovascular trials: What are the drivers of benefit and adverse effect?. Journal of Diabetes 1:4, 227-229
CrossRef672
Ivan Tkáč. (2009) Effect of intensive glycemic control on cardiovascular outcomes and all-cause mortality in type 2 diabetes: Overview and metaanalysis of five trials. Diabetes Research and Clinical Practice 86, S57-S62
CrossRef673
Niels de Fine Olivarius, Volkert Siersma, Lars J. Hansen, Thomas Drivsholm, Mogens Hørder. (2009) Changes in levels of haemoglobin A 1c during the first 6 years after diagnosis of clinical type 2 diabetes. Scandinavian Journal of Clinical & Laboratory Investigation 69:8, 851-857
CrossRef674
Mary Ann Vann. (2009) Perioperative management of ambulatory surgical patients with diabetes mellitus. Current Opinion in Anaesthesiology 22:6, 718-724
CrossRef675
D. John Betteridge. (2009) CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone. Fundamental & Clinical Pharmacology 23:6, 675-679
CrossRef676
E. Renard. (2009) Bariatric surgery in patients with late-stage type 2 diabetes: expected beneficial effects on risk ratio and outcomes. Diabetes & Metabolism 35:6, 564-568
CrossRef677
Nahla N Younis, Handrean Soran, Reena Sharma, Valentine Charlton-Menys, Paul N Durrington. (2009) Lipoprotein glycation in atherogenesis. Clinical Lipidology 4:6, 781-790
CrossRef678
Alan Cole, David M. Nathan, Elizabeth Savaria-Porter, Paul Copeland, Alexander Turchin, Melanie Brunt, Randall Zusman, Jo-Ann Barrett, Deborah Wexler, Emily Case, Graham T. McMahon, Elizabeth Mort. (2009) An Algorithm for the Care of Type 2 Diabetes. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 8:4, 156-165
CrossRef679
Ivan Tkáč, Zvonko Milićević, György Jermendy. (2009) How to interpret results of the HEART2D trial?. Diabetes Research and Clinical Practice 86, S53-S56
CrossRef680
Jan Gunst, Miet Schetz. (2009) Clinical benefits of tight glycaemic control: effect on the kidney. Best Practice & Research Clinical Anaesthesiology 23:4, 431-439
CrossRef681
Dieter Mesotten, Greet Van den Berghe. (2009) Clinical benefits of tight glycaemic control: focus on the intensive care unit. Best Practice & Research Clinical Anaesthesiology 23:4, 421-429
CrossRef682
J.-P. Laaban, S. Daenen, D. Léger, S. Pascal, V. Bayon, G. Slama, F. Elgrably. (2009) Prevalence and predictive factors of sleep apnoea syndrome in type 2 diabetic patients. Diabetes & Metabolism 35:5, 372-377
CrossRef683
B. H. R. Wolffenbuttel, L. J. Klaff, R. Bhushan, J. L. Fahrbach, H. Jiang, S. Martin. (2009) Initiating insulin therapy in elderly patients with Type 2 diabetes: efficacy and safety of lispro mix 25 vs. basal insulin combined with oral glucose-lowering agents. Diabetic Medicine 26:11, 1147-1155
CrossRef684
J. Ma, W. Yang, N. Fang, W. Zhu, M. Wei. (2009) The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: A meta-analysis. Nutrition, Metabolism and Cardiovascular Diseases 19:9, 596-603
CrossRef685
Riccardo Candido, Stella Bernardi, Terri J Allen. (2009) Linking diabetes and atherosclerosis. Expert Review of Endocrinology & Metabolism 4:6, 603-624
CrossRef686
Arnold Melman, Elena Zotova, Mimi Kim, Joseph Arezzo, Kelvin Davies, Michael DiSanto, Moses Tar. (2009) Longitudinal studies of time-dependent changes in both bladder and erectile function after streptozotocin-induced diabetes in Fischer 344 male rats. BJU International 104:9, 1292-1300
CrossRef687
F. M. Turnbull, C. Abraira, R. J. Anderson, R. P. Byington, J. P. Chalmers, W. C. Duckworth, G. W. Evans, H. C. Gerstein, R. R. Holman, T. E. Moritz, B. C. Neal, T. Ninomiya, A. A. Patel, S. K. Paul, F. Travert, M. Woodward. (2009) Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52:11, 2288-2298
CrossRef688
Gianpaolo Reboldi, Giorgio Gentile, Fabio Angeli, Paolo Verdecchia. (2009) Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus. Expert Review of Cardiovascular Therapy 7:11, 1349-1361
CrossRef689
E. Mannucci, M. Monami, C. Lamanna, F. Gori, N. Marchionni. (2009) Prevention of cardiovascular disease through glycemic control in type 2 diabetes: A meta-analysis of randomized clinical trials. Nutrition, Metabolism and Cardiovascular Diseases 19:9, 604-612
CrossRef690
Stephen C. Bain. (2009) Treatment of Type 2 Diabetes Mellitus with Orally Administered Agents: Advances in Combination Therapy. Endocrine Practice 15:7, 750-762
CrossRef691
A. J. Garber. (2009) Restaging insulin therapy for patients with type 2 diabetes. Diabetes, Obesity and Metabolism 11, 1-5
CrossRef692
(2009) Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. American Journal of Transplantation 9, S1-S155
CrossRef693
Scott Drab. (2009) Translating clinical guidelines into clinical practice: Role of the pharmacist in type 2 diabetes management. Journal of the American Pharmacists Association 49:6, e152-e162
CrossRef694
B G Schwartz, R A Kloner. (2009) How to save a life during a clinic visit for erectile dysfunction by modifying cardiovascular risk factors. International Journal of Impotence Research 21:6, 327-335
CrossRef695
Giuseppe Mancia, Stéphane Laurent, Enrico Agabiti-Rosei, Ettore Ambrosioni, Michel Burnier, Mark J Caulfield, Renata Cifkova, Denis Clément, Antonio Coca, Anna Dominiczak, Serap Erdine, Robert Fagard, Csaba Farsang, Guido Grassi, Hermann Haller, Anthony Heagerty, Sverre E Kjeldsen, Wolfgang Kiowski, Jean Michel Mallion, Athanasios Manolis, Krzysztof Narkiewicz, Peter Nilsson, Michael H Olsen, Karl Heinz Rahn, Josep Redon, José Rodicio, Luis Ruilope, Roland E Schmieder, Harry AJ Struijker-Boudier, Pieter A van Zwieten, Margus Viigimaa, Alberto Zanchetti. (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Journal of Hypertension 27:11, 2121-2158
CrossRef696
Christian Lerch, Bernd Richter. (2009) Extent of glycemic control in type 2 diabetes mellitus: Close, but no cigar. Nutrition, Metabolism and Cardiovascular Diseases 19:9, 593-595
CrossRef697
Richard E. Pratley, Thérèse McCall, Penny R. Fleck, Craig A. Wilson, Qais Mekki. (2009) Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies. Journal of the American Geriatrics Society 57:11, 2011-2019
CrossRef698
David Rigau Comas, José Álvarez-Sabin, Antonio Gil Núñez, Sonia Abilleira Castells, Francesc Xavier Borras Pérez, Pedro Armario García, Enrique Arrieta Antón, Eugenio Marañón Fernández, Juan Carlos Martí Canales, Ana Morales Ortiz, Juan Carlos Reverter Calatayud, Esther Sancristóbal Velasco, Ivan Solà Arnau, Pablo Alonso Coello. (2009) Guía de práctica clínica sobre prevención primaria y secundaria del ictus. Medicina Clínica 133:19, 754-762
CrossRef699
Eduard Montanya, Giorgio Sesti. (2009) A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clinical Therapeutics 31:11, 2472-2488
CrossRef700
Christine T. Cigolle, Caroline S. Blaum, Jeffrey B. Halter. (2009) Diabetes and Cardiovascular Disease Prevention in Older Adults. Clinics in Geriatric Medicine 25:4, 607-641
CrossRef701
Farhan Aslam, Attiya Haque, Joanne Foody, L Veronica Lee. (2009) Peripheral Arterial Disease: Current Perspectives and New Trends in Management. Southern Medical Journal 102:11, 1141-1149
CrossRef702
Sean D Sullivan, Rafael Alfonso-Cristancho, Chris Conner, Mette Hammer, Lawrence Blonde. (2009) A Simulation of the Comparative Long-term Effectiveness of Liraglutide and Glimepiride Monotherapies in Patients with Type 2 Diabetes Mellitus. Pharmacotherapy 29:11, 1280-1288
CrossRef703
Alexandra Jauregui, Daniel H Mintz, Peter Mundel, Alessia Fornoni. (2009) Role of altered insulin signaling pathways in the pathogenesis of podocyte malfunction and microalbuminuria. Current Opinion in Nephrology and Hypertension 18:6, 539-545
CrossRef704
Holman, Rury R., Farmer, Andrew J., Davies, Melanie J., Levy, Jonathan C., Darbyshire, Julie L., Keenan, Joanne F., Paul, Sanjoy K., . (2009) Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. New England Journal of Medicine 361:18, 1736-1747
Full Text705
K. L. Hoehn, A. B. Salmon, C. Hohnen-Behrens, N. Turner, A. J. Hoy, G. J. Maghzal, R. Stocker, H. Van Remmen, E. W. Kraegen, G. J. Cooney, A. R. Richardson, D. E. James. (2009) Insulin resistance is a cellular antioxidant defense mechanism. Proceedings of the National Academy of Sciences 106:42, 17787-17792
CrossRef706
Bianca Hemmingsen, Søren S Lund, Christian Gluud, Allan Vaag, Thomas Almdal, Jørn Wetterslev, Bianca Hemmingsen. 2009. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. .
CrossRef707
S. Akalin, K. Berntorp, A. Ceriello, A. K. Das, E. S. Kilpatrick, T. Koblik, C. S. Munichoodappa, C. Y. Pan, W. Rosenthall, M. Shestakova, B. Wolnik, V. Woo, W. Y. Yang, M. T. Yilmaz, . (2009) Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control. International Journal of Clinical Practice 63:10, 1421-1425
CrossRef708
S. Jabbour. (2009) Type 2 diabetes and HbA1c goal: time for individualised therapy. International Journal of Clinical Practice 63:10, 1408-1409
CrossRef709
Dirk Sander, Mark T. Kearney. (2009) Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives. Journal of Neurology 256:10, 1603-1619
CrossRef710
Anthony L. McCall. (2009) When is evidence of lack of harm enough? Has the rosiglitazone controversy ended?. Current Diabetes Reports 9:5, 325-328
CrossRef711
Brian F. Leas, Bettina Berman, Kathryn M. Kash, Albert G. Crawford, Richard W. Toner, Neil I. Goldfarb, David B. Nash. (2009) Quality Measurement in Diabetes Care. Population Health Management 12:5, 265-271
CrossRef712
Tamara Isakova, Orlando M Gutiérrez, Myles Wolf. (2009) A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney International 76:7, 705-716
CrossRef713
G. A. Thomson, R. Craig. (2009) Where now for insulin glargine - a time for pragmatic medicine?. International Journal of Clinical Practice 63:10, 1413-1415
CrossRef714
D. S. Lasserson, P. Glasziou, R. Perera, R. R. Holman, A. J. Farmer. (2009) Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia 52:10, 1990-2000
CrossRef715
R. Peter, G. Dunseath, S. D. Luzio, R. Chudleigh, S. R. Choudhury, D. R. Owens. (2009) Relative and absolute contributions of postprandial and fasting plasma glucose to daytime hyperglycaemia and HbA 1c in subjects with Type 2 diabetes. Diabetic Medicine 26:10, 974-980
CrossRef716
David C. W. Lau. (2009) Le cholestérol alimentaire et autres considérations nutritionnelles chez les personnes atteintes de diabète. International Journal of Clinical Practice 63, 44-51
CrossRef717
Jan Cederholm, Björn Zethelius, Peter M. Nilsson, Katarina Eeg-Olofsson, Björn Eliasson, Soffia Gudbjörnsdottir. (2009) Effect of tight control of HbA1c and blood pressure on cardiovascular diseases in type 2 diabetes: An observational study from the Swedish National Diabetes Register (NDR). Diabetes Research and Clinical Practice 86:1, 74-81
CrossRef718
George Steiner. (2009) How Can We Improve the Management of Vascular Risk in Type 2 Diabetes: Insights from FIELD. Cardiovascular Drugs and Therapy 23:5, 403-408
CrossRef719
Morali D. Sharma, Alan J. Garber. (2009) What is the best treatment for prediabetes?. Current Diabetes Reports 9:5, 335-341
CrossRef720
Christian Weber, Oliver Schnell. (2009) The Assessment of Glycemic Variability and Its Impact on Diabetes-Related Complications: An Overview. Diabetes Technology & Therapeutics 11:10, 623-633
CrossRef721
George G. Rhoads, Mikhail Kosiborod, Richard W. Nesto, Vivian A. Fonseca, Shou-En Lu, Quanwu Zhang, Joanne M. Foody. (2009) Comparison of Incidence of Acute Myocardial Infarction in Patients With Type 2 Diabetes Mellitus Following Initiation of Neutral Protamine Hagedorn Insulin Versus Insulin Glargine. The American Journal of Cardiology 104:7, 910-916
CrossRef722
D. C. W. Lau. (2009) Dietary cholesterol and other nutritional considerations in people with diabetes. International Journal of Clinical Practice 63, 15-21
CrossRef723
Natale Vazzana, Francesca Santilli, Chiara Cuccurullo, Giovanni Davì. (2009) Soluble forms of RAGE in internal medicine. Internal and Emergency Medicine 4:5, 389-401
CrossRef724
A. J. Scheen, M. H. Tan, D. J. Betteridge, K. Birkeland, O. Schmitz, B. Charbonnel, . (2009) Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17). Diabetic Medicine 26:10, 1033-1039
CrossRef725
Kristian B. Filion, Lawrence Joseph, Jean-François Boivin, Samy Suissa, James M. Brophy. (2009) Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis. Pharmacoepidemiology and Drug Safety 18:10, 973-976
CrossRef726
A. Liebl. (2009) Insulin intensification â the rationale and the target. International Journal of Clinical Practice 63, 1-5
CrossRef727
Isabelle Bourdel-Marchasson, J. Doucet, B. Bauduceau, G. Berrut, J. -F. Blickle, P. Brocker, T. Constans, A. Fagot-Campagna, E. Kaloustian, V. Lassmann-Vague, P. Lecomte, D. Simon, D. Tessier, C. Verny, U. M. Vischer. (2009) Key priorities in managing glucose control in older people with diabetes. The Journal of Nutrition, Health and Aging 13:8, 685-691
CrossRef728
Matteo Anselmino, Lars Rydén. (2009) Strategies to enhance cardiovascular disease prevention in patients with diabetes. Current Opinion in Cardiology 24:5, 461-467
CrossRef729
William T. Cefalu. (2009) Diabetes: HOME reveals new data on a cornerstone of treatment. Nature Reviews Endocrinology 5:9, 478-479
CrossRef730
Sunder Mudaliar. (2009) Serum glucose control in diabetic patients with cardiovascular disease: Should we be less aggressive?. Current Atherosclerosis Reports 11:5, 384-390
CrossRef731
Stuart W. Zarich. (2009) Antidiabetic agents and cardiovascular risk in type 2 diabetes. Nature Reviews Endocrinology 5:9, 500-506
CrossRef732
P. Conthe, J. Szymaniec. (2009) De los algoritmos a la práctica clínica en el manejo óptimo del paciente diabético. Revista Clínica Española 209, 18-27
CrossRef733
Niall JJ MacDougall, Sanjay Amarasinghe, Keith W Muir. (2009) Secondary prevention of stroke. Expert Review of Cardiovascular Therapy 7:9, 1103-1115
CrossRef734
David B. Sacks. (2009) Therapy: Intensive glucose control in the ICU: is SUGAR NICE?. Nature Reviews Endocrinology 5:9, 473-474
CrossRef735
C. Mathieu, R. Cuddihy, R.F. Arakaki, R.M. Belin, J.-M. Planquois, J.N. Lyons, C.R. Heilmann. (2009) A Comparison Between Simplified and Intensive Dose-Titration Algorithms Using AIR Inhaled Insulin for Insulin-Naive Patients with Type 2 Diabetes in a Randomized Noninferiority Trial. Diabetes Technology & Therapeutics 11:s2, S-53-S-61
CrossRef736
Yaseen M. Arabi, Hani M. Tamim, Asgar H. Rishu. (2009) Hypoglycemia with intensive insulin therapy in critically ill patients: Predisposing factors and association with mortality*. Critical Care Medicine 37:9, 2536-2544
CrossRef737
J.-P. Riveline, J. Teynie, S. Belmouaz, S. Franc, D. Dardari, M. Bauwens, V. Caudwell, S. Ragot, F. Bridoux, G. Charpentier, R. Marechaud, S. Hadjadj. (2009) Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system. Nephrology Dialysis Transplantation 24:9, 2866-2871
CrossRef738
Michael R. Jones, Sunder Mudaliar, Eric Hernandez-Triana, Ambika G. Unnikrishnan, Yu-Ling Lai, Stacey L. Abby, Soamnauth Misir, Xiaoping Jin, Sukumar Nagendran. (2009) Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes. Current Medical Research and Opinion 25:9, 2239-2249
CrossRef739
Lawrence A. Notaro, Mohammed H. Usman, James F. Burke, Aqeel Siddiqui, Keith R. Superdock, Michael D. Ezekowitz. (2009) Secondary Prevention in Concurrent Coronary Artery, Cerebrovascular, and Chronic Kidney Disease: Focus on Pharmacological Therapy. Cardiovascular Therapeutics 27:3, 199-215
CrossRef740
Ke-Ke Jin, Lei Chen, Jing-Ye Pan, Jian-Min Li, Yang Wang, Fang-Yan Wang. (2009) Acupressure Therapy Inhibits the Development of Diabetic Complications in Chinese Patients with Type 2 Diabetes. The Journal of Alternative and Complementary Medicine 15:9, 1027-1032
CrossRef741
Richard M. Cubbon, Matthew B. Kahn, Stephen B. Wheatcroft. (2009) Effects of insulin resistance on endothelial progenitor cells and vascular repair. Clinical Science 117:5, 173-190
CrossRef742
Ali Yazdanyar, Anne B. Newman. (2009) Evolving concepts of cardiovascular disease prevention in older adults. Current Cardiovascular Risk Reports 3:5, 366-373
CrossRef743
Raphaël Duivenvoorden, Eric de Groot, Erik S.G. Stroes, John J.P. Kastelein. (2009) Surrogate markers in clinical trials—Challenges and opportunities. Atherosclerosis 206:1, 8-16
CrossRef744
A. S. Wierzbicki. (2009) Storms, tea cups and the adverse effects of statins. International Journal of Clinical Practice 63:9, 1268-1270
CrossRef745
DR Owens, J Rosenstock, GB Bolli. (2009) Insulin glargine and cancer: cause and effect unproven. Practical Diabetes International 26:7, 256-257
CrossRef746
M. Fisher. (2009) Improving cardiovascular risk - applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes. International Journal of Clinical Practice 63:9, 1354-1368
CrossRef747
N. R. Webster, H. F. Galley. (2009) Does strict glucose control improve outcome?. British Journal of Anaesthesia 103:3, 331-334
CrossRef748
G. Charpentier, S. Halimi, . (2009) Earlier triple therapy with pioglitazone in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 11:9, 844-854
CrossRef749
Baqiyyah Conway, Rhobert W. Evans, Linda Fried, Sheryl Kelsey, Daniel Edmundowicz, Trevor J. Orchard. (2009) Free fatty acids are associated with pulse pressure in women, but not men, with type 1 diabetes mellitus. Metabolism 58:9, 1215-1221
CrossRef750
M. L. Simoons. (2009) Angiotensin-converting enzyme inhibition by perindopril in cardiovascular disease. European Heart Journal Supplements 11:Suppl E, E4-E8
CrossRef751
A. Kautzky-Willer, A. Handisurya. (2009) Metabolic diseases and associated complications: sex and gender matter!. European Journal of Clinical Investigation 39:8, 631-648
CrossRef752
Alex J. Graveling, Brian M. Frier. (2009) Hypoglycaemia: An overview. Primary Care Diabetes 3:3, 131-139
CrossRef753
M. Hanefeld. (2009) The role of pioglitazone in modifying the atherogenic lipoprotein profile. Diabetes, Obesity and Metabolism 11:8, 742-756
CrossRef754
Bruno Geloneze, Sylka R. Geloneze, Carla Fiori, Christiane Stabe, Marcos A. Tambascia, Elinton A. Chaim, Brenno D. Astiarraga, Jose Carlos Pareja. (2009) Surgery for Nonobese Type 2 Diabetic Patients: An Interventional Study with Duodenal–Jejunal Exclusion. Obesity Surgery 19:8, 1077-1083
CrossRef755
Helen C. Cooper, Robert Geyer. (2009) What can complexity do for diabetes management? Linking theory to practice. Journal of Evaluation in Clinical Practice 15:4, 761-765
CrossRef756
K Lipska, SE Inzucchi, M Kosiborod, HM Krumholz. (2009) Intensive glucose control and cardiovascular outcomes. The Lancet 374:9689, 522-523
CrossRef757
V. G. Athyros, A. Hatzitolios, A. Karagiannis, T. P. Didangelos, F. Iliadis, S. Dolgyras, T. Vosnakidis, P. Vasiliadis, I. Malias, K. Tziomalos, M. Samouilidou, D. P. Mikhailidis. (2009) Initiative for a new diabetes therapeutic approach in a Mediterranean country: the INDEED study. Current Medical Research and Opinion 25:8, 1931-1940
CrossRef758
R. J. MacIsaac, G. Jerums, A. J. Weekes, M. C. Thomas. (2009) Patterns of glycaemic control in Australian primary care (NEFRON 8). Internal Medicine Journal 39:8, 512-518
CrossRef759
Anthony J. Joseph, Eli A. Friedman. (2009) Diabetic Nephropathy in the Elderly. Clinics in Geriatric Medicine 25:3, 373-389
CrossRef760
José Ma Lobos Bejarano, Miguel Angel Royo-Bordonada, Carlos Brotons, Luís Álvarez-Sala, Pedro Armario, Antonio Maiques, Dídac Mauricio, Susana Sans, Fernando Villar, Angel Lizcano, Antonio Gil-Núñez, Fernando de Álvaro, Pedro Conthe, Emilio Luengo, Alfonso del Río, Olga Cortés, Ana de Santiago, Miguel A. Vargas, Mercedes Martínez, Vicenta Lizarbe. (2009) Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008. Atención Primaria 41:8, 463.e1-463.e24
CrossRef761
Nancy A. Thornberry, Baptist Gallwitz. (2009) Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Practice & Research Clinical Endocrinology & Metabolism 23:4, 479-486
CrossRef762
Pierre-Jean Guillausseau. (2009) Intensive glucose control and cardiovascular outcomes. The Lancet 374:9689, 523-524
CrossRef763
J. L. Sievenpiper, C. W. C. Kendall, A. Esfahani, J. M. W. Wong, A. J. Carleton, H. Y. Jiang, R. P. Bazinet, E. Vidgen, D. J. A. Jenkins. (2009) Effect of non-oil-seed pulses on glycaemic control: a systematic review and meta-analysis of randomised controlled experimental trials in people with and without diabetes. Diabetologia 52:8, 1479-1495
CrossRef764
J. H. O'Keefe, M. D. Carter, C. J. Lavie. (2009) Primary and Secondary Prevention of Cardiovascular Diseases: A Practical Evidence-Based Approach. Mayo Clinic Proceedings 84:8, 741-757
CrossRef765
Isabelle Bourdel-Marchasson, J. Doucet, B. Bauduceau, G. Berrut, J. -F. Blickle, P. Brocker, T. Constans, A. Fagot-Campagna, E. Kaloustian, V. Lassmann-Vague, P. Lecomte, D. Simon, D. Tessier, C. Verny, U. M. Vischer. (2009) Key priorities in managing glucose control in older people with diabetes. The Journal of Nutrition, Health and Aging
CrossRef766
Jose Agustin Arguedas, Marco I Perez, James M Wright, Jose Agustin Arguedas. 2009. Treatment blood pressure targets for hypertension. .
CrossRef767
Allison Hedley Dodd, Margaret S. Colby, Kristina S. Boye, Cheryl Fahlman, Sunny Kim, Ronette R. Briefel. (2009) Treatment approach and HbA 1c control among US adults with type 2 diabetes: NHANES 1999–2004*. Current Medical Research and Opinion 25:7, 1605-1613
CrossRef768
Brandy Patterson, Anjali V Fields, Richard P Shannon. (2009) New insights into myocardial glucose metabolism: surviving under stress. Current Opinion in Clinical Nutrition and Metabolic Care 12:4, 424-430
CrossRef769
C. Morath, M. Zeier. (2009) Transplantation in type 1 diabetes. Nephrology Dialysis Transplantation 24:7, 2026-2029
CrossRef770
David Aguilar, Biykem Bozkurt, Kumudha Ramasubbu, Anita Deswal. (2009) Relationship of Hemoglobin A1C and Mortality in Heart Failure Patients With Diabetes. Journal of the American College of Cardiology 54:5, 422-428
CrossRef771
Amna A. Shaghouli, Baiju R. Shah. (2009) The Prescription of Insulin Pen Devices Versus Syringes for Older People with Diabetes. Diabetes Technology & Therapeutics 11:7, 439-442
CrossRef772
Y. Kawashima, J. Chen, H. Sun, D. Lann, R. J. Hajjar, S. Yakar, D. LeRoith. (2009) Apolipoprotein E deficiency abrogates insulin resistance in a mouse model of type 2 diabetes mellitus. Diabetologia 52:7, 1434-1441
CrossRef773
Jacob Ilany. (2009) Providing cardiovascular benefits with safe diabetes therapy. Therapy 6:4, 455-457
CrossRef774
CD Lathia, D Amakye, W Dai, C Girman, S Madani, J Mayne, P MacCarthy, P Pertel, L Seman, A Stoch, P Tarantino, C Webster, S Williams, JA Wagner. (2009) The Value, Qualification, and Regulatory Use of Surrogate End Points in Drug Development. Clinical Pharmacology & Therapeutics 86:1, 32-43
CrossRef775
(2009) Journal Club. Medizinische Klinik 104:7, 567-577
CrossRef776
Sabreena Basu, Guillermo E Umpierrez. (2009) Does normalization of blood glucose reduce the rate of cardiovascular events?. Therapy 6:4, 459-461
CrossRef777
Clive Rosendorff, Henry R Black. (2009) Evidence for a lower target blood pressure for people with heart disease. Current Opinion in Cardiology 24:4, 318-324
CrossRef778
Rachandeep Singh, Ravi Nistala, Samy I McFarlane, Adam Whaley-Connell. (2009) Glycemic control and cardiovascular disease in a high-risk chronic kidney disease population. Therapy 6:4, 507-513
CrossRef779
Anushka Patel, Rohina Joshi, Bastiaan de Galan. (2009) Trials of cardiovascular risk factor management in type 2 diabetes. Current Opinion in Cardiology 24:4, 288-294
CrossRef780
Larry A. Weinrauch, Eldrin F. Lewis. (2009) Aiming for the Best Control of Glycemia in Patients With Heart Failure and Type 2 Diabetes. Journal of the American College of Cardiology 54:5, 429-431
CrossRef781
S. Prato. (2009) Megatrials in type 2 diabetes. From excitement to frustration?. Diabetologia 52:7, 1219-1226
CrossRef782
Robert R Henry, A Michael Lincoff, Sunder Mudaliar, Michael Rabbia, Cathy Chognot, Matthias Herz. (2009) Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. The Lancet 374:9684, 126-135
CrossRef783
Siobhan HM Brown, Ahmed H Abdelhafiz. (2009) Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction. Therapy 6:4, 515-529
CrossRef784
Irene A. Weiss, Guy Valiquette, Monica D. Schwarcz. (2009) Impact of Glycemic Treatment Choices on Cardiovascular Complications in Type 2 Diabetes. Cardiology in Review 17:4, 165-175
CrossRef785
Ryan E. Wolff, Larry F. Wolff, Bryan S. Michalowicz. (2009) A Pilot Study of Glycosylated Hemoglobin Levels in Periodontitis Cases and Healthy Controls. Journal of Periodontology 80:7, 1057-1061
CrossRef786
Louis Monnier, Claude Colette, David R. Owens. (2009) Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept. Diabetes/Metabolism Research and Reviews 25:5, 393-402
CrossRef787
Bernhard Ludvik, Helmut Brath, Thomas Wascher, Hermann Toplak. (2009) Stellenwert von Langzeit-Insulin-Analoga in der Therapie des Diabetes mellitus Typ 2. Wiener klinische Wochenschrift 121:13-14, 473-482
CrossRef788
A. J. Scheen. (2009) Rosiglitazone: to be or not to be?. Diabetologia 52:7, 1448-1450
CrossRef789
Victoria Alabraba, Adele Farnsworth, Rebecca Leigh, Paul Dodson, Stephen C.L. Gough, Theresa Smyth. (2009) Exubera Inhaled Insulin in Patients with Type 1 and Type 2 Diabetes: The First 12 Months. Diabetes Technology & Therapeutics 11:7, 427-430
CrossRef790
Catherine Fiévet, Bart Staels. (2009) Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease. Current Atherosclerosis Reports 11:4, 281-288
CrossRef791
W. van Biesen, S. Van Laecke, R. Vanholder. (2009) Treatment of type 2 diabetes in chronic kidney disease: meekly follow the herd or call to arms?. Nephrology Dialysis Transplantation 24:7, 2286-2287
CrossRef792
David M. Kendall, Robert M. Cuddihy, Richard M. Bergenstal. (2009) Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use. European Journal of Internal Medicine 20, S329-S339
CrossRef793
Gilles Lemesle, Laurent Bonello, Axel de Labriolle, Gabriel Maluenda, Asmir I. Syed, Sara D. Collins, Itsik Ben-Dor, Rebecca Torguson, Kimberly Kaneshige, Zhenyi Xue, William O. Suddath, Lowell F. Satler, Kenneth M. Kent, Joseph Lindsay, Augusto D. Pichard, Ron Waksman. (2009) Prognostic Value of Hemoglobin A1C Levels in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention With Stent Implantation. The American Journal of Cardiology 104:1, 41-45
CrossRef794
M. Odette Gore, Darren K. McGuire. (2009) Cardiovascular disease and type 2 diabetes mellitus: Regulating glucose and regulating drugs. Current Cardiology Reports 11:4, 258-263
CrossRef795
Airani Sathananthan, Adrian Vella. (2009) Personalized pharmacotherapy for Type 2 diabetes mellitus. Personalized Medicine 6:4, 417-422
CrossRef796
Samy I McFarlane, James R Sowers. (2009) Diabetes and cardiovascular disease: time for individualized risk reduction. Therapy 6:4, 451-453
CrossRef797
Rodica Pop-Busui, Elif Oral, David Raffel, Jaeman Byun, Valida Bajirovic, Anuradha Vivekanandan-Giri, Aaron Kellogg, Subramaniam Pennathur, Martin J. Stevens. (2009) Impact of rosiglitazone and glyburide on nitrosative stress and myocardial blood flow regulation in type 2 diabetes mellitus. Metabolism 58:7, 989-994
CrossRef798
The BARI 2D Study Group. (2009) A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. New England Journal of Medicine 360:24, 2503-2515
Full Text799
Alethea N. Hill, Cathy Roche, Susan J. Appel. (2009) Signs of improvement. The Nurse Practitioner 34:6, 12-22
CrossRef800
Zachary Bloomgarden, Guang Ning. (2009) What is the evidence base for the randomized controlled trial?. Journal of Diabetes 1:2, 73-75
CrossRef801
A. Ferland, P. Brassard, S. Lemieux, J. Bergeron, P. Bogaty, F. Bertrand, S. Simard, P. Poirier. (2009) Impact of high-fat /low-carbohydrate, high-, low-glycaemic index or low-caloric meals on glucose regulation during aerobic exercise in Type 2 diabetes. Diabetic Medicine 26:6, 589-595
CrossRef802
Oluf PEDERSEN. (2009) Intensified multifactorial treatment of patients with Type 2 diabetes: What can be achieved and does it pay off?. Journal of Diabetes 1:2, 83-89
CrossRef803
G. Schernthaner. (2009) Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors. International Journal of Clinical Practice 63:6, 912-929
CrossRef804
Michael R. MacDonald, Mark C. Petrie, Miles Fisher, John J. V. McMurray. (2009) Pharmacologic management of patients with both heart failure and diabetes. Current Heart Failure Reports 6:2, 126-132
CrossRef805
Larry A. Allen, Adrian F. Hernandez, Christopher M. O'Connor, G. Michael Felker. (2009) End Points for Clinical Trials in Acute Heart Failure Syndromes. Journal of the American College of Cardiology 53:24, 2248-2258
CrossRef806
Nanae Fukaya, Kazuki Mochizuki, Masaya Shimada, Toshinao Goda. (2009) The α-glucosidase inhibitor miglitol decreases glucose fluctuations and gene expression of inflammatory cytokines induced by hyperglycemia in peripheral leukocytes. Nutrition 25:6, 657-667
CrossRef807
U.-M. Vischer, B. Bauduceau, I. Bourdel-Marchasson, J.-F. Blickle, T. Constans, A. Fagot-Campagna, E. Kaloustian, V. Lassman-Vague, P. Lecomte, D. Simon, D. Tessier, C. Verny, J. Doucet. (2009) A call to incorporate the prevention and treatment of geriatric disorders in the management of diabetes in the elderly. Diabetes & Metabolism 35:3, 168-177
CrossRef808
Marco Roffi, Franz R. Eberli. (2009) Diabetes and acute coronary syndromes. Best Practice & Research Clinical Endocrinology & Metabolism 23:3, 305-316
CrossRef809
J.M. Lobos, M.Á. Royo-Bordonada, C. Brotons, L. Álvarez-Sala, P. Armario, A. Maiques, D. Mauricio, S. Sans, F. Villar, Á. Lizcano, A. Gil-Núñez, F. de Álvaro, P. Conthe, E. Luengo, A. del Río, O. Cortés, A. de Santiago, M.A. Varga, M. Martínez, V. Lizarbe. (2009) Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008. Revista Clínica Española 209:6, 279-302
CrossRef810
Chih-Chen Lu, Bang-Ping Jiann, Chun-Chin Sun, Hing-Chung Lam, Chih-Hsun Chu, Jenn-Kuen Lee. (2009) Association of Glycemic Control with Risk of Erectile Dysfunction in Men with Type 2 Diabetes. Journal of Sexual Medicine 6:6, 1719-1728
CrossRef811
George M. Hall, Grainne Nicholson. (2009) Current Therapeutic Drugs for Type 2 Diabetes, Still Useful After 50 Years?. Anesthesia & Analgesia 108:6, 1727-1730
CrossRef812
Kaivan Khavandi, Ali Khavandi, Omar Asghar, Adam Greenstein, Sarah Withers, Anthony M. Heagerty, Rayaz A. Malik. (2009) Diabetic cardiomyopathy – a distinct disease?. Best Practice & Research Clinical Endocrinology & Metabolism 23:3, 347-360
CrossRef813
Joachim P. Sturmberg, Carmel M. Martin. (2009) Complexity and health - yesterday's traditions, tomorrow's future. Journal of Evaluation in Clinical Practice 15:3, 543-548
CrossRef814
Veronique Guyomard, Phyo Kyaw Myint. (2009) Optimum control of blood glucose for prevention and treatment of ischemic and hemorrhagic stroke. Current Treatment Options in Cardiovascular Medicine 11:3, 201-211
CrossRef815
H.-C. Diener, C. Weimar. (2009) Update of secondary stroke prevention. Nephrology Dialysis Transplantation 24:6, 1718-1724
CrossRef816
Ole-Petter R. Hamnvik, Graham T. McMahon. (2009) Balancing Risk and Benefit with Oral Hypoglycemic Drugs. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 76:3, 234-243
CrossRef817
Ole-Petter R. Hamnvik, Graham T. McMahon. (2009) Glycemic Targets for Patients with Type 2 Diabetes Mellitus. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 76:3, 227-233
CrossRef818
P. P. Toth. (2009) Clinical insights from the Fenofibrate Intervention and Event Lowering in Diabetes study: a community practice perspective. International Journal of Clinical Practice 63:6, 903-911
CrossRef819
Andreas Thomas, Martin Schönauer, Frank Achermann, Oliver Schnell, Markolf Hanefeld, Hans-Jürgen Ziegelasch, John Mastrototaro, Lutz Heinemann. (2009) The “Glucose Pentagon”: Assessing Glycemic Control of Patients with Diabetes Mellitus by a Model Integrating Different Parameters from Glucose Profiles. Diabetes Technology & Therapeutics 11:6, 399-409
CrossRef820
Katherine E. Nori Janosz, Kerstyn C. Zalesin, Wendy M. Miller, Peter A. McCullough, Barry A. Franklin. (2009) Impact of surgical and nonsurgical weight loss on diabetes resolution and cardiovascular risk reduction. Current Diabetes Reports 9:3, 223-228
CrossRef821
A. Giaccari, G. Sorice, G. Muscogiuri. (2009) Glucose toxicity: The leading actor in the pathogenesis and clinical history of type 2 diabetes – mechanisms and potentials for treatment. Nutrition, Metabolism and Cardiovascular Diseases 19:5, 365-377
CrossRef822
José M. Lobos, Miguel Ángel Royo-Bordonada, Carlos Brotons, Luis Álvarez-Sala, Pedro Armario, Antonio Maiques, Dídac Mauricio, Susana Sans, Fernando Villar, Ángel Lizcano, Antonio Gil-Núñez, Fernando de Álvaro, Pedro Conthe, Emilio Luengo, Alfonso del Río, Olga Cortés, Ana de Santiago, Miguel A. Vargas, Mercedes Martínez, Vicenta Lizarbe. (2009) Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008. Clínica e Investigación en Arteriosclerosis 21:3, 124-150
CrossRef823
George L Bakris, Vivian A Fonseca, Kumar Sharma, Ernest M Wright. (2009) Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications. Kidney International 75:12, 1272-1277
CrossRef824
Suma Dronovalli, Basil O. Burney, George L. Bakris. (2009) Glycemic control and cardiovascular disease in chronic kidney disease. Current Diabetes Reports 9:3, 243-248
CrossRef825
(2009) Glucose Control and Vascular Complications in Type 2 Diabetes. New England Journal of Medicine 360:19, 2031-2032
Full Text826
Shiny Mathewkutty, Darren K McGuire. (2009) Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment. Expert Review of Cardiovascular Therapy 7:5, 541-549
CrossRef827
Suellen M. Curkendall, Jaime L. Natoli, Charles M. Alexander, Brian H. Nathanson, Tracy Haidar, Robert W. Dubois. (2009) Economic and Clinical Impact of Inpatient Diabetic Hypoglycemia. Endocrine Practice 15:4, 302-312
CrossRef828
David Verhaert, James D. Thomas. (2009) Dysglycemia and Acute Myocardial Infarction. JACC: Cardiovascular Imaging 2:5, 600-603
CrossRef829
Dominique Simon. (2009) Rosiglitazone. Primary Care Diabetes 3:2, 123-124
CrossRef830
G. Wolf. (2009) Diabetes und Niere – Update 2009. Der Diabetologe 5:3, 190-199
CrossRef831
Ramiro A Sanchez, Miryam Ayala, Hugo Baglivo, Carlos Velazquez, Guillermo Burlando, Oswaldo Kohlmann, Jorge Jimenez, Patricio López Jaramillo, Ayrton Brandao, Gloria Valdes, Luis Alcocer, Mario Bendersky, Agustín José Ramirez, Alberto Zanchetti. (2009) Latin American guidelines on hypertension*. Journal of Hypertension 27:5, 905-922
CrossRef832
Cyrus DeSouza, Vivian Fonseca. (2009) Therapeutic targets to reduce cardiovascular disease in type 2 diabetes. Nature Reviews Drug Discovery 8:5, 361-367
CrossRef833
Nigel A. Calcutt, Mark E. Cooper, Tim S. Kern, Ann Marie Schmidt. (2009) Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nature Reviews Drug Discovery 8:5, 417-430
CrossRef834
Kushwin Rajamani, Peter G Colman, Li Ping Li, James D Best, Merryn Voysey, Michael C D'Emden, Markku Laakso, John R Baker, Anthony C Keech. (2009) Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. The Lancet 373:9677, 1780-1788
CrossRef835
Neil R Poulter. (2009) Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE. Journal of Hypertension 27:Suppl 1, S3-S8
CrossRef836
Kausik K Ray, Sreenivasa Rao Kondapally Seshasai, Shanelle Wijesuriya, Rupa Sivakumaran, Sarah Nethercott, David Preiss, Sebhat Erqou, Naveed Sattar. (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. The Lancet 373:9677, 1765-1772
CrossRef837
M. Kellerer. (2009) Update Typ-2-Diabetes anhand ausgewählter aktueller Publikationen. Der Diabetologe 5:3, 177-189
CrossRef838
E. Jaeckel, F. Lehner. (2009) Pankreas- und Inseltransplantation. Der Internist 50:5, 536-549
CrossRef839
Arturo R. Rolla. (2009) Addressing the Need to Tailor Treatment to the Spectrum of Type 2 Diabetes: New Perspectives. Diabetes Technology & Therapeutics 11:5, 267-274
CrossRef840
P M Dodson. (2009) Management of diabetic retinopathy: could lipid-lowering be a worthwhile treatment modality?. Eye 23:5, 997-1003
CrossRef841
Arash Rashidi, Jackson T. Wright. (2009) Drug Treatment of Hypertension in Older Hypertensives. Clinics in Geriatric Medicine 25:2, 235-244
CrossRef842
T. Lohmann, M. Möhlig, A. Pfeiffer. (2009) ACCORD, ADVANCE und VADT – Paradigmenwechsel in der Diabetologie?. Clinical Research in Cardiology Supplements 4:S2, 196-199
CrossRef843
N. Görlitz, M. Hummel. (2009) Insulintherapie bei Intensivpatienten. Der Diabetologe 5:3, 219-229
CrossRef844
Jodi R. Godfrey, Michelle F. Magee. (2009) Toward Optimal Health: Current Approaches to Standards of Care for Diabetes in Women. Journal of Women's Health 18:5, 605-610
CrossRef845
Sandra L. Tunis, Michael E. Minshall, Christopher Conner, John I. McCormick, Jovana Kapor, Jean-François Yale, Danielle Groleau. (2009) Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis*. Current Medical Research and Opinion 25:5, 1273-1284
CrossRef846
Paul Zimmet. (2009) Preventing diabetic complications: A primary care perspective. Diabetes Research and Clinical Practice 84:2, 107-116
CrossRef847
Giuseppe Mancia, Guido Grassi. (2009) Protection of patients with diabetes, with or without hypertension: implications of ADVANCE for clinical practice. Journal of Hypertension 27:Suppl 1, S19-S23
CrossRef848
H.-H. Parving, B. M. Brenner, John. J. V. McMurray, D. de Zeeuw, S. M. Haffner, S. D. Solomon, N. Chaturvedi, M. Ghadanfar, N. Weissbach, Z. Xiang, J. Armbrecht, M. A. Pfeffer. (2009) Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrology Dialysis Transplantation 24:5, 1663-1671
CrossRef849
Hertzel C. Gerstein. (2009) Is it possible to reduce cardiovascular risk with glucose-lowering approaches?. Nature Reviews Endocrinology 5:5, 270-275
CrossRef850
Theodore Mazzone. (2009) Hyperglycaemia and coronary heart disease: the meta picture. The Lancet 373:9677, 1737-1738
CrossRef851
J-F. Blicklé, N. Hancu, M. Piletic, V. Profozic, M. Shestakova, M-P. Dain, S. Jacqueminet, A. Grimaldi. (2009) Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study. Diabetes, Obesity and Metabolism 11:4, 379-386
CrossRef852
Babak Razani, Clay F Semenkovich. (2009) Getting away from glucose: stop sugarcoating diabetes. Nature Medicine 15:4, 372-373
CrossRef853
L. F. Meneghini, A. Dornhorst, S. Sreenan. (2009) Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study. Current Medical Research and Opinion 25:4, 1029-1035
CrossRef854
L. Juurinen, M. Tiikkainen, J. Saltevo, K. Nikkilä, H. Lanki, E. Leppävuori, T. Kock, T. Teikari-Myyrä, R. Kauppinen-Mäkelin, A. Kotronen, H. Yki-Järvinen. (2009) Nateglinide combination therapy with basal insulin and metformin in patients with Type 2 diabetes. Diabetic Medicine 26:4, 409-415
CrossRef855
Elbert S Huang, Priya John, Medha N Munshi. (2009) Multidisciplinary approach for the treatment of diabetes in the elderly. Aging Health 5:2, 207-216
CrossRef856
Mandeep Bajaj, Ishwarlal Jialal. (2009) Type 2 Diabetes Treatment and Macrovascular Complications—Fat and Sugar Make a Dangerous Soufflé. Metabolic Syndrome and Related Disorders 7:2, 79-82
CrossRef857
L. Lundby Christensen, T. Almdal, T. Boesgaard, L. Breum, E. Dunn, B. Gade-Rasmussen, C. Gluud, C. Hedetoft, A. Jarloev, T. Jensen, T. Krarup, L. B. Johansen, S. S. Lund, S. Madsbad, E. Mathiesen, J. Moelvig, F. Nielsen, H. Perrild, O. Pedersen, M. Roeder, S. B. Sneppen, O. Snorgaard, L. Tarnow, B. Thorsteinsson, A. Vaag, H. Vestergaard, J. Wetterslev, N. Wiinberg, . (2009) Study rationale and design of the CIMT trial: The Copenhagen Insulin and Metformin Therapy Trial. Diabetes, Obesity and Metabolism 11:4, 315-322
CrossRef858
Rajesh Peter, Alan Rees. (2009) Diabetes and cardiovascular disease: new perspectives. Current Opinion in Lipidology 20:2, 145-146
CrossRef859
Chulsoo Park, Chehao Hsu, Gundappa Neelakanta, Hamid Nourmand, Michelle Braunfeld, Christopher Wray, Randolph H. Steadman, Ke-Qin Hu, Ronald T. Cheng, Victor W. Xia. (2009) Severe Intraoperative Hyperglycemia Is Independently Associated With Surgical Site Infection After Liver Transplantation. Transplantation 87:7, 1031-1036
CrossRef860
Stephen Colagiuri, Daniel Davies. (2009) The value of early detection of type 2 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity 16:2, 95-99
CrossRef861
Stefano Del Prato. (2009) Diabetes: Genes, diabetes and cardiovascular risk prediction. Nature Reviews Endocrinology 5:4, 192-193
CrossRef862
J. N. Basile. (2009) Antihypertensive therapy, new-onset diabetes, and cardiovascular disease. International Journal of Clinical Practice 63:4, 656-666
CrossRef863
Tamar Polonsky, Theodore Mazzone, Michael Davidson. (2009) The Clinical Implications of the CHICAGO Study for the Management of Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus. Trends in Cardiovascular Medicine 19:3, 94-99
CrossRef864
Inzucchi, Silvio E., Siegel, Mark D., . (2009) Glucose Control in the ICU — How Tight Is Too Tight?. New England Journal of Medicine 360:13, 1346-1349
Full Text865
The NICE-SUGAR Study Investigators. (2009) Intensive versus Conventional Glucose Control in Critically Ill Patients. New England Journal of Medicine 360:13, 1283-1297
Full Text866
Harold Bays. (2009) From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Current Medical Research and Opinion 25:3, 671-681
CrossRef867
Roger E. Kelley, Alireza Minagar. (2009) Memory Complaints and Dementia. Medical Clinics of North America 93:2, 389-406
CrossRef868
Alan M. Weiss. (2009) Cardiovascular Disease in Women. Primary Care: Clinics in Office Practice 36:1, 73-102
CrossRef869
George L. Bakris, James R. Sowers. (2009) Treatment of hypertension in patients with diabetes—an update. Journal of the American Society of Hypertension 3:2, 150-155
CrossRef870
Georgia Soldatos, Mark E Cooper. (2009) Does intensive glycemic control for type 2 diabetes mellitus have long-term benefits for cardiovascular disease risk?. Nature Clinical Practice Endocrinology & Metabolism 5:3, 138-139
CrossRef871
Rohina Joshi, BE de Galan, John Chalmers, Vlado Perkovic, Anushka Patel. (2009) Routine blood pressure lowering and intensive glucose control in patients with Type 2 diabetes: the ADVANCE trial. Expert Review of Endocrinology & Metabolism 4:2, 111-118
CrossRef872
Tom Skyhøj Olsen. (2009) Blood glucose in acute stroke. Expert Review of Neurotherapeutics 9:3, 409-419
CrossRef873
Gherardo Mazziotti, Simonetta Bossoni, Stefania Orini, Petronilla Salimbeni, Carmine Gazzaruso, Bruno S. Solerte, Pierpaolo Vescovi, Giuseppe Romanelli, Andrea Giustina. (2009) TREATMENT WITH METFORMIN IS PROTECTIVE AGAINST LIMITATIONS IN INSTRUMENTAL ACTIVITIES OF DAILY LIVING IN OLDER SUBJECTS WITH TYPE 2 DIABETES MELLITUS. Journal of the American Geriatrics Society 57:3, 562-564
CrossRef874
John Y. C. Chan, Malgorzata Leyk, Brian M. Frier, Meng H. Tan. (2009) Relationship between HbA 1c and hypoglycaemia in patients with type 2 diabetes treated with different insulin regimens in combination with metformin. Diabetes/Metabolism Research and Reviews 25:3, 224-231
CrossRef875
Kay-Tee Khaw. (2009) Elevated HbA1c level: a risk factor for cardiovascular disease mortality in patients with chronic heart failure?. Nature Clinical Practice Endocrinology & Metabolism 5:3, 130-131
CrossRef876
Howard Fillit, David T. Nash, Diana Shineman. (2009) Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” Primary prevention of dementia in Alzheimer's disease: A perspective from prevention research in cardiovascular disease and stroke. Alzheimer's and Dementia 5:2, 149-153
CrossRef877
Christoph K. Naber, Rajendra H. Mehta, Claus Jünger, Uwe Zeymer, Harm Wienbergen, Georg V. Sabin, Raimund Erbel, Jochen Senges, Anselm Gitt. (2009) Impact of Admission Blood Glucose on Outcomes of Nondiabetic Patients With Acute ST-Elevation Myocardial Infarction (from the German Acute Coronary Syndromes [ACOS] Registry). The American Journal of Cardiology 103:5, 583-587
CrossRef878
D. M. Nathan. (2009) Medical management of hyperglycaemia in type 2 diabetes mellitus. Reply to Woo V [letter] and Eizirik DL [letter]. Diabetologia 52:3, 554-555
CrossRef879
M. Jecht. (2009) Kardiale Arrhythmie und nächtliche Hypoglykämie bei Patienten mit einem Diabetes mellitus Typ 1. Der Diabetologe 5:2, 122-123
CrossRef880
Federico Bilotta, Remo Caramia, Francesca P. Paoloni, Roberto Delfini, Giovanni Rosa. (2009) Safety and Efficacy of Intensive Insulin Therapy in Critical Neurosurgical Patients. Anesthesiology 110:3, 611-619
CrossRef881
V. Woo. (2009) Important differences: Canadian Diabetes Association 2008 clinical practice guidelines and the consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:3, 552-553
CrossRef882
Michael S. Lauer. (2009) Comparative Effectiveness Research: The View From the NHLBI. Journal of the American College of Cardiology 53:12, 1084-1086
CrossRef883
N. Younis, H. Soran, M. Hassanein. (2009) Cardiovascular disease and intensive glucose lowering in type 2 diabetes. QJM 102:4, 293-296
CrossRef884
Alan Chait. (2009) Preventing cardiovascular disease in type 2 diabetes: Where do things stand with glycemic control? Part two. Current Diabetes Reports 9:1, 9-10
CrossRef885
Derek D. Mafong, Robert R. Henry. (2009) The role of incretins in cardiovascular control. Current Hypertension Reports 11:1, 18-22
CrossRef886
Ellen Strahlman. (2009) Response to “Rosiglitazone no longer recommended”. The Lancet 373:9663, 544
CrossRef887
A. J. Bleyer, D. Hire, G. B. Russell, J. Xu, J. Divers, Z. Shihabi, D. W. Bowden, B. I. Freedman. (2009) Ethnic variation in the correlation between random serum glucose concentration and glycated haemoglobin. Diabetic Medicine 26:2, 128-133
CrossRef888
John G.F. Cleland, Luigi Tavazzi, Jean-Claude Daubert, Ahmed Tageldien, Nick Freemantle. (2009) Cardiac Resynchronization Therapy. Journal of the American College of Cardiology 53:7, 608-611
CrossRef889
Edward S. Horton. (2009) Defining the Role of Basal and Prandial Insulin for Optimal Glycemic Control. Journal of the American College of Cardiology 53:5, S21-S27
CrossRef890
Jayanta T. Mukherjee, Richard W. Nesto. (2009) The “legacy effect” associated with intensive glucose control in patients with type 2 diabetes. Current Diabetes Reports 9:1, 63-64
CrossRef891
Christopher D Saudek, Rita R Kalyani. (2009) Does comorbidity affect the benefit of intensive glycemic control in older patients with type 2 diabetes mellitus?. Nature Clinical Practice Endocrinology & Metabolism 5:2, 78-79
CrossRef892
Wolfgang Motz, Rolf Dörr. (2009) ESC/EASD-Leitlinien zu Diabetes und kardiovaskulären Erkrankungen. Herz 34:1, 21-29
CrossRef893
Stefan G De Hert, Philippe J Van der Linden. (2009) Clinical trials: evidence based and clinically relevant or not?. Current Opinion in Anaesthesiology 22:1, 68-70
CrossRef894
E. Ferrannini, V. Fonseca, B. Zinman, D. Matthews, B. Ahrén, S. Byiers, Q. Shao, S. Dejager. (2009) Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity and Metabolism 11:2, 157-166
CrossRef895
Gerald H Tomkin. (2009) The effect of antidiabetic drugs on genes regulating lipid metabolism. Current Opinion in Lipidology 20:1, 10-16
CrossRef896
Stuart W. Zarich. (2009) Potential of glucose-lowering drugs to reduce cardiovascular events. Current Diabetes Reports 9:1, 87-94
CrossRef897
GC Hawthorne, AJ Yarnall. (2009) Recent clinical trials in diabetes – implications for managing older patients. Reviews in Clinical Gerontology 19:01, 25
CrossRef898
Travis E. Sonnett, Terri L. Levien, Joshua J. Neumiller, Brian J. Gates, Stephen M. Setter. (2009) Colesevelam hydrochloride for the treatment of type 2 diabetes mellitus. Clinical Therapeutics 31:2, 245-259
CrossRef899
Michelle M. Averill, Karin E. Bornfeldt. (2009) Lipids versus glucose in inflammation and the pathogenesis of macrovascular disease in diabetes. Current Diabetes Reports 9:1, 18-25
CrossRef900
Duckworth, William, Abraira, Carlos, Moritz, Thomas, Reda, Domenic, Emanuele, Nicholas, Reaven, Peter D., Zieve, Franklin J., Marks, Jennifer, Davis, Stephen N., Hayward, Rodney, Warren, Stuart R., Goldman, Steven, McCarren, Madeline, Vitek, Mary EllenHenderson, William G., Huang, Grant D., . (2009) Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. New England Journal of Medicine 360:2, 129-139
Full Text901
G. Paolisso, A. J. Sinclair. (2009) Effective clinical practice for older people with type 2 diabetes. Glucose regulation is important but other strategies also need to be included. The Journal of Nutrition, Health and Aging
CrossRef902
Jodi R. Godfrey, Ralph L. Sacco. (2009) Toward Optimal Health: A Renewed Look at Stroke in Women. Journal of Women's Health 18:1, 13-18
CrossRef903
Pilar Mazón-Ramos, Alberto Cordero-Fort, Juan Quiles-Granado, Josep Guindo-Soldevila. (2009) Temas de actualidad en hipertensión arterial y diabetes. Revista Española de Cardiología 62, 14-27
CrossRef904
Kazuo Eguchi, Joji Ishikawa, Satoshi Hoshide, Thomas G. Pickering, Joseph E. Schwartz, Kazuyuki Shimada, Kazuomi Kario. (2009) Night Time Blood Pressure Variability Is a Strong Predictor for Cardiovascular Events in Patients With Type 2 Diabetes. American Journal of Hypertension 22:1, 46-51
CrossRef905
Jay S. Skyler, Richard Bergenstal, Robert O. Bonow, John Buse, Prakash Deedwania, Edwin A.M. Gale, Barbara V. Howard, M. Sue Kirkman, Mikhail Kosiborod, Peter Reaven, Robert S. Sherwin. (2009) Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. Journal of the American College of Cardiology 53:3, 298-304
CrossRef906
Kasia Lipska, Silvio E. Inzucchi. (2009) Cardiovascular risk-benefit ratio of thiazolidinediones. Current Cardiovascular Risk Reports 3:1, 42-50
CrossRef907
D. M. Nathan, J. B. Buse, M. B. Davidson, E. Ferrannini, R. R. Holman, R. Sherwin, B. Zinman. (2009) Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 52:1, 17-30
CrossRef908
Moritoki Egi, Rinaldo Bellomo. (2009) Blood glucose control in critically ill patients: The impact of diabetes. Critical Care Medicine 37:1, 382-383
CrossRef909
John M Galla, Stephen J Nicholls. (2009) Pharmacologic therapy for coronary atherosclerosis in patients with Type 2 diabetes mellitus. Expert Review of Cardiovascular Therapy 7:1, 85-93
CrossRef910
Won Jun Kim, Chang Beom Lee, Cheol Young Park, Se Eun Park, Eun Jung Rhee, Won Young Lee, Ki Won Oh, Sung Woo Park, Dae Jung Kim, Hae Jin Kim, Seung Jin Han, Hong Keum Cho. (2009) Effects of Adding ω-3 Fatty Acids to Simvastatin on Lipids, Lipoprotein Size and Subspecies in Type 2 Diabetes Mellitus with Hypertriglyceridemia. Korean Diabetes Journal 33:6, 494
CrossRef911
D.B. McNamara, S.N. Murthy, A.N. Fonseca, C.V. Desouza, P.J. Kadowitz, V.A. Fonseca. (2009) Animal models of catheter-induced intimal hyperplasia in type 1 and type 2 diabetes and the effects of pharmacologic intervention. Canadian Journal of Physiology and Pharmacology 87:1, 37-50
CrossRef912
Taishiro Chikamori. (2009) Management of ischemic heart disease in the elderly. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 46:5, 391-394
CrossRef913
Philip R. Liebson. (2009) Diabetes Control and Cardiovascular Risk, Part II: Intensive Glucose Control - UKPDS Follow-Up. Preventive Cardiology 12:1, 51-58
CrossRef914
Richard Bergenstal, Andrew Lewin, Timothy Bailey, Denise Chang, Titus Gylvin, Victor Roberts. (2009) Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Current Medical Research and Opinion 25:1, 65-75
CrossRef915
Yusuke Moritoh, Koji Takeuchi, Tomoko Asakawa, Osamu Kataoka, Hiroyuki Odaka. (2009) The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. European Journal of Pharmacology 602:2-3, 448-454
CrossRef916
Katherine R. Tuttle. (2009) More Is Not Always Better: Intensive Glycemic Control in Type 2 Diabetes. American Journal of Kidney Diseases 53:1, 12-15
CrossRef917
Su Kyung Park, Mi-Kyoung Park, Ji Hye Suk, Mi Kyung Kim, Yong Ki Kim, In Ju Kim, Yang Ho Kang, Kwang Jae Lee, Hyun Seung Lee, Chang Won Lee, Bo Hyun Kim, Kyung Il Lee, Mi Kyoung Kim, Duk Kyu Kim. (2009) Cause-of-Death Trends for Diabetes Mellitus over 10 Years. Korean Diabetes Journal 33:1, 65
CrossRef918
Lars Rydén, Klas Malmberg, Linda Mellbin. (2009) Is glucose normalization an evidence-based treatment for patients with type 2 diabetes mellitus?. Nature Clinical Practice Endocrinology & Metabolism 5:1, 8-9
CrossRef919
Daniel E. Mumme, Michelle A. Mathiason, Kara J. Kallies, Shanu N. Kothari. (2009) Effect of laparoscopic Roux-en-Y gastric bypass surgery on hemoglobin A1c levels in diabetic patients: a matched-cohort analysis. Surgery for Obesity and Related Diseases 5:1, 4-10
CrossRef920
James B. Meigs, Frederick A. Masoudi. (2009) Cardiovascular disease is prevented over the long term by better blood glucose control. Current Cardiovascular Risk Reports 3:1, 33-34
CrossRef921
Patrick J. O’Connor, JoAnn M. Sperl-Hillen, Thomas E. Kottke. (2009) Disease management strategies to optimize cardiovascular risk in type 2 diabetes mellitus. Current Cardiovascular Risk Reports 3:1, 71-77
CrossRef922
Wineke Bakker, Etto C. Eringa, Pieter Sipkema, Victor W. M. Hinsbergh. (2009) Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. Cell and Tissue Research 335:1, 165-189
CrossRef923
F. H. Lawler. (2009) Reasons to Exercise Caution When Considering a Screening Program for Type 2 Diabetes Mellitus. Mayo Clinic Proceedings 84:1, 34-36
CrossRef924
A. M. Sheehy, D. B. Coursin, R. A. Gabbay. (2009) Back to Wilson and Jungner: 10 Good Reasons to Screen for Type 2 Diabetes Mellitus. Mayo Clinic Proceedings 84:1, 38-42
CrossRef925
A. Pazin-Filho, A. Kottgen, A. G. Bertoni, S. D. Russell, E. Selvin, W. D. Rosamond, J. Coresh. (2008) HbA1c as a risk factor for heart failure in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia 51:12, 2197-2204
CrossRef926
Anuradha Vivekanadan-Giri, Jeffrey H. Wang, Jaeman Byun, Subramaniam Pennathur. (2008) Mass spectrometric quantification of amino acid oxidation products identifies oxidative mechanisms of diabetic end-organ damage. Reviews in Endocrine and Metabolic Disorders 9:4, 275-287
CrossRef927
Evan A. Stein. (2008) Additional Lipid Lowering Trials Using Surrogate Measurements of Atherosclerosis by Carotid Intima-Media Thickness. Journal of the American College of Cardiology 52:25, 2206-2209
CrossRef928
Hemanth Bolusani, R Peter, A Rees. (2008) Therapy and clinical trials: glycaemia and prevention of macroangiopathy in type 2 diabetes. Current Opinion in Lipidology 19:6, 629-630
CrossRef929
Matthijs F.L. Meijs, Lioe-Ting Dijkhorst-Oei, Reina van Loo, Renate J. Bosma, Cas W. Weykamp, Jos P.M. Wielders. (2008) Does carbamylated hemoglobin still affect the analysis of HbA 1c in uremic and hyperglycemic patients?. Clinical Chemistry and Laboratory Medicine 46:12, 1791-1792
CrossRef930
Vasilios G Athyros, Konstantinos Tziomalos, Asterios Karagiannis, Dimitri P Mikhailidis. (2008) Preventing macrovascular complications of diabetes: where do we stand with glycemic control?. Expert Opinion on Investigational Drugs 17:12, 1777-1779
CrossRef931
David Aguilar. (2008) Management of type 2 diabetes in patients with heart failure. Current Treatment Options in Cardiovascular Medicine 10:6, 465-475
CrossRef932
Irl B. Hirsch, Bruce W. Bode, Belinda P. Childs, Kelly L. Close, William A. Fisher, James R. Gavin, Barry H. Ginsberg, Charles H. Raine, Carol A. Verderese. (2008) Self-Monitoring of Blood Glucose (SMBG) in Insulin- and Non–Insulin-Using Adults with Diabetes: Consensus Recommendations for Improving SMBG Accuracy, Utilization, and Research. Diabetes Technology & Therapeutics 10:6, 419-439
CrossRef933
Denise G. Simons-Morton. (2008) The Glycemia-Cardiovascular Disease Hypothesis. Clinical and Translational Science 1:3, 185-186
CrossRef934
Robert E. Ratner, Christopher P. Cannon, Hertzel C. Gerstein, Richard W. Nesto, Patrick W. Serruys, Gerrit-Anne van Es, Nikheel S. Kolatkar, Barbara G. Kravitz, Andrew Zalewski, Peter J. Fitzgerald. (2008) Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): Study design and baseline characteristics. American Heart Journal 156:6, 1074-1079
CrossRef935
B. Radbill, B. Murphy, D. LeRoith. (2008) Rationale and Strategies for Early Detection and Management of Diabetic Kidney Disease. Mayo Clinic Proceedings 83:12, 1373-1381
CrossRef936
Louis Monnier, Claude Colette. (2008) Fasting glucose and postprandial glycemia: which is the best target for improving outcomes? The Apollo and 4-T Trials. Expert Opinion on Pharmacotherapy 9:16, 2857-2865
CrossRef937
G McKay. (2008) What's new for the DPP-4 inhibitors?. Practical Diabetes International 25:9, 342-344
CrossRef938
A. Liebl. (2008) Differenzierte Insulintherapie des Typ-2-Diabetes. Der Diabetologe 4:7, 516-524
CrossRef939
(2008) SUR receptor activity vs. incidence of hypoglycaemia and cardiovascular mortality with sulphonylurea therapy for diabetics. Diabetes, Obesity and Metabolism 10:11, 1128-1129
CrossRef940
Carmine Zoccali, Elvira Puntorieri. (2008) Type-2 diabetes and endothelial dysfunction: exploring the road to disease in the reverse direction. Journal of Hypertension 26:11, 2096-2100
CrossRef941
Markku Laakso. (2008) Diabetes as a 'cardiovascular disease equivalent': implications for treatment. Nature Clinical Practice Cardiovascular Medicine 5:11, 682-683
CrossRef942
Marco A. Costa. (2008) A sweet summer for drug-eluting stents in patients with diabetes mellitus. Catheterization and Cardiovascular Interventions 72:5, 610-611
CrossRef943
MW Savage. (2008) Newer agents for blood glucose control in type 2 diabetes: the NICE draft proposals. Practical Diabetes International 25:9, 353-354
CrossRef944
Jane Jeffrie Seley. (2008) Does Tight Glycemic Control Increase the Risk of Death?. AJN, American Journal of Nursing 108:11, 31
CrossRef945
Holman, Rury R., Paul, Sanjoy K., Bethel, M. Angelyn, Matthews, David R., Neil, H. Andrew W., . (2008) 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine 359:15, 1577-1589
Full Text946
Chalmers, John, Cooper, Mark E., . (2008) UKPDS and the Legacy Effect. New England Journal of Medicine 359:15, 1618-1620
Full Text947
(2008) Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine 359:14, 1519-1521
Full Text948
M. Tiburcy, W.-H. Zimmermann. (2008) Therapie des Diabetes mellitus Typ 2 und kardiovaskuläre Komplikationen. Der Kardiologe 2:5, 417-429
CrossRef949
Sanjay Kaul, George A. Diamond. (2008) Rosiglitazone and cardiovascular risk. Current Atherosclerosis Reports 10:5, 398-404
CrossRef950
Anthony L. McCall. (2008) Does the method of obtaining glycemic control influence cardiovascular outcomes?. Current Diabetes Reports 8:5, 341-344
CrossRef951
Christopher T. Kodl, Elizabeth R. Seaquist. (2008) Practical strategies to normalize hyperglycemia without undue hypoglycemia in type 2 diabetes mellitus. Current Diabetes Reports 8:5, 375-382
CrossRef952
Theodosios Filippatos, Haralampos J Milionis. (2008) Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert Opinion on Investigational Drugs 17:10, 1599-1614
CrossRef953
Rimei Nishimura, Daisuke Tsujino, Kentaro Taki, Aya Morimoto, Naoko Tajima, Rimei Nishimura. (2008) Does HbA1c represent a valid index for tight control of glucose in type 1 diabetes?. Diabetes Research and Clinical Practice 82:1, e23-e24
CrossRef954
F. Labrousse-Lherminé, P. Gourdy. (2008) Prise en charge d’une hyperglycémie au cours d’un infarctus du myocarde. Archives des Maladies du Coeur et des Vaisseaux - Pratique 2008:171, 26-28
CrossRef955
Goldfine, Allison B., . (2008) Assessing the Cardiovascular Safety of Diabetes Therapies. New England Journal of Medicine 359:11, 1092-1095
Full Text956
Allison B Goldfine. (2008) Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway. Current Opinion in Cardiology 23:5, 502-511
CrossRef957
Philip R. Liebson. (2008) Diabetes Control and Cardiovascular Risk: ACCORD, ADVANCE, AVOID, and SANDS. Preventive Cardiology 11:4, 230-236
CrossRef958
E. S. Kilpatrick, A. K. Das, C. Ørskov, K. Berntorp. (2008) Good glycaemic control: an international perspective on bridging the gap between theory and practice in type 2 diabetes. Current Medical Research and Opinion 24:9, 2651-2661
CrossRef959
M Fisher. (2008) Advances in diabetes care?. Practical Diabetes International 25:7, 258-260
CrossRef960
Sonal Singh, Yoon K Loke. (2008) The safety of rosiglitazone in the treatment of Type 2 diabetes. Expert Opinion on Drug Safety 7:5, 579-585
CrossRef961
George L. Bakris, James R. Sowers, . (2008) ASH Position Paper: Treatment of Hypertension in Patients With Diabetes-An Update. The Journal of Clinical Hypertension 10:9, 707-713
CrossRef962
N. Hermanns. (2008) Führt eine normoglykämische Einstellung zu einer erhöhten kardiovaskulären Mortalität?. Der Diabetologe 4:6, 448-450
CrossRef963
Angela Botts, Medha Munshi. (2008) Diabetes in the elderly. Current Cardiovascular Risk Reports 2:5, 382-389
CrossRef964
A. G. Fraser. (2008) Echocardiographic epidemiology--an emerging tool for early diagnosis, studying pathophysiology, predicting prognosis, and testing treatments. European Heart Journal 30:6, 642-644
CrossRef965
P. D. Home. (2008) Impact of the UKPDS—an overview. Diabetic Medicine 25, 2-8
CrossRef966
E. S. Kilpatrick. (2008) Estimated average glucose (eAG): fit for purpose?. Diabetic Medicine 25:8, 899-901
CrossRef967
J. M. Ritter. (2008) Chronic disease: when in doubt, consider accrual into a randomized controlled trial (RCT). British Journal of Clinical Pharmacology 66:2, 169-172
CrossRef968
Steven Kaufman. (2008) Normalization of glucose in the intensive care unit: Does one size really fit all?*. Critical Care Medicine 36:8, 2448-2449
CrossRef969
Hermes Florez, Jennifer Marks, Carlos Abraira. (2008) Treating diabetes in the elderly: what is the impact for cardiovascular health?. Aging Health 4:4, 333-335
CrossRef970
Ken Shaw. (2008) Institute of Diabetes for Older People: surviving a sweet old age. Practical Diabetes International 25:6, 221-222
CrossRef971
Dluhy, Robert G., McMahon, Graham T., . (2008) Intensive Glycemic Control in the ACCORD and ADVANCE Trials. New England Journal of Medicine 358:24, 2630-2633
Full Text972
Krumholz, Harlan M., Lee, Thomas H., . (2008) Redefining Quality — Implications of Recent Clinical Trials. New England Journal of Medicine 358:24, 2537-2539
Full Text973
Cefalu, William T., . (2008) Glycemic Targets and Cardiovascular Disease. New England Journal of Medicine 358:24, 2633-2635
Full Text974
The ADVANCE Collaborative Group. (2008) Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine 358:24, 2560-2572
Full Text975
Heidi Ledford. (2008) Aggressive approach to diabetes proves harmful. Nature
CrossRef976
Juneyoung Lee. (2008) Meta-analysis. Journal of Korean Endocrine Society 23:6, 361
CrossRef977
Tae Sun Park, Hong-Sun Baek, Ji-Hyun Park. (2008) General Principles for Diabetes Mellitus Management. Journal of the Korean Medical Association 51:9, 806
CrossRef978
Woo Je Lee, Kyung Soo Ko, Byoung Doo Rhee. (2008) Intensive Glucose Control and Cardiovascular Outcomes: Focused on Recent Clinical Trials. Journal of Korean Endocrine Society 23:5, 289
CrossRef979
Amy B Kauffman, Thomas Delate, Kari L Olson, Alicia A Cymbala, Kara A Hutka, Sheila L Kasten, Jon R Rasmussen. (2008) Relationship between Haemoglobin A1C Values and Recurrent Cardiac Events. Clinical Drug Investigation 28:8, 501-507
CrossRef980
Willmann Liang, Calista Y.R. Tan, Lisa Ang, Nada Sallam, David J. Granville, James M. Wright, Ismail Laher. (2008) Ramipril Improves Oxidative Stress-Related Vascular Endothelial Dysfunction in db/db Mice. The Journal of Physiological Sciences 58:6, 405-411
CrossRef
- Letters
